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ABSTRACT 
Marie Ann Voice, School of Immunity and Infection, College of Medical and Dental 
Sciences, University of Birmingham. 
A thesis submitted to the University of Birmingham for the degree of  
DOCTOR OF PHILOSOPHY 
 
CD4
+
 T cells modulate an immune response through the production of effector cytokines. In 
some circumstances the effector function of CD4
+
 T cells is diminished, which may have 
beneficial (peripheral tolerance) or detrimental (exhaustion, senescence) consequences. Here I 
characterise a population of CD4
+
 cells in human peripheral blood which exhibit complete 
hyporesponsiveness to in vitro stimulation, as indicated by an absence of CD69 upregulation 
and the failure to secrete any of thirteen candidate cytokines. These T cells had an effector 
memory phenotype (CD45RA
-
CCR7
-/+
CD62L
lo
CD27
lo
), but their intermediate expression of 
PD-1 did not suggest a state of exhaustion. Although regulatory T cells (CD25
hi
CD127
lo
) 
contributed to the hyporesponsive population it was not predominated by this phenotype. 
However, the possibility that these hyporesponsive cells represent a non-classical regulatory 
subset could not be excluded.   
CD4
+
 T cells can enter the central nervous system (CNS) via the blood cerebrospinal fluid 
barrier, but their biological activity and recruitment pathways are under-defined. Preliminary 
studies had suggested that hyporesponsive CD4
+
 T cells were enriched in uninflamed human 
cerebrospinal fluid (CSF). However, this investigation found that CSF and brain-derived 
CD4
+
 T cells readily upregulate CD69 upon activation (mouse, human) and have robust IFNγ 
responses (rat). This evidence supports a role for CD4
+
 T cells in CNS immune surveillance 
and immunity.  
This investigation also showed that the proportion of CCR7
+
 and CCR7
-
 memory CD4
+
 T 
cells in the CSF was a direct reflection of the distribution in the peripheral blood in both 
mouse and man. This suggests that CSF recruitment is not CCR7-dependent as is previously 
described, and shows effector memory cells enter the CSF space in the absence of 
neuropathology. Such findings have implications for the understanding of normal immune 
function in the CNS, and the protective or pathogenic contribution of CD4
+
 T cells to 
neuroinflammatory disorders such as multiple sclerosis. 
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CHAPTER 1 
 
GENERAL INTRODUCTION
Chapter 1  1 
1 GENERAL INTRODUCTION 
1.1  The foundations of human immunity. 
1.1.1 The innate immune system.  
The ability of an organism to protect itself against pathogenic invasion is an evolutionary 
conserved feature that likely predates the emergence of multicellular organisms over 600 
million years ago
[1]
. Mechanisms of host defence in humans have evolved to protect against a 
plethora of pathogens (e.g. bacterium, viruses, fungi, helminth) and are therefore multi-
layered and complex. The first line of protection against such organisms is the physical 
barriers that must be breached in order to access the body. In humans, potentially vulnerable 
sites for pathogen entry include the skin, gut and respiratory mucosa. Consequentially the 
evolution of immune modifications at these sites is heavily favoured
[2]
. Taking the skin as an 
example site, such mechanisms include keratinisation and desquamation of the tissue 
surface
[3]
, production of sweat and anti-microbial organic acids
[4]
, and commensal skin flora 
which inhibits the colonisation of pathogenic microbes
[5]
.   
Once a pathogen has breached these physical barriers, the second line of immune defence is a 
collection of fast-acting cellular and humoral responses that fall under the definition of ‘innate 
immunity’. With consideration to the cellular component, all innate immune cell lineages are 
derived from haematopoietic stem cells (HSC) in the bone marrow
[6]
. These pluripotent cells 
differentiate into multi-potent common myeloid progenitors (CMP) which can then 
differentiate into granulocytes (neutrophils, eosinophils, basophils) or monocytes
[7]
. A 
summary of some important features of these cells is shown in Table 1.1. 
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Origin 
Lineage 
Precursor 
Niche 
signals 
Lineage 
Precursor 
Niche 
signals 
Cell Type Summary of function 
Haematopoietic 
stem cell 
Common 
myeloid 
progenitor 
GM-CSF Myloblast 
G-CSF 
GM-CSF 
IL-3      
IL-4 
Neutrophil 
Rapid response to bacterial infection. 
Phagocytosis and microbe killing though 
hydrolytic enzyme and superoxide 
production (ROS). Degranulation and 
release of NET's to trap and kill microbes. 
GM-CSF 
IL-3 
IL-4 
Basophil 
Protection from ectoparasites through 
degranulation; release of histamine, 
proteoglycans, proteolytic enzymes. 
Source of IL-4 cytokine. 
GM-CSF 
IL-3       
IL-5 
Eosinophil  
Protection from parasites and multi-
cellular pathogens. Degranulation to 
release cytotoxic inflammatory mediators 
including; cationic proteins, cytokines, 
leukotrienes, ROS. 
GM-CSF          
M-CSF 
Monocyte 
GM-CSF            
M-CSF 
macrophage 
Phagocytosis of apoptotic cells, cellular 
debris, microbes. Production of monokines 
(CSF, IL-1, IFNα, IFNβ, TNFα). Support 
of adaptive immunity (antigen 
presentation) 
GM-CSF 
IL-4 
Dendritic cell 
Antigen processing and presentation. 
Support of adaptive immunity. 
 Table 1.1 Summary of the lineage and function of notable innate immune cells. Table includes an overview of some important cytokines and 
growth factors involved in the differentiation of each lineage. The summary of function includes some of the most significant roles of each cell 
type. G-CSF; granulocyte colony stimulating factor, GM-CSF; granulocyte macrophage-colony stimulating factor, M-CSF; macrophage-colony 
stimulating factor, SCF; stem cell factor, IL-1, IL-3, IL-4, IL-5, IL-6; Interleukin family members, TNFα; Tumour necrosis factor alpha, IFNα 
and IFNβ; Interferon alpha and beta, ROS; Reactive oxygen species, NET; Neutrophil extracellular trap. 
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A conserved feature of innate immune cells is the ability to recognise molecular motifs on 
potential invaders and mount an appropriate molecular response. This is achieved through a 
series of pathogen recognition receptors (PRR’s) which recognise a variety of pathogen-
associated molecular patterns (PAMP’s) that are specific to non-host cellular structures. 
Examples of PAMP’s include; 1) double stranded RNA and unmethylated CpG DNA motifs 
(viral), 2) lipopolysaccharide and lipoteichoic acid (bacterial) and 3) β-glycan and mannan 
(fungal)
[8]
. Once PRR signalling is triggered, an intracellular signalling cascade is initiated 
that results in the release of numerous inflammatory mediators. These mediators are 
recognised by receptors expressed by multiple immune cell types, and thus the clearing of the 
pathogen is orchestrated. The recognition and clearance of pathogens is enhanced by serum 
proteins that form components of the complement system
[9]
. Two pathways of the 
complement system are triggered by the binding of acute phase response proteins (C-reactive 
protein or mannose-binding lectin) directly to the bacterial surfaces. These proteins are 
elevated in inflammation and the resulting proteolytic cascade of complement products can; 
1) enhance phagocytosis (C3b protein), 2) act as a chemoattractant for other innate immune 
cells (C5a proteins), 3) activate eosinophils and basophil degranulation (C3A and C5A), 4) 
form a membrane attack complex that results in the osmotic lysis of bacterial cells (C5b, C6, 
C7, C8, C9 association)
[10]
.  
1.1.2 Adaptive immunity. 
Innate immune function provides generalised protection against classes of pathogens that is 
largely non-specific, but such function is rapid and essential for survival. In complex 
organisms an additional arm of defence is provided through ‘adaptive’ immune function. 
Early adaptive immune cells acquired the expression of recombinase enzymes to rearrange 
gene segments in their pathogen recognition receptors
[1,11]
. This generation of receptor 
diversity permitted the recognition of an almost infinite number of antigens and thus 
broadened both the specificity and range of the immune response. However, an inherent 
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danger of such a mechanism is the risk of generating reactivity against self-antigen. 
Therefore, protective molecular processes that prevent self-reactivity have co-evolved, 
although are not always fail-safe. 
Through the ability to maintain expanded clonal populations of pathogen specific cells 
following an infection the basis of immunological memory is formed
[12,13]
. Immune memory 
is a key feature of adaptive immunity and is defined by rapid recall responses upon re-
exposure to an infectious agent, coupled with enhanced immune protection against a 
secondary reinfection. B cell and T cells are two predominant cell types which form the basis 
of adaptive immunity in vertebrates, and are described in the following chapters with an 
emphasis upon human T cell biology.   
1.2  Overview of B cell biology. 
 B cells undergo development in the bone marrow and recognise antigen through expression 
of their B cell receptor (BCR). Systematic gene rearrangement (somatic recombination) of the 
BCR immunoglobulin genes generates receptor diversity
[14]
. Mature B cells migrate to the 
lymph nodes, and may become short lived plasma cells if their BCR recognises cognate 
antigen in the medullary region
[15]
. These produce large quantities of moderate affinity 
immunoglobulin (soluble BCR) of an IgM isoform and are important in the immediate 
immune response
[16]
. Production of immunoglobulin with high affinity requires B cell – T cell 
interaction
[17]
. If a BCR recognises an antigen it can internalise this complex and process the 
antigen into peptides. These peptides can be presented to T cells via major histocompatibility 
complex (MHC). If the peptide antigen is recognised by T cells, the T cell interaction induces 
B cell proliferation and migration to the dark zone of germinal centres within the lymph 
nodes
[18].  These ‘centroblasts’ undergo somatic hypermutation of their BCR through 
expression of activation induced deaminase enzyme, which introduces point mutations into 
the BCR’s antigen recognition sequence[19]. Centroblasts migrate to the light zone of the 
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germinal centre and become centrocytes. Through their interaction with follicular dendritic 
cells and T cells, centrocytes with an increased affinity for antigen are maintained whilst those 
with decreased affinity die by apoptosis
[18]
. High affinity B cells undergo class switching of 
their immunoglobulin heavy chain and differentiate into long lived plasma cells or memory B 
cells
[20]
. Long lived plasma cells produce large quantities of high affinity soluble 
immunoglobulin which may; 1) Neutralise soluble antigens, 2) Increase phagocytosis through 
pathogen opsonisation, 3) Activate the complement cascade via an immunoglobulin mediated 
pathway (the classical pathway). Memory B cells are maintained in the periphery and have the 
potential to differentiate rapidly into plasma cells upon re-exposure to antigen
[21]
.  
1.3  T cell biology. 
1.3.1 T cell development. 
In addition to supporting B cell function T cells have an integral role in multiple aspects of 
the immune response. The development of pre-T cells begins in the bone marrow through 
differentiation of HSC into common lymphoid progenitor (CLP) cells. CLP then differentiate 
into early T lineage progenitors (ETP) under the influence of cytokine mediators such as the 
interleukin family (IL) members IL-2, IL-4, IL-7, IL-9 and IL-10
[22,23]
. ETP lack their antigen 
recognition receptor (T cell receptor) but maintain the stem cell marker CD34
[24]
. ETP 
migrate from the bone marrow to the thymus to undergo maturation. In around 95% of T cells 
their T cell receptor (TCR) is an α/β protein heterodimer joined by disulphide bonds, whereas 
the remaining 5% have an alternative γ/δ chain arrangement[25]. Variation of TCR antigen 
specificity is a result of genetic recombination events where combinatorial splicing of 
receptor genes results in variation in the proteins amino acid sequence. In the subscapular 
region of the thymus cells with pre-TCR complexes are formed as rearrangement of the β-
chain genes precedes complete α-chain development[26,27]. Rearrangement of the α-chain 
coincides with the acquisition of both CD4 and CD8 TCR co-receptors
[28]
. With expression of 
functional TCR complete, positive selection of double positive thymocytes occurs through 
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interaction with MHC receptor presented by cortical thymic epithelial cells. Cells that do not 
recognise peptides presented via MHC die by neglect, whereas cells that moderately bind 
MHC receive survival signals and migrate through the corticomedullary region via acquisition 
of the chemokine receptor CCR7
[29]
.  
In the medulla thymocytes interact with dendritic cells (DC) and medullary epithelial cells, 
the latter of which expresses a repertoire of tissue specific antigens under the control of 
transcription factors such as the AIRE gene promotor
[30,31]
. Double positive thymocytes which 
bind strongly to self-antigen MHC complex are deleted by apoptosis through negative 
selection. Thymocytes which remain lose expression of either CD4 or CD8 depending on 
their MHC isoform recognition and become mature single positive cells. Although only 1-3% 
of progenitors which enter the thymus survive
[32,33]
, these mechanisms ensure highly self-
reactive mature T cells are not released into the periphery whilst maintaining a repertoire of 
cells that can bind antigen-MHC complex.  
1.3.2 Naïve T cell activation and intracellular signalling. 
Following maturation in the thymus T cells circulate in the blood in a ‘naïve’ antigen-
inexperienced state (Tnaive). In order to encounter antigen and activate these cells must home 
to secondary lymphoid organs
[34]
. This is achieved through surface expression of the adhesion 
molecule CD62L (L-selectin) and the chemokine receptor CCR7. CD62L and CCR7 interact 
with glycosylated peripheral node addressins
[35]
 and CCL21
[36]
 respectively. These ligands are 
expressed on high endothelial venules and facilitate T cell migration into lymph nodes. 
Peripheral DC loaded with tissue-derived antigens also migrate to the secondary lymphoid 
organs via afferent lymphatic vessels in a CCR7-dependent manner
[37,38]
. DC present 
processed peptide antigen to the naïve T cells via MHC complex in the T cell zones of the 
lymph nodes. CD8
+
 T cells typically bind antigen presented by MHC I receptors whereas 
CD4
+
 T cells bind antigen-MHC II complex. Intracellular antigens are presented by MHC I 
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whereas MHC II presents extracellular antigens that have been endocytosed by the APC. 
However, this is not a stringent characterisation as presentation of intracellular antigen by 
MHC II is also documented
[39]
.  
The αβ heterodimer that forms the TCR is part of a larger TCR complex which includes the 
transmembrane protein CD3 (ε,δ,γ,ζ chains) (Figure 1.1). CD3 transduces the signal from the 
TCR and other co-receptor input through the phosphorylation of ITAM sequences 
(immuoreceptor tyrosine-based activation motifs) in its cytoplasmic tail. ITAM 
phosphorylation induces membrane translocation and clustering of signalling mediators 
leading to a cascade of intracellular events. These result in the nuclear translocation of 
transcription factors which interact with gene promotors to initiate T cell gene expression. Fig 
1.1 depicts some important molecules and signalling pathways associated with CD4
+
 T cell 
activation. Co-stimulatory signals from receptors such as CD28, ICOS and CD40L are 
essential for complete T cell activation
[40]
. Primed APC upregulate ligands for these receptors 
in response to danger signals in the local environment. These signals provides a check point 
for the initiation of T cell responses, whilst engagement of inhibitory receptors such as 
CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) which shares ligands with CD28 can 
attenuate an activation event
[41]
.  
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Figure 1.1 Simplified schematic diagram of some important molecular pathways in CD4
+
 T cell activation. Antigen-MHC II complex 
recognition by the T cell receptor (TCR) leads to phosphorylation of ITAM motifs on the CD3 zeta chains. This signal is amplified through 
activation of Src-family kinases Lck, Fyn and ZAP70. Lck is associated with CD4 and is also activated through signalling via CD28 co-
stimulation and its dephosphorylation by CD45. ZAP70 activates LAT (linker of activated T cells) which induces the phospholipase-C-gamma-
1 pathway (PLCγ1) via SOS (son of sevenless) and GRB2 (growth factor receptor bound protein 2). Production of the secondary messenger 
DAG then interacts with PKCƟ (protein kinase C theta) and initiates a mitogen-activated protein kinase pathway (MAP3K). This results in the 
activation of IKK (IκB kinase) which phosphorylates inhibitory IκB molecules. This releases the inflammatory transcription factor NF- κB for 
nuclear translocation. PKCƟ is also shown to influence AP-1 transcription activity independent of JNK-dependent activation, and thus links 
NF- κB to AP-1 activity.  
ZAP70- and LAT-associated mediators also phosphorylate the guanine nucleotide exchange factor VAV-1. VAV-1 activates a cascade of 
mitogen-activated protein kinase kinase (MKK) activity which results in the activation of MAPK family members p38 and JNK. These directly 
phosphorylate components of the AP-1 transcription factor complex, which itself modulates inflammatory gene activation. 
An increase in intracellular calcium (Ca
2+) is initially induced through PLCγ1 mediated inositol triphosphate action on endoplasmic reticulum 
receptors (pathway not shown). This initial rise causes an influx of extracellular Ca2
+
 through membrane calcium release activated calcium 
channels (CaCn). Increased Ca
2+
 prevents the inhibitory effects of calmodulin (calm) upon calcineurin. Calcineurin dephosphorylates the 
transcription factor NFAT, which is released into the nucleus and activates gene transcription.  
This diagram is modified from QIAGEN’s original image which can be found at [508]. 
Modifications include adaptations from Figure 1. N.R.J Gascoigne  (2008)
[509]
. 
Chapter 1  10 
 
 
1.3.3 Phenotypic markers of T cell activation. 
T cell activation can be identified by changes in surface receptors expressed at the cell 
membrane. The type II c-lectin superfamily member CD69 is a highly glycosylated 
transmembrane protein that is detectable within 1h of TCR-induced T cell activation
[42]
. CD69 
is also rapidly upregulated by phorbol esters such as PMA (phorbol myristate acetate)
[43]
, 
which by-passes TCR signalling by passing through the T cell membrane and directly 
activating protein kinase C Ɵ (PKCƟ). CD69 expression is maintained for up to 72h post 
activation in T cell cultures
[42]
, yet its true role in the T cell response is under defined. The 
cytoplasmic domain of CD69 is stunted and the accessory signalling components required for 
signal transduction are not fully established. In addition, no definitive ligand for CD69 has 
been identified although in studies of recombinant protein interaction the extracellular domain 
of CD69 has shown binding to galectin which is expressed by DC
[44]
. Despite its strong 
association with activation there is significant evidence that CD69 negatively regulates T cell 
function. Studies have identified a paradoxical re-upregulation of CD69 on terminally 
differentiation cells that progressively lose their functionality (see section 1.6.2), suggesting 
its involvement in inhibiting T cell responses
[45,46]
. In mouse models, when TCR-transgenic 
mice are injected with TCR-specific antigen the activation and proliferation of T cells is 
unaffected by a CD69
-/-
 background
[47]
. Conversely, in a model of inflammatory arthritis 
CD69 deficient mice show an exaggerated disease phenotype
[48]
. There is also evidence that 
CD69 negatively regulates the induction of pro-inflammatory CD4
+
 T cell subsets such as 
Th17 cells via inhibition of subset associated transcription factors
[49]
. 
CD25 is also upregulated upon T cell activation and correlates with an increased sensitivity of 
activated T cells to IL-2. CD25 is upregulated via de novo transcription and is detectable at 6h 
post activation with PMA or anti-CD3 stimulation
[50]
. Therefore, CD25 protein upregulation 
is typically first observed from 6-12h and therefore lags behind CD69, but is maintained for a 
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longer duration
[51]
. Other markers of T cell activation that upregulate later than CD25 include 
the transferrin receptor (CD71) and the MHC II variant HLA-DR
[51]
. 
1.3.4 Memory and antigen recall in the T cell compartment. 
During the resolution of an immune response, populations of clonally expanded effector T 
cells contract in a process that facilitates the maintenance of immunological ‘space’ and 
permits diversity within the T cell repertoire. >90% of activated effector T cells die by 
activation induced cell death (AICD) and studies in CD95 deficient mice have indicated that 
this is mediated by FAS/FAS ligand induced apoptosis
[52,53]
. Mechanisms which govern this 
contraction phase are still incompletely defined, although mouse models of lymphocytic 
choriomeningitis virus (LCMV) and listeria monocytogenes (LM) infection have indicated 
that the contraction of CD8
+
 effector T cells is independent of the antigen load, pathogen 
clearance and the magnitude of the expansion phase
[54]
. In mouse studies it is found that a 
population of 2-10% of effector cells persist to become memory T cells irrespective of the 
pathogen type. The ability to survive the contraction phase may be a characteristic that is pre-
programmed early in the inflammatory response
[55]
 and involve the persistent expression of 
the IL-7 receptor α-subunit (CD127). IL-7 receptor signalling is essential for the homeostatic 
maintenance of memory T cell populations
[56]
. The mechanisms governing the generation of 
long lived memory T cells are controversial and inconsistent between mice and men. Three 
models by which memory T cells are generated are described below. A consistent feature 
between these models is that the T cell memory pool can be divided into two distinct 
populations of central memory (Tcm) and effector memory (Teff) cells based on their 
expression of homing receptors and migratory behaviour. This classic paradigm was first 
proposed by F. Sallusto et al in 1999 and demonstrates that Tcm maintain expression of 
CD62L and CCR7 like Tnaive cells, whereas Teff lose expression of both these markers
[57]
. 
Therefore, although both Tcm and Teff are found in the blood Tcm typically circulate between 
the blood and lymphatics system whereas Teff home to peripheral tissues.  
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 Model 1 – Linear differentiation model 
Early studies of CD8
+ 
T cell differentiation in mice indicated that the generation of memory 
was a linear progression from Tnaive to Tmemory via short lived effector cells
[58,59]
. Following 
LCMV infection effector CD8
+
 T cell populations gave rise to memory Teff which then 
differentiated into lymphoid homing Tcm (Figure 1.2A). Therefore, homeostatic turnover of 
terminally differentiated Tcm populations provide the maintenance of memory. This is in 
keeping with findings showing Tcm have a greater proliferative capacity than Teff
[60]
. However, 
this is inconsistent with other areas of biology where progressive differentiation is usually 
accompanied by a decrease in replicative potential.  
 
 
 
 Model 2 – Asymmetric division model 
This model proposes that activated Tnaive cells divide asymmetrically to generate populations 
of short lived effector cells, memory Tcm and memory Teff populations. This is achieved 
through reorganisation of the mitotic spindles to disproportionally segregate signalling 
proteins and transcriptional regulators amongst Tnaive cell progeny
[61]
. It is proposed that 
asymmetric division is an early event in Tnaive cell activation and is irreversible beyond a very 
few cellular divisions. This model is consistent with early findings by N. Manjunath et al 
(2001). Here a fluorescent GFP reporter which is lost during differentiation showed that long 
lived Tnaive progeny (CCR7
+ 
Tcm) differentiate independently from short lived effector cells
[62]
. 
Figure 1.2A Diagram shows a linear differentiation model of memory T cell formation 
and antigen recall response. Figure adapted from [63]. 
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In addition, the balance between the lineages could be influenced in vitro by exogenous IL-2 
and IL-15 
[62]
. 
 
Figure 1.2B An asymmetric differentiation model of memory T cell formation and 
antigen recall response. Figure adapted from [63]. 
 
 Model 3 – Stem cell-like memory maintenance. 
Memory T cells have historically been compared to stem cells given their ability to self-renew 
to maintain their frequency in the periphery.  Recently, a population stem cell like memory 
cells (TSCM) has been defined
[64]
. These represent 2-3% of both the CD8
+
 and CD4
+
 T cell 
populations and maintain Tnaive characteristics (CD45RA
+
) in addition to stem cell properties 
(c-Kit expression, elevated wnt signalling)
[65]
. However, these TSCM have undergone antigen-
driven clonal expansion, have robust cytokine responses ex vivo and proliferate in response to 
IL-7 and IL-15
[64]
. As these cells are shown to be highly proliferative, multipotent and 
persistent in lymphoid organs it is proposed that they represent the precursors of all effector T 
cells. Therefore, TSCM are pivotal in this latest model of differentiation and as asymmetric 
division is a feature strongly associated with stem cell biology there is some overlap between 
the asymmetric and TSCM models (Figure 1.2C). Although this differentiation model has been 
applied to CD4
+
 T cell biology the majority of understanding comes from work in CD8
+
 T 
cells. There is little work which temporally relates the complex lineage differentiation of 
CD4
+
 T helper subsets (section 1.5.1) to this model of memory formation. 
Chapter 1  14 
 
 
 
 
 
1.3.5 Tissue specific homing of effector memory T cells.   
The primary role of Teff is to elicit rapid effector function at the site of infection (or 
reinfection). In contrast, Tcm populations have a greater proliferative capacity and greater 
resistance to apoptosis, so are more accredited with the maintenance of immune memory
[66]
. 
However, following reactivation the cytokine responses of Tcm populations are shown to be 
almost as robust as their Teff counterparts
[67,68]
. Therefore, the definition of Tcm and Teff is 
largely based on the anatomical location of each population (lymph node versus peripheral 
tissue) as opposed to their functional capacity.  
To provide the most effective immune surveillance effector memory T cells preferentially 
migrate to the tissue where the inflammatory response was initiated. Therefore, a notable 
proportion of these populations are sequestered in the tissues and their representation in the 
blood is an underestimation of their frequency
[69,70]
. Peripheral tissue migration occurs at post-
capillary venules which have endothelial expression of chemokine receptor ligands and 
adhesion molecules. The pattern of adhesion receptors which may recognise these ligands is 
imprinted by activating DC at the time of T cell differentiation
[71]
. The processes that 
Figure 1.2C An ‘self-renewal’ model of memory T cell differentiation via a common 
stem-cell like central memory progenitor (TSCM). Adapted from [510]. 
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underpin T cell recruitment to peripheral tissue can be summarised in the following four 
stages;  
1. Capture – Teff cells are captured onto the luminal surface of the endothelium and are 
slowed against the blood flow. This involves the interaction of endothelial selectin 
molecules with highly glycosylated protein ligands on the T cell surface. These 
ligands can have specific carbohydrate modifications at particular residues that 
increase their specificity. For example, skin homing Teff express a CLA (cutaneous 
lymphocyte antigen) which is a modified form of the more ubiquitous PSGL-1 (P-
selectin glycoprotein ligand-1). This binds P-selectin that is constitutively expressed in 
the vascular beds of the skin
[72]
.  
2. Activation - Selectin-mediated capture causes the T cells to roll along the 
endothelium and permits more firm binding of chemokine receptors. Chemokine 
receptors are transmembrane G protein coupled receptors which transduce an 
intracellular signal upon binding their chemokine ligands
[73]
. These ligands can be 
expressed by vascular endothelium constitutively and/or upregulated in inflammation. 
Chemokine receptor binding activates the cell by elevating intracellular cyclic AMP 
and initiating RHO GTPase and phospholipase C mediated signalling pathways
[73]
. 
Through these pathways integrin receptors are activated via the intracellular protein 
talin and firm adhesion is achieved
[74]
. Chemokine receptor expression is strongly 
associated with tissue specific homing of Teff subsets. For example, CCR4 and CCR10 
expression are associated with skin homing signals via their respective interactions 
with CCL17 and CCL27
[75,76]
. Conversely, CCR9/CCL25 interaction is association 
with intestinal tropism
[77,78]
.  
3. Adhesion – Integrins are heterodimeric transmembrane proteins that become activated 
through chemokine receptor signalling. Conformational changes within integrins 
increase the receptors affinity for immunoglobulin superfamily members expressed by 
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vascular endothelium
[79]. The integrin heterodimer α4β7 binds MAdCAM-1 (mucosal 
vascular cell adhesion molecule 1)
[80,81]. α4β1 (VLA-4) and αLβ2 (LFA-1) preferentially 
bind VCAM-1 (vascular cell adhesion protein 1) and ICAM-1 (Intracellular adhesion 
molecule 1) respectively
[82]
. Integrin binding mediates the firm arrest of T cells on the 
endothelial surface, cytoskeletal rearrangements involved in lymphocyte ‘crawling’, 
and early transendothelial migration events
[83]
.  
4. Transendothelial migration – Two defined modes of transendothelial migration 
(TEM) are the paracellular and transcellular routes
[84]
. Paracellular migration requires 
the crawling of lymphocytes to an endothelial cell-cell interface and remodelling of 
tight junctions to allow passage through the barrier. This is facilitated by ICAM-1-
induced cytoskeletal contraction to pull apart and weaken endothelial tight 
junctions
[84,85]
. In studies of leukocyte extravasation, junctional adhesion molecules 
(JAMs) (which normally dimerise at cell junctions) are shown to interact with LFA-1 
(JAM-A) and VLA-4 (JAM-B/C) to facilitate lymphocyte passage
[86,87]
. Homophilic 
interactions between PECAM-1 molecules (platelet endothelial cell adhesion 
molecule-1) that are expressed by leukocytes and endothelial cells are also a 
significant step in paracellular TEM
[88]
. In contrast, transcellular migration involves 
the passage of immune cells through the middle of endothelial cells, typically where 
the endothelial layer is thin or weakened. ICAM-1 is enriched around the leukocyte 
interface and this induces cytoskeletal remodelling of the endothelial cell
[85]
 which is 
also facilitated by JAM-A and PECAM-1
[89]
. Such interactions form a channel through 
the endothelial cell via the linking of ICAM-1 rich caveolae forming vesiculo-vacuolar 
organelles
[90]
. Therefore, a pore is formed directly through the endothelial cell to 
facilitate diapedesis.  
Once beyond the endothelial barrier the migration of T cells away from the vasculature is 
mediated by tissue-specific stromal factors and chemokine gradients. Interestingly, the 
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persistence of memory T cells within peripheral compartments is not uniform within the 
population. Work examining CD8
+
 memory subsets in organs including the skin, gut, lungs 
and reproductive tracts has identified populations of ‘tissue resident’ memory (TRM) cells that 
are distinct from those which continuously circulated between blood and tissue
[70,91,92]
. 
Parabiosis experiments in mice demonstrate that traceable antigen-specific CD8
+
 T cells from 
each mouse do not readily equilibrate in certain tissues such as the gut mucosa
[93,94]
. This 
implies that these cells do not recirculate between animals and are maintained within the 
donor tissues. TRM are distinctive from Teff as they constitutively express αE integrin (CD103) 
and CD69
[70,95]
. TRM are also characterised in the CD4
+
 T cell compartments, although the 
expression of CD103 in these subsets is not as elevated as in their CD8
+
 counterparts. It is 
proposed that TRM are derived from circulating Teff but the signals that regulate this 
conversion are incompletely defined. As CD69 is more classically associated with T cell 
activation it is possible that the presence of persistent antigen may promote the TRM 
phenotype. However, in a mouse model of lung infection influenza-specific CD4
+
 TRM persist 
in the lungs long after antigen clearance indicating the stability of the TRM population 
irrespective of persistent antigen and inflammation
[96]
.  
Another characterised role of CD69 expression in regulating migration is exemplified in the 
lymph nodes, where activated CD69
hi
 T cells are retained through the inhibition of 
sphingosine-1 phosphate receptor 1 (S1P1) expression
[97]
. S1P1 is required for lymph node 
egress via chemotactic attraction to its ligand (S1P) which is at a higher concentration in the 
circulation than in the lymph. This process is modulated by the drug FTY720 (Fingolimod) 
which blocks S1P/ S1P1 binding and prevents self-reactive T cells leaving the lymph nodes
[98]
. 
However, the reciprocal expression of CD69 and S1P1 or other mediators is not currently 
described in studies of TRM. Alternatively, as CD103 is an integrin subunit it is suggested that 
its adhesion properties may be involved in TRM tissue retention
[99]
. 
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In non-inflamed peripheral tissues the egress of circulating Teff is dependent on their 
upregulation of the chemokine receptor CCR7 which binds CCL21 ligand on the afferent 
tissue lymphatics
[100]
. In human skin up to 50% of skin-derived memory CD4
+ 
T cells express 
CCR7
[69]
. Such a finding is difficult to reconcile with the original definition of Teff cells which 
are distinguishable from Tcm by their lack of CCR7 expression. Interestingly, in vivo studies 
tracing the origins and fate of cutaneous CD4
+
 memory T cells have suggested that a 
population of CCR7
+
CD62L
int 
Teff can recirculate between both the peripheral tissue and the 
lymphatics via the blood
[101]
. These recirculating cells may be distinct from classical Teff that 
lack CCR7 expression and whose fate on tissue entry remains undefined. It is clear that the 
definition of memory can be considered more complex than the Tcm/Teff paradigm
[57]
. 
Processes that drive the generation and migration patterns of memory CD4
+
 T cell subsets are 
essential for the maintenance of long-lasting peripheral immunity. A deeper understanding of 
these mechanisms is essential for the recognition and prevention of aberrant T cell responses 
in inflammatory pathologies. 
1.4  CD8+ T cells and other killer cell subsets. 
CD8
+
 T cells are characterised by their ability to recognise antigens presented by MHC I. 
Expression of the CD8 glycoprotein facilitates this interaction through binding to the non-
polymorphic MHC I α3 domain[102]. As MHC I is associated with the presentation of 
intracellular antigens, CD8
+ 
T cells are most recognised for their cytotoxic response against 
virally infected and transformed tumour cells. Once activated, cytotoxic T cell subsets begin 
producing effector cytokines such as interferon gamma (IFNγ). IFNγ has pleotropic autocrine 
and paracrine functions including; 1) the enhancement of natural killer cell (NK cell) 
activity
[103]
, 2) activation of granulocytes and monocytes
[104]
, 3) T cell subset 
differentiation
[105]
, and 4) the upregulation of adhesion molecules on endothelium to promote 
the trafficking of immune cells to inflamed tissues
[106]
. CD8
+ 
cells produce cytokine and 
proliferate rapidly, initiating target cell killing through release of perforin and granzyme 
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proteins. Perforin punctuates the target cell membrane to allow granzyme entry. This triggers 
a cascade of serine proteases resulting in caspase mediate apoptosis and lethal mitochondrial 
ROS production
[107]
. Alternatively, CD8
+
 T cells can induce caspase-dependent apoptosis via 
upregulation of FAS ligand, which binds to target cells expressing the FAS death receptor 
(CD95)
[108]
. 
NK cell subsets share cytolytic killing features with the CD8
+
 T cell lineage and can eliminate 
infected, stressed and transformed cells. NK cells are part of the innate lymphoid cell family, 
which are derived from lymphoid progenitors but lack a TCR receptor so do not recognise 
antigen specifically. These cells are shown to develop in multiple sites (e.g. bone marrow, 
thymus, lungs and uterus
[109]
) and distinguish stressed from unaffected cells by integrating 
changes in cellular motifs on cell surfaces. These changes are recognised through a multitude 
of self-recognition receptors, for example the KIR family (killer cell immunoglobulin-like 
receptor) which can detect downregulation of MHC I on virally infected cells
[110]
. NK cells 
are often identified by varying surface expression of CD56 and CD161. These markers can 
also identify other innate lymphoid subsets such as natural killer T cells and natural killer-like 
T cells
[111]
. The existence of such populations demonstrates the overlap between innate and 
adaptive immune function. 
1.5  CD4+ T cells. 
1.5.1 CD4+ T cell differentiation. 
By modulating the function of other innate and adaptive immune cells CD4
+
 T cells (Thelper 
cells) are considered master orchestrators of complete immune responses. Upon activation 
Tnaive cells proliferate rapidly forming a pool of multipotent progenitors termed Th0 cells
[112]
. 
This expansion is driven by autocrine and paracrine IL-2 signalling through the IL-2 receptor 
complex. At this phase the IL-2 receptor is converted into its highest affinity state via 
expression of the IL-2Rα subunit (CD25)[113]. During the expansion phase Tnaive differentiate 
into a number of Thelper subsets with specific effector functions. The antigen avidity, duration 
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and input from co-receptors are determinants of this differentiation phase and prime Thelper 
responses to be most appropriate for optimal pathogen clearance. The cytokine milieu 
provided by local APC and other resident cells is dependent on the nature of initial pathogenic 
insult, which in turn polarises the differentiation of Thelper cells
[114]
.  
Cytokines are small soluble proteins that bind to their corresponding cell surface receptors. 
There are many subtypes of cytokine receptors with numerous structural conformations. For 
example, the common gamma chain cytokine family are composed of various combinations of 
heterodimeric or heterotrimeric transmembrane subunits which determine their specificity for 
IL-2, IL-4 IL-7, IL-9, IL-15 and IL-21
[115]
. A common mechanism of cytokine receptor signal 
transduction is via receptor association with Janus kinase (JAK) molecules that phosphorylate 
STAT family members (signal transducer and activator of transcription). Nuclear 
translocation of STATs initiates the transcription of key regulators that determine the 
differentiation pathway of effector Thelper cells (Figure 1.3). However, not all cytokine 
receptors signal via the JAK/STAT pathway. For example, the tumour necrosis factor alpha 
(TNFα) receptors TNFR1 and TNFR2 signal via various adaptor proteins including TRADD 
(TNFR1-associated death domain protein), TRAF2 (TNF receptor-associated factor 2) and 
RIP (receptor-interacting protein). Together with other mediators these activate 
proinflammatory pathways via NF-κB and AP-1 transcription factors and can also mediate 
caspase-dependent apoptotic pathways
[116]
. 
Historically, two ‘flavours’ of T helper cell were described by Mosmann and Coffman which 
were defined as Th1 and Th2 subsets
[117]
. Th1 genes are expressed through Tbet transcription 
factor activity
[118]
 which promotes IFNγ production. In contrast, GATA3 induced IL-4, IL-5 
and IL13 secretion and is characteristic of Th2 subsets
[119]
. These Th2 cytokines promote B 
cell activation, proliferation and class switching. Cytokine-induced polarisation towards a 
particular phenotype is enhanced by inhibiting genes that promote alternative lineage 
differentiation.  For example, IL-4 induced GATA3 expression transiently inhibits IFNγ 
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production and thus limits Th1 differentiation
[120]
. Many additional Thelper subsets have been 
defined in subsequent decades (Figure 1.3). A degree of plasticity between Thelper lineages is 
also documented, where a particular subtype can acquire phenotypic traits of another under 
strong polarising conditions
[121]
. For example, fate mapping experiments in mice have 
demonstrated that under chronic neuroinflammatory conditions (experimental autoimmune 
encephalomyelitis (EAE)), differentiated Th17 cells switch on IFNγ production which is an 
atypical cytokine for this lineage
[122]
. A detailed synopsis of every characterised Thelper 
subtype is beyond the reach of this introduction. However, what is important to note is that 
differentiated CD4
+
 Thelper cells are defined by their ability to make cytokine and this is the 
mechanism by which they elicit their various effector functions.   
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Figure 1.3 Cytokine signalling and CD4
+
 T cell differentiation. Top panel; On interaction with cognate antigen–MHC II complex presented by 
antigen presenting cells (APC), naïve CD4
+
 T cells proliferate to produce a pool of multi-potent progenitor cells (T0). These differentiate to form 
various effector Thelper subsets, which is driven by the presence of cytokines in the surrounding milieu. Bottom panel; Extracellular cytokines 
regulate gene expression through interaction with their relevant receptors at the T cell membrane. Receptor activation induces the activation of 
associated JAKs (janus-activated kinases), which phosphorylate the cytokine receptors cytoplasmic tail. JAK activation can be inhibited through the 
activity of SOCS (suppressor or cytokine signalling) and other PTPs (protein tyrosine phosphatases). Receptor phosphorylation triggers the 
recruitment and phosphorylation of STATs (signal transducer and activator of transcription). STATs dimerise and are translocated to the nucleus 
where they promote the expression of their associated master regulators of T cell programming (top panel). The various transcriptional programs of 
the Thelper lineages are associated with specific patterns of cytokine secretion.  These modulate the behaviour of other immune cells and introduce 
diversity into the way specific pathogens are controlled. 
 
This diagram is an adapted representation of figures presented in [511] (top panel) and [512] (bottom panel). 
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1.5.2 Regulatory CD4+ T cell subsets. 
CD4
+
 T cells have the potential to elicit profound damage to the hosts if their activation is not 
strictly regulated. Therefore, if mechanisms assigned to prevent the generation of dangerous 
and self-reactive T cells in the thymus should fail there are additional processes in the 
periphery to protect against aberrant T cell activation. One such mechanism is the presence of 
regulatory T cell subsets (Treg) which are transcriptionally programmed to modulate the 
activity of other immune cells. Some molecular processes through which regulatory subsets 
suppress inflammatory and autoimmune responses are summarised in Table 1.2.  
Treg either develop naturally during thymic maturation (nTreg) or differentiate in the periphery 
following conventional Tnaive activation (iTreg) (Figure 1.3). Expression of the transcription 
factor FOXP3 is essential for nTreg development in mice and humans. Mice with loss-of-
function mutations in FOXP3 develop fatal multi-organ inflammatory pathologies attributed 
to loss of Treg induced tolerance
[123]
. nTreg gain FOXP3 expression in the medullary region of 
the thymus as indicated by experiments using FOXP3 reporter gene constructs
[124]
. pre-Treg 
programming may occur before the SP thymocyte stage through undefined mechanisms, but 
strong recognition of self-peptide MHC II complex presented by medullary APC is essential 
for nTreg maturation
[125]
. Adequate co-stimulation is important for this process as CD28 
deficiency significantly reduces the frequency of peripheral nTreg
[126]
. Intensive signalling to 
nTreg induces the upregulation of CD25, which rescues the population from negative selection 
through an increased responsiveness to IL-2. Both IL-2 and IL-7 are shown to be important in 
Treg development in mice in conjunction with other stromal factors such as glucocorticoid-
induced TNFR-related protein (GITR) and lymphopoietin
[124]
. nTreg thymic emigrants are 
phenotypically naïve and are recognised by CD45RA
+
CD25
hi
CD127
lo
FOXP3
lo
 expression in 
humans
[127]
. When activated naïve nTreg differentiate into effector Treg (CD45RA
-
) they 
upregulate FOXP3 and co-inhibitory mediators. These can limit proinflammatory responses in 
the local environment (Table 1.2).   
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Treg marker/ 
molecular 
signature 
Mechanism Target Outcome Ref 
CTLA-4  
Competitive inhibition of CD28 mediated co-
stimulation. Reduced presentation of 
CD80/CD86 by APC 
T cells ↓ TCR costimulation [128,129]  
IDO production by DC - altered tryptophan 
metabolism 
 T cells ↑ anergy, ↑ apoptosis 
[130,131]  
Treg ↑ Treg activity 
CD73-CD39 
Sequential extracellular metabolism of 
adenosine. Binds A2A receptors on both 
conventional T cells and Treg. 
CD4
+
 T cell 
↓ TCR signalling ↓ IL-2 signalling [132]  
↑ CTLA-4 expression  
[133] 
↑ PD-1 expression  
Treg ↑ FOXP3 expression  [134] 
CD25  Sequestration/consumption of IL-2   T cells 
↓ IL-2 signalling and effector cell 
proliferation 
 [135] 
Granzyme/perforin Cytolysis of target cell - cell death  T cells 
↓ Effector cell availability 
[136,137] 
FASL FAS/FAS ligand induced apoptosis - cell death 
 CD8
+
 T 
cells 
[138] 
TCR-peptide MHC 
binding 
Bystander effect DC 
Prevents DC interaction with effector T 
cells 
[139] 
Cytokines 
IL-10 Modulation of DC function, polarisation of 
effector T cell differentiation 
DC ↓CD40, ↓IL-12, ↑ IL-10, ↓CD80/CD86,  
Reviewed 
in [140]  
TGF-β CD4
+
 T cell ↑ Treg differentiation [141,142]  
IL-35* 
Enhances Treg survival and IL-10 production 
(*is not expressed by human Treg) 
CD4
+
 T cell ↓ Th1, Th17, ↑ Treg differentiation [143]  
 
    Table 1.2 Summary of some notable molecular mechanisms associated with regulatory T cell function.  
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Like conventional CD4
+
 T cells the differentiation of nTreg can be polarised by the local 
cytokine milieu to optimise their suppressive function. For example, co-expression of FOXP3 
and GATA3 by effector Treg is important in suppressing Th17-mediated inflammation
[144]
. 
Selective deletion of STAT3 in intestinal FOXP3
+
 Treg, which increases susceptibility to Th17 
driven inflammation in a model of colitis
[145]
. The effector Treg pool can also be divided into 
circulating and tissue resident subpopulations and CD103
+
 subsets are enriched in the skin 
and lungs
[146,147]
. Whereas naïve Treg can represent around 10% of circulating CD4
+
 T cells in 
adults, effector Treg represent only 1-4%. Similar to Thelper cells the naïve Treg population 
decreases with age in line with thymic involution whereas the effector pool is expanded. In 
contrast to nTreg, the iTreg population are derived from conventional naive CD4
+
 T cells in the 
periphery and only contribute to the effector Treg pool
[148]
. The nTreg and iTreg populations are 
phenotypically similar, making it challenging to distinguish between the populations in the 
periphery. Conventional CD4
+
 T cells also transiently upregulate CD25 and FOXP3 during 
activation which adds further to the complexity of separating these populations
[51,149]
. 
Interestingly, CD25
hi
FOXP3
+
 Thelper cells share features with Treg which is informative about 
their biology. Mouse Treg can be hyporesponsive to in vitro stimulation so historically the 
population was synonymous with an anergic T cell phenotype
[150]
 (see section 1.6.1). 
Subsequent studies have demonstrated that conventional CD25
hi
FOXP3
+
 Thelper cells also 
show abrogated cytokine secretion and proliferation in vitro, indicating that FOXP3 
upregulation may negatively regulate T cell activation
[151]
. FOXP3 also influences the 
expression of NFAT family member NFATc2. TCR-induced upregulation of NFAT drives 
FOXP3-dependent inhibition of cytokine production (IL-2) and forms a negative-feedback 
loop further suppressing NFAT activity
[152,153]
.  
FOXP3 expression has a significant role in Treg homeostasis and Treg have a higher 
proliferative capacity than conventional CD4
+
 T cells in vivo. In mice CD25
hi 
Treg incorporate 
more BrdU dye into their replicating DNA than non-Treg subsets which indicates that they 
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undergo more mitotic divisions
[154]
. Analysis of human blood populations shows that a greater 
percentage of Treg express the proliferation marker Ki-67 than non-Treg
[155]
. This higher 
proliferative capacity is offset by an accelerated rate of apoptosis which maintains Treg 
homeostasis, particularly following clonal expansion
[156]
. Treg have an intrinsic propensity to 
undergo apoptosis through their expression of FOXP3, which promotes the expression of pro-
apoptotic BCL-2 family members Bim and PUMA
[157]
. Bim and PUMA antagonise the effects 
of anti-apoptotic Mcl-1 which releases Mcl-1-dependent inhibition of apoptosis initiators 
BAX and BAK
[158]
. This intrinsic apoptosis pathway is counterbalanced by IL-2 availability 
and production by other local effector T cells. IL-2 signalling via CD25 overrides the activity 
of Bim and PUMA by promoting Mcl-1 activity, thus inhibiting the apoptosis pathway. The 
Treg population then expands until the local IL-2 is depleted through the suppression of 
effector cells. FOXP3 pathway again predominates and thus a feedback mechanism is 
provided by which Treg homeostasis is maintained
[156]
.  
Although FOXP3 is important in maintaining some Treg populations the suppressive function 
of Treg cannot be wholly attributed to FOXP3 expression. Conventional CD4
+
 T cells which 
upregulate FOXP3
+
 do not actively suppress other non-Treg cells in vitro
[151]
. Other regulatory 
populations have also been described that lack expression of FOXP3 or CD25. For example, 
Tr1 regulatory cells are characterised by their expression of anti-inflammatory IL-10 
cytokine
[159]
. Tr1 cells may also be derived from Th17/Th1 lineages in chronic inflammatory 
conditions and their suppressive function may have a role in inhibiting autoimmune 
responses
[160,161]
. In contrast, a characterised Th3 regulatory subset is predominantly defined 
by TGF-β-mediated suppression[162].  
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1.6 T cell hyporesponsiveness and its implications for T cell-mediated 
immunity. 
1.6.1 T cell anergy as a form of peripheral tolerance. 
T cell intrinsic mechanisms have been characterised which limit T cell activation and promote 
tolerance. The concept of ‘anergy’ describes how CD4+ T cells become hyporesponsive to 
TCR stimulation in the absence of sufficient co-stimulation
[163,164]
. This is a protective 
mechanism by which TCR recognition of self or non-pathogenic peptides will not trigger an 
immune response without additional ‘danger signals’ from mediators upregulated in 
inflammation. Some in vitro models of anergy induction include; 1) TCR stimulation with 
anti-CD3 coated beads in the absence of anti-CD28
[165]
, 2) low affinity peptide presentation 
by APC
[166]
, 3) peptide presentation by quiescent APC (e.g. resting B cells)
[167]
, 4) induction 
of calcium dependent pathways by the calcium ionophore ionomycin
[168]
. A unifying 
mechanism behind the hyporesponsiveness in these models is an imbalance of signalling, 
leading to a combination of exacerbated NFAT transcription factor activity and diminished 
contribution of AP-1
[169]
. AP-1 assembly and translocation is required for IL-2 production 
which is abrogated through deficiencies in upstream MAPK activity.  
As NFAT signalling is Ca
2+
 dependent, its role in the anergic pathway is demonstrated 
through the hyporesponsive state induced by ionomycin. Conversely, anergy is reversed by 
the calcineurin inhibitor cyclosporine A which blocks NFAT activity
[170,171]
. Over activity of 
NFAT promotes the expression of E3 ubiquitin ligases Cbl-b, GRAIL and ITCH
[172]
. Gene 
knock out mice for these ubiquitin ligases have  anergy-resistant T cells which are hyper-
responsive to TCR 
[173–175]
. Ultimately these mice develop severe early onset multi-system 
autoimmunity, thus exemplifying the importance of anergising processes in the maintenance 
of self-tolerance. E3 ligases function by tagging ubiquitin motifs on to signalling components 
involved in TCR transduction
[164]
. Ubiquitination targets these proteins for proteasome 
degradation thus preventing TCR signalling. Cbl-b is shown to dephosphorylate and 
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ubiquitinylate PLC-γ and so inhibits Ca2+ signalling in the anergised state[176]. Both ITCH and 
another related E3-ligase NEDD4 monoubiquitinylate PKCƟ and PLC-γ, with the latter 
disrupting LAT-associated signalling
[177]
. LAT then cannot translocate to the ‘immunological 
synapse’ (IS) which represents the foci of signalling molecules clustered around the TCR 
complex upon antigen recognition. In anergic cells LAT is excluded from the lipid raft 
membrane formations required for its recruitment to the IS
[178]
.  Cbl-b also inhibits IS 
recruitment through the ubiquitination of PI3K (phosphoinositide 3-kinase) which prevents 
the interaction of CD28 with the TCRζ chains[179]. In addition, Cbl-b negatively regulates 
VAV-1 which prevents the cytoskeletal rearrangements required for trafficking of TCR 
signalling component
[180,181]
. The function of Cbl-b overlaps with GRAIL with both reducing 
JNK transcription factor activity. GRAIL also inhibits actin cytoskeletal remodelling by 
inhibiting RHO GTPase, which itself is essential for actin polymerisation
[182]
.  
The physiological translation of the anergic T cell phenotype is controversial. In vivo mouse 
models of anergy include; 1) injection of superantigen SEB (staphylococcal enterotoxin B), 
which binds the TCR Vβ8 repertoire to MHC II with high affinity in an antigen independent 
manner
[183]
 leading to prolonged overstimulation of Vβ8 T cells. 2) the adoptive transfer of 
transgenic T cells into a host that expresses the cognate antigen endogenously (e.g. tumour 
antigens)
[184]
, and 3) immunisation with soluble peptide in the absence of adjuvant into 
transgenic animal which recognise that peptide
[185]
. It is speculated that the hyporesponsive T 
cell phenotype is governed by variable molecular mechanisms in these different models
[186]
. 
Biochemical inconsistencies between the in vivo versus in vitro anergic state are also 
described
[187]
. Firstly, in vivo anergy can be induced in naïve T cell subsets whereas the nature 
of in vitro anergy describes hyporesponsiveness in effector subsets that don’t respond to a 
restimulation event. Secondly, in vivo hyporesponsive T cells require chronic persistence of 
cognate antigen in the periphery to remain ‘tolerised' but reverse their anergic-like state 
following antigen clearance
[188]
. In contrast, reversal of in vitro anergy is unrelated to antigen 
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removal but requires the presence of IL-2
[189]
. Addition of IL-2 restores AP-1 related 
pathways and inhibits the expression of anergy-related genes. Lastly, in in vivo anergy TCR 
signalling defects are further upstream than in cell culture systems and include diminished 
phosphorylation of ZAP70 as opposed to defects further down in the MAPK chain
[190]
. In 
light of these differences R.H Schwartz et al have redefined in vivo anergy as ‘adaptive 
tolerance’[187,188,190]. However, the phenomenon of adaptive tolerance in human physiology is 
under defined and no true ‘tolerised’ CD4+ T cells have been identified ex vivo.  Further 
understanding hyporesponsiveness in T cell populations has implications for peripheral 
tolerance, mechanisms underpinning autoimmunity and initiating factors that drive the failure 
of anti-tumour responses.  
1.6.2 T cell exhaustion. 
In addition to the mechanisms of T cell suppression required for the maintenance of self-
tolerance ‘exhausted’ T cells also demonstrate a hyporesponsive phenotype with distinctive 
characteristics. T cell ‘exhaustion’ describes a progressive decline in functionality in response 
to chronic antigen stimulation such as persistent viral load or in a tumour microenvironment. 
Processes which underpin T cell exhaustion are best defined in the CD8
+
 T cell subset, with 
chronic LCMV infection in mice commonly used as a model for inducing the exhausted 
state
[191]
. In humans an analogous phenotype is also recapitulated in Hepatitis C (HCV) or 
human immunodeficiency virus (HIV) infection. In contrast to T cell anergy or tolerance, 
exhaustion is characterised by a progressive step-wise cessation of functionality, beginning 
with reduced proliferation and IL-2 production, followed by loss of TNFα and IFNγ 
secretion
[46]
. In infection, high antigen load and excessive co-stimulation promote the 
exhausted phenotype and so different exhaustion models show variable outcomes depending 
on the severity of infection. For example, IFNγ production in HIV is maintained but 
accompanied by a loss of cytotoxic function whereas HCV infection is associated with 
diminished IFNγ expression[192–194].  
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Exhausted CD8
+
 T cells express a host of inhibitory receptors including PD-1 (programmed 
cell death receptor 1), TIM-3 (T cell immunoglobulin mucin-3), LAG-3 (lymphocyte-
activation gene 3) and CTLA-4
[195]
. Of these PD-1 is the most extensively studied and has a 
significant role in dampening anti-tumour responses
[196]
. PD-1 interacts with the ligands PD-
L1 or PD-L2 which are highly represented in some tumour microenvironments
[197]
. The 
binding of PD-1 to its ligands induces phosphorylation of its cytoplasmic tail which recruits 
tyrosine phosphatases such as SHP-1 and SHP-2
[198]
. The localisation of these phosphatases to 
TCR microdomains results in dephosphorylation of important proximal signalling 
components such as ZAP70, which then prevents T cell activation
[199]
. PD-1 activation also 
induces cell cycle arrest in G1-S phase though AKT inhibition and induction of the cyclin-
dependent kinase (CDK) inhibitor p27
[200,201]
. Attenuation of AKT signalling also inhibits the 
anti-apoptotic Bcl family member Bcl-xL, which increases a cells propensity to undergo 
apoptosis.  
PD-1 is an associative but not definite marker of exhaustion as it is also upregulated on 
functional T cells where it may serve to attenuate T cell activation
[202,203]
. Consistent with its 
association with activation CD8
+
 T cells acquire PD-1 expression in the early stages of 
chronic infection and PD-1 or PD-L1 antibody blockade rescues the exhaustive phenotype at 
this point
[204]
. Additionally, transfer of murine PD-1
hi
 CD8
+ 
cells from a LCMV
+
 host to a 
pathogen free donor reverses the exhausted phenotype if sufficiently early in the immune 
response
[205]
. However, in chronic infection these PD-1
hi
 cells further differentiate and alter 
their transcriptional profile through upregulation of the transcription factor eomesodermin and 
downregulation of Tbet
[206]
.  At this stage cells fail to proliferate without persistent antigen 
presentation and cannot be maintained homeostatically by IL-7 and IL-15. These cells do not 
survive on adoptive transfer and are beyond the point of rescue by PD-1 intervention. 
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The physiological rationale behind the persistence of exhausted T cells in the periphery is 
unknown. The fact that exhausted cells accumulate and are not cleared from the body suggests 
that they have some immunological relevance. The progression to ‘exhaustion’ may serve to 
prevent excessive collateral inflammatory damage in response to viral infection by self-
limiting the anti-viral response. Therefore, although the ability to clear virus declines, filling 
of the CD8
+
 T cell niche with exhausted cells may represent a trade-off to minimise damage 
and prevent autoimmunity 
[207]
. However, in the context of anti-tumour immunity the 
accumulation of exhausted T cells is considered to be deleterious with their inhibitory 
receptors presenting an attractive target for anti-cancer therapies
[208,209]
.  
Although exhaustion is classically associated with CD8
+
 T cells an exhausted CD4
+
 T cell 
phenotype is described. Shared features between the CD4
+ 
and CD8
+ 
subsets include high PD-
1 and inhibitory receptor expression, but transcriptional profiling studies have demonstrated 
notable differences in their transcription factor activity and the nature of their loss-of-
function
[210]
. The importance of the relationship between the CD4
+
 and CD8
+
 compartments 
in exhaustion is also documented. Robust CD4
+
 T cell responses are essential for providing 
sufficient help to the CD8
+
 compartment
[211]
 and virus-specific CD4
+
 T cells restore the 
function of exhausted CD8
+
 T cells in murine LCMV infection
[212]
. Conversely, Treg  activity 
enhances CD8
+
 T cell exhaustion and hampers viral clearance
[213]
. Treg cytokines such as IL-
10 and TGFβ also have a role in promoting exhaustion in chronic viral infection[214,215]. As the 
understanding of CD4
+
 T cells in exhaustion lags behind that of their CD8
+
 counterparts, 
further examining their behaviour is essential and has implications for anti-viral vaccine 
development and cancer therapeutics.   
1.6.3 T cell senescence. 
Senescence describes dysregulated cellular responses caused by environmental stressors 
which inhibit normal growth and differentiation. Ageing and senescence are inextricably 
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linked due to cumulative cellular stresses that occur over time. However, by limiting the 
replication of aged cells that are exposed to repeated DNA damaging events senescence 
ultimately serves to prevent oncogenesis
[216,217]
. T cell dysfunction in senescence significantly 
contributes to diminished immunity and vaccine responses in elderly populations. In addition, 
chronic infection, cancer and other immunological stressors which drive differentiation 
accelerate senescence in T cell subsets. For example, the age-associated senescent T cell 
phenotype is reproducible in young individuals with chronic HIV and CMV infections
[218,219]
. 
CMV seropositivity also correlates with increased comorbidity and mortality in ageing
[220]
. 
Modelling of senescence in mice is limited by their shortened life span, replicative differences 
in T cell turnover and the lack of pathogen-driven T cell proliferation in sterile housing 
facilities.  Therefore, studies which contribute to the current understanding of T cell 
senescence are often modelled on a background of chronic infection in humans.  
Senescence is classically attributed to the shortening of telomeres, which are repeated 
hexameric sequences at the end of chromosomes that protect DNA integrity. T cells 
upregulate telomerase activity following activation which preserves telomere length during 
clonal expansion and homeostatic cell division
[221]
. However, replicative T cell senescence is 
associated with diminished telomerase activity and DNA damage
[222]
. Together this causes 
cell cycle arrest at G1 phase through an elevation in CDK inhibitor activity, including p16, 
p21, p38 and p53 proteins
[217,223]
. Senescent T cells are commonly characterised by loss of 
CD28 and CD27 expression. In long term cell culture experiments most senescent CD8
+
 T 
cells are CD28
-
 and  CD27
-
CD28
-
 cells are more frequent in elderly individuals
[224,225]
. 
Although diminished CD28 signalling itself inhibits telomerase activity this alone is 
insufficient to define where their terminal differentiation ends and senescence begins
[226]
.  
CD27
-
CD28
-
 CD4
+
 and CD8
+
 T cells can elicit robust IFNγ responses despite a reduced 
replicative capacity
[227,228]
. Therefore additional distinguishing features of senescent T cells 
include; 1) gain of CD57 expression, which is inversely associated with the loss of CD28 on 
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HIV-specific senescent T cells
[229]
, 2) the inability to facilitate B-cell responses through loss 
of CD40L expression
[230]
, and 3) expression of killer cell lectin-like receptors, which promote 
NK cell-like cytolytic activity that is independent of TCR activation
[231]
.  
As exhaustion and senescence are modelled in the same systems it is questioned whether they 
are interrelated
[232]
. Despite an apparent connection between exhaustion and senescence there 
is evidence that biochemically these represent independent cellular states. Firstly, effector 
cytokine expression is systematically lost in exhaustion but senescent T cells maintain 
dysregulated cytokine profiles. The latter is partially attributed to a lineage skewing towards a 
Th1 phenotype
[227,233]
. Secondly, there is evidence that senescent T cells are resistant to 
apoptosis in vitro whereas exhausted cells are highly prone to cell death
[234]
. This is consistent 
with the accumulation of CD27
-
CD28
- 
T cells in ageing, but the anti-apoptotic signals that 
maintain the population are not fully elucidated in vivo. Lastly, PD-1 signalling has a 
significant role in T-cell exhaustion but is not classically associated with senescence. 
Although PD-1 activity leads to inhibition of CDK activity via p27, senescence blocks cell 
cycle processes via alternative CDK inhibitors
[200,232,235]
.  Despite this distinction, functional 
block of PD-1 is shown to inhibit telomere shortening and increases telomerase activity in 
HIV-specific CD8
+
 T cells, thus supporting a connection between exhaustion and 
senescence
[236]
.   
Whether induced through senescence, exhaustion, or anergy-related processes there are 
circumstances where hyporesponsiveness in the T cell compartment may be considered 
beneficial or detrimental to the immune response. There is evidence that common modalities 
contribute to diminished T cell activity and mechanisms of hyporesponsiveness may 
synergise, thus exacerbating a cells deactivated phenotype
[232]
. This has contributed to 
discontinuity in the literature regarding the classification of each state, particularly regarding 
the CD4
+
 T cell subset. Additionally, there is little insight into the frequency or characteristics 
Chapter 1  35 
 
of hyporesponsive T cells in normal adults in the absence of ageing or chronic infection. In 
my investigation CD4
+
 T cells that fail to produce cytokine responses in vitro are examined 
for features that may account for their altered behaviour, including those related to anergy, 
exhaustion and senescence.  
1.7  Immune Privilege – Tissue-mediated T cell suppression. 
Tissues described as ‘immune privileged’ have an intrinsic inability to regenerate and have 
multiple tolerogenic mechanisms protecting them from immune-mediated inflammatory 
damage. The ovaries, testis, placenta, eye and central nervous system (CNS) are traditionally 
considered to be immune privileged sites, where tissue explants are less readily rejected than 
in other non-privileged sites
[237,238]
. In the context of supressing T cell responses in the ocular 
compartment some notable mechanisms associated with immune privilege include; 
 Physical barriers (e.g. the blood-retinal barrier) - Endothelial and basement 
membrane modifications such as tight junctions and the impermeable ‘Bruch’s 
membrane’ prevent immune cell access and prevent dissemination of tissue specific 
antigens
[239]
. The absence of lymphatics network prevents antigen drainage into nearby 
lymph nodes. 
 Constitutive expression of inhibitory T cell ligands – Ocular tissue presents PD-L1 
and FASL which promotes apoptosis of infiltrating PD-1
+
 and FAS
+
 T cells
[240,241]
. 
 Production of soluble T cell mediators – Secretion of anti-inflammatory TGFβ into 
the ocular fluid compartments suppresses T cell activation whilst promoting Treg 
induction. Production of VIP (vasoactive intestinal peptide) and IDO also promotes 
Treg activity whilst inhibiting inflammatory pathways
[242–244]
.  
 Downregulation of antigen presentation – MHC I expression is restricted in ocular 
tissues
[245]
. Cytotoxic T cells are ignorant to the presence of their antigen which 
prevents cytolytic damage of ocular tissue. 
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Whilst upholding evidence supporting the aforementioned adaptations, immune ‘privilege’ 
may now be considered inappropriate phraseology to describe some tissue sites included in 
the original definition. Dynamic interaction between immune privileged tissues and resident 
or infiltrating immune cells is now described. This is well described in the CNS which may be 
considered more immune ‘modified’ than immune ‘privileged’ per se[246]. Evidence that T 
cells are recruited to the CNS in both health and disease has significant implications for the 
understanding of CNS immunity. 
1.8 T cell migration into the central nervous system. 
The CNS was historically regarded as ‘immune privileged’ and disconnected from peripheral 
immune processes in the absence of pathology. It is now established that the CNS has an 
absolute requirement for immune surveillance and that resident and infiltrating immune cells 
contribute to immune homeostasis and support neuronal function. There are approximately 
1000 leukocytes per ml of cerebrospinal fluid (CSF) and 60% of these are lymphocytes
[247]
. 
CD4
+
 T cells strongly predominate this lymphocyte compartment and are over represented in 
the CSF comparative to the blood
[247,248]
. Naïve CD4
+
 T cells are largely excluded from the 
CSF compartment with the population mostly composed of a Tcm phenotype as defined by 
expression of CD45RO
+
 with CCR7
+ 
or CD27
hi[247,249]
. It is proposed that the homogeneity of 
this population is achieved through selective recruitment of T cells from the blood to CSF
[250]
. 
However, endothelial modifications associated with CNS vasculature (collectively referred to 
as the blood brain barrier; BBB) were once thought to inhibit T cell migration completely. 
Although the fundamental concepts of this model hold true this ideology is now considered 
over simplistic as the CNS vasculature is not uniform. Therefore, the BBB properties (as they 
are classically defined) are only applicable to distinct areas of the CNS and spinal cord 
microvasculature
[251]
. By studying the migration of encephalitogenic T cells across cerebral 
microvessels investigators have identified sites where CNS T cell migration can occur
[252]
. 
These sites include the blood-leptomeningeal barrier (BLMB) and blood-cerebrospinal fluid 
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barrier (BCSFB) which are well characterised in the context of T cell migration by B. 
Engelhardt and R.M Ransohoff (2012)
[253]
. The structure and molecular motifs associated 
with CNS barriers are described below in line with current understanding of homeostatic T 
cell migration.  
1. The blood brain-barrier (BBB). 
 The BBB represents a collection of structural adaptations associated with the CNS 
parenchymal spinal cord microvasculature
[254]
. Tight and adherins junctions between 
endothelial cells and a dense basement membrane (basal lamina) are the initials barriers to 
migrating T cells. Embedded within the basal lamina are pericytes, which contribute to tight 
junction formation, extracellular matrix secretion, vascular flow control and can phagocytose 
cellular debris and pathogens
[255,256]
. The inner most barrier is the glia limitans perivascularis, 
which is compose of astrocyte cell formations in the outermost parenchymal layers
[257]
. 
Astrocyte ‘foot end’ cellular projections associate with the basal lamina ensheathing the 
vasculature. At the level of capillaries these structures are tightly fused together to form the 
‘neurovascular unit’[258]. However, arteriolar branches penetrating the brain parenchyma may 
have perivascular spaces (PVS) between the endothelial layer and glia limitans 
perivascularis
[259]
. PVS are also seen in the post-capillary venules, which are the primary site 
of T cell migration in the periphery. PVS are continuous with the subarachnoid space and are 
filled with cerebrospinal fluid (CSF) which allows molecular exchange between the CSF and 
interstitial fluids
[260,261]
. Within the PVS there are CD11c
+
 dendritic cells and perivascular 
macrophages which can process CNS antigen
[262,263]
. These PVS cells are continuously 
replenished by recruitment from the circulation whereas parenchymal microglia are 
embryonically-derived and self-maintained. 
Perivascular macrophages are phenotypically similar to microglia and both cell types express 
the markers F4/80, MHC II and CD11b
[264]
. CD45 can be used to distinguish between these 
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populations as elevated expression is observed upon peripherally-derived perivascular 
populations
[265,266]
.   
In the absence of endothelial activation only pre-activated T cells can cross the BBB, as 
demonstrated by live intravital imaging of BBB migration across spinal cord microvessels. 
When encephalitogenic Th1 cells are traced this way the migration rate is extremely 
inefficient and dependent on VLA-4/VCAM-1 interaction with subsequent LFA-1/ICAM-1 
signalling
[252]
. The latter may have a role in extravasation by facilitating T cell ‘crawling’ to 
BBB regions that are permissive for TEM
[267]
. Breach of the BBB is strongly associated with 
neuroinflammatory diseases such as multiple sclerosis (Section 1.11).  
 
 
2. The blood-leptomeningeal barrier (BLMB). 
The BLMB describes the vasculature associated with the meningeal vessels. Here vessels 
traverse the subarachnoid space between the arachnoid mater (dura and skull side) and the 
glia limitans superficialis (parenchymal side). The glia limitans superficialis and 
perivascularis represent analogous structures at distinct anatomical locations, although the 
former has an additional ‘pia mater’ membrane[268]. Pia mater is fluid-impermeable and 
retains the CSF within the subarachnoid cavities. The subarachnoid space is densely 
Figure 1.4A CD4
+
 T cell migration across the blood brain barrier (BBB). Figure 
represents an adaptation from [253]. 
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populated with MHC II
+
 APC suggesting antigen presentation is highly significant 
here
[269,270]
. Murine intravital microscopy studies show activated T cells accumulate within 
the leptomeningeal compartments rapidly after adoptive transfer irrespective of their antigen-
specificity
[252]
. This mode of migration is inefficient without prior endothelial activation, but 
such work suggests that T cell migration across the BLMB is more permissive than the BBB. 
This is consistent with differential patterns of endothelial adhesion molecule expression 
between the vasculatures. P-selectin is constitutively expressed by the BLMB endothelium 
and is upregulated in inflammation, which facilitates the ‘capture’ phase of T cell 
migration
[252,271]
. BLMB and BBB endothelium are also exposed to differential rates of blood 
flow. Vascular flow is shown to alter endothelial permeability, tight junction formation and 
adhesion molecule expression which may influence migration kinetics
[272,273]
. Despite these 
observations other studies have found a complete absence of T cell adhesion to  resting 
BLMB vasculature in mice
[274]
. Therefore, the BLMB is unlikely to be the primary route of T 
cell migration into CNS without underlying inflammatory processes. 
 
 
 
 
Figure 1.4B CD4
+
 T cell migration across the blood leptomeningeal barrier 
(BLMB).  Figure represents an adaptation from [253]. 
Chapter 1  40 
 
3. The blood-cerebrospinal fluid barrier (BCSFB). 
The BCSFB typically refers to the barrier between the blood and CSF at the anatomical level 
of the choroid plexus (CP). The CP is a highly villous ependymal epithelial structure that 
encloses a dense network of fenestrated capillaries. The CP forms out pouches of the 
ventricular lining and hangs into the lateral, 3
rd
 and 4
th
 ventricles
[275]
. The CP produces CSF 
through diffusion, selective transport and secretion of plasma molecules across the epithelial 
surface into the ventricular space. For migrating T cells to pass from blood to ventricles they 
must firstly cross the CP microvasculature. CP capillaries are fenestrated so migration here is 
more permissive than at the BBB and BLMB
[276,277]
. Secondly, an extravasation step across 
the epithelium (basolateral to apical side) is required. This is rate limiting due to a network of 
inter-epithelial tight junctions
[278,279]
. Dendritic cells and macrophages are also found within 
the CP stroma and at the apical surface of CP epithelium
[280,281]
. The association of APC with 
the CP again demonstrates the importance of CNS antigen presentation in the CSF 
compartment.  
CD4
+
 T cells are associated with the CP stroma in both unchallenged mice and normal post-
mortem human CP tissue
[271,282]
. As there is continuous flow of CSF from the ventricles 
throughout the subarachnoid and perivascular cavities the CP is considered as the primary 
source of CSF T cells in healthy individuals. The cellular composition of CSF is consistent 
when sampling from the ventricles or the lumbar spine region which supports this theory
[283]
. 
Despite these observations the molecular mechanisms behind CD4
+
 T cells recruitment via 
the BCSFB are not fully elucidated. Most candidate chemokine and adhesion molecules 
linked to BCSFB migration are associated with the epithelial barrier and stroma but not the 
endothelial layer. These include VCAM-1 and ICAM-1 which are restricted to the apical 
surface of the CP epithelium in normal mice
[284]
. Therefore, these are more likely to have a 
role in late diapedesis or tethering T cells to the ventricular walls than early stage TEM per se. 
The majority of CSF CD4
+
 T cells express CCR7 so a role for this receptor in BCSFB 
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migration has been proposed
[247,271]
. However, reports investigating the localisation of CCR7 
ligands CCL19 and CCL21 in CNS are conflicting. In mice, constitutive expression of CCL19 
but not CCL21 is shown in brain and spinal cord post capillary venules whereas both CCL19 
and CCL21 upregulate in EAE
[285]
. Similarly, CCL19 mRNA has been detected in non-
diseased human brain homogenates and is upregulated in neuroinflammation, but here there 
was no involvement of CCL21 irrespective of disease status
[286]
. This is in contrast to a study 
by P. Kivisakk et al (2004) where a positive immunofluorescence signal for CCL21 is 
reported at the CP epithelium in normal human post-mortem brain tissue
[249]
. Specific CCL21 
expression at the CP suggests that if BCSFB migration is CCR7-dependent this ligand has a 
more dominant role than CCL19. 
P-selectin is one of few ligands that are definitively associated with uninflamed CP 
endothelium
[271]
. This is localised to larger stromal venules of the CP but not the microvessels 
as identified by immunohistochemistry performed on post-mortem human tissue
[271]
. Studies 
of P-selectin
-/-
 mice show that the accumulation of CD4
+
 T cells observed within the CP is P-
selectin dependent
[252]
. Human CSF T cells are also shown to express higher levels of the P-
selectin ligand PSGL-1 than T cells in the blood which supports P-selectin/PSGL-1 
involvement in BCSFB recruitment 
[271,287]
.  
Chemokine receptors are fundamentally important for T cell transmigration (section 1.5.5). 
However, although CXCR3
+
 CD4
+
 T cells are enriched in uninflamed CSF the receptor 
requirements for homeostatic BCSFB migration are not defined
[288]
. In contrast, a plethora of 
chemokine receptor interactions are associated with pathogenic T cell infiltrates in multiple 
sclerosis and are discussed in Section 1.11.  
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1.9 The role of T cells in CNS immune surveillance. 
The primary function of CSF T cells is to perform immune surveillance and this proposal is 
supported by numerous findings. Firstly, the presence of MHC II
+
 APC in the CSF space 
suggests these cells interact and activate CD4
+
 T cells in situ
[289]
. Secondly, 
immunocompromised individuals are predisposed to CNS infection and tumours
[290]
. Lastly, 
pharmacological block of T cell migration into CNS can result in reactivation of latent 
endemic viruses. Treatment of MS patients with the α4-integrin inhibitor Natalizumab can 
result in loss of John Cunningham virus (JC virus) control in the brain leading to 
oligodendrocyte death and fatal demyelination
[291]
.  
In order to appreciate how CSF CD4
+
 T cells can perform immune surveillance their access to 
parenchymal antigens (via APC), residency within the CNS compartment and their 
recirculation back to the periphery require consideration. Parenchymal protein antigens in the 
associated interstitial fluid (ISF) are largely separated from the CSF compartment. However, 
injection of fluorescence tracers into the CSF can be tracked to the parenchymal 
interstitium
[292]
. This shows that the ISF and CSF interconnect in the perivascular spaces 
providing access for perivascular APC to uptake and present soluble CNS antigens to T cells. 
An elegant analogy by B. Engelhardt et al (2011) describes the processes required for 
Figure 1.4C CD4
+
 T cell migration across the blood cerebrospinal fluid barrier 
(BCSFB)   at the choroid plexus. Figure represents an adaptation from [253]. 
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immune surveillance as the workings of a medieval castle
[257]
. Activated T cells cross the 
outer walls of the castle, which represents normal homeostatic routes of migration (BCSF, 
BLMB). In the CSF space (castle moat) macrophages and DC (castle guards) may present 
CNS antigens to the patrolling T cells to inform them of any dangers to the castle inhabitants 
(neurons). If their specific antigen is presented by the guards the patrolling T cells become 
activated and open the outer walls (BBB endothelial activation) to let in more troops. 
Cytokines released by the T cells further activate myeloid cells which secrete factors such as 
matrix metalloproteinase enzymes (MMP) that facilitate the breach of the inner castle wall 
(the glia limitans). The patrolling T cells can then access the castle and protect the inhabitants 
from infectious invaders and damage
[257]
.      
Although the CNS lacks a true lymphatics network it is proposed that the circulation of CSF 
may substitute for its absence. Anecdotally this analogy is consistent with the predominating 
CSF T cell subset which expresses the lymph node homing chemokine CCR7
[247,248]
. The CSF 
turns over 4 times daily
[293]
 and is resorbed by either; 1) direct reabsorption into the 
circulation via arachnoid granulations which drain into the venous sinuses embedded in the 
dura mater, 2) drainage via the olfactory lymphatics through connections with the 
subarachnoid space (<50% of CSF outflow in animals), 3) drainage via lymphatics associated 
with other cranial or spinal nerves
[294,295]
. CSF reuptake via arachnoid granulations permits the 
transport of soluble CNS antigens into the circulation but is not a described mode of APC and 
T cell efflux. However, lymphatic vessels draining into the cervical lymph nodes in the neck 
(CLN) do provide trafficking route for both antigen and cells
[295]
. The appearance of 
particulate tracer and proteins in the CLN following their injection into the CNS parenchyma 
and subarachnoid space demonstrates the viability of this route for antigen drainage
[296,297]
. In 
addition, APC loaded with EAE-associated myelin antigens are found in the CLN of mice, 
primates and human MS patients
[298,299]
. Although recirculating APC are thought to be 
excluded from the CNS parenchyma a study by M.G. Mohammad et al (2014) has shown that 
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CD11c
+
 and CD11b
+
CD11c
+
 DC migrate to the CLN via a parenchymal route in normal and 
EAE mice. These blood derived-DC follow the path of olfactory neural outgrowths from the 
lateral ventricles to the olfactory bulb (the rostral migratory stream) and here cross into the 
olfactory lymphatics and CLN
[300]
. Together these studies suggest the importance of such 
lymphatic drainage routes for APC recirculation, but there are fewer reports demonstrating 
that CSF T cells egress via the CLN. When stimulated transgenic T cells expressing green 
fluorescent protein are injected into the lateral ventricles they do accumulate in the CLN via 
the nasal mucosa
[301]
. However, in the study by M.G. Mohammad et al (2014) CD3
+
 T cells 
did not share the migratory pathways described for DC
[300]
. Lack of evidence supporting the 
efferent pathways of unmanipulated CSF T cells leaves open questions regarding their 
function and fate once within the CSF spaces. Defining the functionality and migratory 
behaviour of these cells is pivotal for further understanding their role in CNS immunity.  
1.10 The CNS microenvironment promotes immune suppression.  
In the absence of pathology the CNS microenvironment is considered to be highly anti-
inflammatory. Tolerogenic DC which drain from the CNS are important for the induction of 
Treg in the CLN and peripheral tolerance to CNS antigen
[300]
. This is demonstrated by 
pharmacological block of this pathway with Fingolimod which increases disease prevalence 
in a spontaneous mouse model of EAE. Furthermore, the nasal lymphatics that drain into the 
CLN have a significant role in tolerance induction as is demonstrated by a delayed type 
hypersensitivity model when peptides are introduced intranasally
[302]
. However, despite the 
proposed role of the CLN in tolerance induction, disease severity in EAE is reduced when the 
CLN are surgically removed prior to disease onset
[303]
. The lack of disease exacerbation here 
suggests that any tolerogenic role of the CLN is overridden in this neuroinflammatory disease 
model  
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Most work related to T cell suppression in the CNS refers to interactions occurring within the 
CNS parenchyma for the purpose of dampening inflammation. Within the parenchyma 
features of immune privilege are highly applicable such as constitutive FASL and an absence 
of MHC expression
[304,305]
. The default setting for astrocytes and microglia is anti-
inflammatory and serves to promote neural protection. However, as under normal conditions 
T cells rarely penetrate the parenchyma any cell-cell contact mediated suppression is likely 
restricted to astrocyte feet at the glia limitans
[257]
. However, soluble factors secreted by 
astrocytes are important for modulating CSF T cell responses and maintaining the barrier 
integrity. These include cytokines and effector molecules such as TGFβ, IL-10, IL-27 and  
retinoic acid
[306]
.  
Early studies of immune privilege showed that in vitro culture of activated T cells in CSF 
reduces their IFNγ responses[307]. Such suppression is attributed to a plethora of soluble anti-
inflammatory cytokines in the CSF such as TGFβ, VIP, prostaglandin D2 and some 
neuropeptides
[308–311]
. With reference to outer CSF barriers adaptations the CP epithelium is 
shown to be highly dynamic and immune modulatory. CP epithelium constitutively expresses 
IDO and CD73 along with the anti-inflammatory cytokines TGFβ, IL-10 and IL-13[312]. In 
addition, work which demonstrates constitutive PD-L1 expression on brain endothelium 
compliments studies documenting a high level of PD-1 expression by CSF T cells
[313–315]
. 
Here PD-1 interaction may suppress activated T cells upon CSF entry as opposed to being 
indicative of T cell exhaustion
[313]
. Interestingly, PD-L1 is expressed by both microglia and 
perivascular macrophages and negatively regulates T cell activation in both in vitro culture 
and EAE
[316,317]
. CP-associated perivascular macrophages are also skewed towards an M2 
anti-inflammatory phenotype and local DC may also provide an important source of anti-
inflammatory IL-10
[318,319]
. Such findings suggest that the passage of CD4
+
 T cells across the 
CP into the CSF may modulate their phenotype and function. The ability of CSF T cells to 
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make cytokine having undergone such a migration process is examined as part of my 
investigation. 
1.11 Changes in CD4+ T cell CNS recruitment and the pathogenesis of 
multiple sclerosis.  
Multiple sclerosis (MS) is an autoimmune neuroinflammatory disease characterised by lesion 
sites in the brain and spinal cord which are detectable by magnetic resonance imaging
[320]
. 
Disability in MS is caused by demyelination and axonal loss at lesion sites resulting in loss of 
conductivity and neuronal function. A single neurological episode is defined as clinically 
isolated syndrome (CIS) and presents with MS symptoms. However, 60-80% of CIS patients 
experience further episodes and subsequently develop MS
[321]
. The majority of MS patients 
experience recurrent inflammatory flares with intermittent periods of remission that are 
accompanied by some neurological recovery (relapsing remitting MS; RR-MS). In around 
80% of individuals recovery periods are eventually accompanied by progressive disability 
caused by repetitive neuronal damage (secondary progressive MS)
[322]
. Around 10-15% of 
MS patients have progressive disease from the outset with no apparent inflammatory flares 
(primary progressive MS; PP-MS)
[323]
. PP-MS and RR-MS have their own distinctive 
pathophysiology with the former representative of more chronic inflammatory processes 
whilst latter are more acute
[324]
. Risk factors associated with the development of MS are well 
defined and include; 1) an aberrant response to infection (namely Epstein Barr virus)
[325]
, 2) 
HLA polymorphisms that are associated with loss of tolerance to CNS antigens
[326]
, and 3) 
environmental factors including vitamin D deficiency, as vitamin D is important for 
maintaining central tolerance and can skew CD4
+
 T cell responses away from a pro-
inflammatory phenotype
[327,328]
.  
The pathogenesis of MS is multi-factorial and not yet fully understood. However, on a 
cellular level autoreactive T cells which recognise myelin antigen-specific antigens (e.g. 
myelin basic protein and myelin oligodendrocyte glycoprotein) are strongly implicated in the 
Chapter 1  47 
 
immune-mediated damage
[329,330]
. Interestingly, myelin-specific T cells can be identified in 
healthy individuals and these may become suppressive iTreg when exposed to cognate 
antigen
[331–333]
. Therefore, loss of peripheral tolerance is implicated in MS pathogenesis and 
may involve the inability of DC to tolerise T cells in a potent inflammatory environment as is 
seen in particular infections
[334]
. Such processes may involve CNS antigen presentation in the 
CLN as demonstrated in a mouse model of EAE
[300]
.  
With consideration to CD4
+
 T cell function in MS two main contenders that are implicated in 
MS inflammation are effector Th1 and Th17 populations but there is much debate regarding 
their relative contribution to disease. Mice deficient in the IL-12 p40 subunit are resistant to 
EAE which initially suggested a dominant role for a Th1 phenotype. However, mice deficient 
in the alternative IL-12 subunit p35 remain susceptible to EAE
[335]
. p40 is also part of the IL-
23 heterodimer p19/p40 which is required for the maintenance and expansion of Th17.This 
suggests a more dominant role of IL-23 dependent Th17 mediated inflammation in MS 
pathogenesis
[336]
. In addition, when myelin-specific CD4
+
 T cells are polarised to Th17 by IL-
23 and transferred into a naïve host they induce EAE that is symptomatically consistent with 
transfer of IL-12 polarised Th1 cells
[337]
.  The chemokine CCR6 is classically expressed by 
Th17 and CCR6
-/- 
mice do not develop EAE
[338]
 . This is attributed to an inability to home to 
the CNS in the early stages of EAE as the ligand for CCR6 (CCL20) is constitutively 
expressed on CP epithelium in both mice and humans
[338,339]
. Observations that show Th1 are 
numerically dominant in MS relapse may suggest a greater contribution in established 
disease.  In addition, IFNβ is an effective therapy preventing MS relapse and IFNβ inhibition 
of Th1 function is well characterised. However, its effects on the Th17 population are 
conflicting with murine Th17-mediated EAE proving unresponsive to IFNβ treatment[340,341]. 
A degree of plasticity between Th1 and Th17 lineages adds further complexity to their relative 
contribution in MS. Th17 cells can acquire Th1 characteristics such as Tbet mediated IFNγ 
expression
[342,343]
. These cells are found in MS lesions, are highly pro-inflammatory and can 
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penetrate the BBB more efficiently than either Th1 or Th17 cells
[344]
. Findings that show Tbet
-/-
 
Th17 cells are not encephalitogenic upon adoptive transfer into naïve mice supports a role of 
these IFNγ+IL-17+ CD4+ T cells in MS pathogenesis[122].  
 Immunohistochemisty analysis of parenchymal MS lesions reveals an infiltration of T cells 
alongside inflammatory macrophages
[345,346]
. Local resident microglia and astrocytes are also 
shown to be highly activated and secrete neurotoxic factors such as TNFα, IL-1β and nitric 
oxide
[347]
. In the absence of inflammation T cells are restricted to the CSF spaces at the brains 
borders and do not penetrate the glia limitans. Such perivascular retention is logical from a 
surveillance perspective, as it keeps potentially dangerous lymphocytes out of the brain and in 
close proximity to the CNS drainage routes
[348]
. In support of this, evidence suggests that the 
chemokine CXCL12, which is expressed on the basolateral side of the vascular endothelium 
facilitates the retention of CXCR4
+
 CD4
+
 T cells in the PVS and that its upregulation in EAE 
serves as an anti-inflammatory mechanism to limit parenchymal infiltration
[349,350]
. It is 
proposed that an increased permeability of the glia limitans accompanied by a loss of signals 
which retain T cells within the CSF space is significant in MS pathogenesis. In EAE models 
the onset of neurological symptoms is temporally associated with a breach of the glia limitans 
by myelin specific CD4
+
 cells and their reactivation by APC within the PVS is requirement 
for this step
[351–353]
. Although both CD4
+
 and CD8
+
 T cells are found at MS lesion sites it 
appears that CD8
+
 T cells preferentially move into the parenchyma whilst CD4
+
 T cells are 
more readily retained and accumulate in perivascular ‘cuffs’[354,355]. Increased MMP-2 and 
MMP-9 enzyme activity by activated myeloid cells is reported to promote T cell migration 
from PVS across the glia limitans
[351]
. 
In many respects the concepts of immune surveillance and the pathogenesis of MS are 
inextricably related. CNS T cell infiltration in MS is commonly described as a two-step 
process that is comparable to the medieval castle analogy described by Engelhardt et al 
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(2011)
[257,356]
. Switching pathogen-specific for autoreactive CD4
+
 T cells that have broken 
self-tolerance mechanisms, ‘pioneer’ T cells enter the CSF spaces and open the BBB flood 
gates for further inflammatory infiltrates. This is achieved directly through BBB endothelial 
activation by T cell cytokines (IFNγ, IL-1β, TNFα) or indirectly through activation of local 
macrophages
[289]
. Chemokines implicated in this critical stage of inflammatory recruitment 
include the CCR2 ligand (CCL2)
[357–359]
, CCR5 ligands (CCL3/CCL4/CCL5)
[288,360]
, and 
CXCR3 ligands (CXCL9/CXCL10)
[360,361]
. From here the glia limitans is breached and as 
autoimmune inflammation is not resolved like an infectious insult, these processes set up a 
perpetuating cycle of T cell-mediated damage. This is maintained by subsequent BBB 
breakdown and by ectopic tertiary lymphoid organs that are formed in the meninges which 
promotes the reactivation of T and B cells within the CNS
[362–364]
. As homeostatic T  cell 
recruitment pathways are both important for CNS immunity and may be implicated in the 
very early stages of MS pathogenesis, it is important to further understand the characteristics 
of T cells in the CSF space in the absence of disease. This is particularly important given that 
pathogenic Th17 share the same CP entry route as those cells that may protect the CNS from 
infection
[338]
. In addition, the study of non-pathogenic CSF T cells may shed light upon either 
peripheral or CSF-restricted tolerogenic mechanisms which are lost in the onset of 
neuroinflammatory disease.  
1.12 Thesis aims. 
Preliminary studies have examined the cytokine secreting potential of CD4
+
 T cells from the 
blood and CSF of patients with and without neuroinflammatory diseases including multiple 
sclerosis (unpublished data from the Curnow group, University of Birmingham). In these 
investigations, a population of CD4
+
 cells was identified in the peripheral blood and CSF that 
did not make any of seven tested cytokines (IFNγ, TNFα IL-17, IL-21, IL-22, IL-10, IL-5) in 
all patient cohorts. It was then considered whether these cells expressed alternative cytokines 
or whether the absence of a cytokine profile was reflective of a truly hyporesponsive 
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phenotype. It was considered whether the complete absence of a cytokine response in this T 
cell population was an indication of an altered cellular state and may be representative of 
anergy, senescence or exhaustion. As such states are incompletely defined in an ex vivo 
setting this led to the formation of the first two aims of this investigation;  
1) Establish a complete definition of ‘cytokine–ve’ CD4+ T cells in the peripheral 
blood of healthy humans. 
2) Interrogate the phenotype of cytokine–ve CD4+ for features associated with 
regulatory or hyporesponsive T cell biology.   
The next intention of this investigation was to model normal CSF in a cohort of patients 
without inflammatory disease to provide insight into CD4
+
 T cell recruitment from blood to 
CSF. To complement this work, modelling healthy CSF, CP and brain in rodents would 
permit a comparative phenotypic analysis of the T cells in each associated compartment. 
Based on findings in current literature the hypothesis drawn for this work is that recruitment 
of CD4
+
 T cells from blood to CSF will be Tcm specific in both human and rodent 
systems
[247,249]
. The main aims of this line of investigation were to; 
3) Examine the frequency and phenotype of CD4+ T cells in rodent CNS 
compartments.  
4) Investigate the relationship between the phenotype of CD4+ T cells in the blood 
and CSF of patients without inflammatory disease. 
 
As part of preliminary investigations the cytokine expression of CD4
+
 T cells from 
cerebrospinal fluid samples was examined. In individuals without inflammatory disease the 
cytokine responses of the memory CD4
+
 T cell population were diminished comparative to 
the blood (Figure 1.5). This led to many questions regarding their ability of homeostatically 
recruited CD4
+
 T cells to perform immune surveillance; 1) were the cytokine
-ve
 cells observed 
in the peripheral blood enriched in the CSF through direct recruitment? 2) alternatively, was 
the cytokine secreting potential of CSF CD4
+
 T cells switched off as part of their recruitment 
process to prevent inflammatory responses in the CSF space? or 3) were active mechanisms 
of immune suppression operating in the CSF space to dampen the cytokine responses of these 
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cells once within the CNS? The following aims were formulated to begin to address these 
questions; 
5) Confirm that the cytokine responses of CD4+ T cells in ‘normal’ human CSF are 
truly diminished comparative to the blood. 
6) Examine the activation status and cytokine production of CD4+ T cells in rodent 
CNS compartments.  
 
The overall hypothesis for this investigation is that CSF CD4
+
 T cells have diminished 
cytokine responses through specific recruitment of a hyporesponsive central memory 
population from the blood. The rationale behind the proposed hypothesis is that the lack of 
cytokine production by CSF CD4
+
 T cells protects the CNS tissue from inflammatory damage 
and is in keeping with the tissues status as an ‘immune privileged’ site.  
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Figure 1.5 Pilot data showing an absence of IFNγ expression by CSF CD4+ T 
cells in patients without inflammatory disease.  Peripheral blood mononuclear 
cells and cellular isolates from CSF were sampled from patients with relapsing 
remitting multiple sclerosis (RR-MS), non-inflammatory neurological disease 
(ONID) and healthy controls (HC). Cells were stimulated for 3h with 
PMA/ionomycin and percentage of memory CD4
+
 T cells (CD3
+
CD4
+
CD45RO
+
) 
that expressed the cytokine IFNγ was measured by flow cytometry.  Representative 
flow cytometry plots show the percentage of IFNγ+ CD4+ T cells in the memory 
compartment. Data indicates that IFNγ+ cells are under-represented in the CSF of 
individuals without inflammatory disease (HC and ONID group), but elevated in 
the CSF of RR-MS patients. 
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2 MATERIALS AND METHODS 
2.1 Reagents 
2.1.1 Culture medium and solutions  
RPMI medium:   RPMI (Roswell Park Memorial Institute) 1640 [Sigma-Aldrich 
Irvine, UK] supplemented with 1% GPS (2mM l-glutamine, 
100U/ml penicillin, 100ug/ml streptomycin) [HyClone, 
Northumberland, UK] and 1% HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) [Sigma-Aldrich]  
  RPMI 10% 
HIFCS: 
 RPMI 1640 medium supplemented with 10% Heat Inactivated Fetal 
Calf Serum (HIFCS) [Biosera, Ringmer, UK] 
  
PBS:  Phosphate Buffered Saline (8g/l NaCl, 0.26/l KCl, 1.15g/l 
NA2HPO4, 0.2g/ml KH2PO4); 1 PBS tablet added per 100ml 
distilled H20 [Oxoid, Basinstoke,UK]    
  PBS 2% BSA:  PBS, 2% Bovine Serum Albumin (BSA) [Sigma-Aldrich]. 
  MACS buffer:  PBS, 0.5% BSA, 2mM Ethylenediaminetetraacetic acid (EDTA) 
[Sigma-Aldrich].    
  
ACK buffer: 0.15M Ammonium Chloride (NH4Cl), 10mM potassium 
hydrocarbonate (KHCO3), 0.1mM Ethylenediaminetetraacetic acid 
(EDTA) [all Sigma-Aldrich] in dH20.    
  4% PFA:  37% Formaldehyde solution [252549, Sigma-Aldrich] diluted to 4% 
in PBS. 
  
Cryopreservation 
Solution: 
Tissue freezing medium containing 50% 0.05M Sodium Phosphate 
Buffer (pH 7.3), 30% Ethylene Glycol (Sigma-Aldrich E9129), 20% 
Glycerol (Sigma-Aldrich G15516) in dH20. 
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2.1.2 Additional Reagents  
Reagent 
Product 
number 
Company 
Additional 
Information 
Nuclease free water AM9932 Ambion® (Life Technologies)   
Cell Permeabilization 
Kit 
GAS001S-
100 
GAS002S-
100 
Caltag-Medsystems Limited, 
UK 
  
Compensation beads 01-1111  eBioscience  One Comp eBeads 
Tissue-Tek™ Cryo-OCT 14-373-65 Fisher Scientific   
Ficoll-Paque Plus 17-1440-03 
GE Healthcare, Bioscience, 
Amersham, UK 
  
Recombinant human 
cytokines 
11340025 
11340073 
11340153 
Immunotools, Germany rhIL-2, rhIL-7, rhIL-15 
Dynabeads Human T-
activator CD3/CD28 
1131D Invitrogen   
Hoechst 33258  H21491 Invitrogen 
 Stock of10mg/ml in 
DMSO 
Sytox Blue s34857 Invitrogen   
Heparin Sodium HeparinLEO® Leo Laboratories LTD, UK   
CD4 microbeads 130-097-048 Miltenyi Biotech  
lyophilized anti-
human CD4 
microbeads 
CD45 Microbeads 130-097-153 Miltenyi Biotech 
Anti-mouse 
(lyophilized)  
Memory CD4+ T cell 
Isolation Kit (human) 
130-091-893  Miltenyi Biotech   
Pan T cell microbeads 130-090-320 Miltenyi Biotech Anti-rat OX52 
Treg isolation kit 130-091-301 Miltenyi Biotech Anti-human 
µMACS one-step cDNA 
kit 
130-091-902 Miltenyi Biotech   
µMACS mRNA isolation 
kit 
130-075-201 Miltenyi Biotech   
Annexin Buffer (X10) N/A N/A 
0.1M Hepes pH7.4, 
1.4M NaCl, 25mM 
CaCl2 in dH20 
DNAse I enzyme 10104159001 Roche Applied Science, UK   
Fast start universal 
probe master 
4913957001 Roche Applied Science, UK   
Velcade (Bortezomib) sc-217785 Santa Cruz Biotech Inc.   
Brefeldin A B5936 Sigma-Aldrich, UK   
Evans Blue  E2129 Sigma-Aldrich, UK   
Formaldehyde solution F15587 Sigma-Aldrich, UK   
Ionomycin I9657-1mg Sigma-Aldrich, UK   
PMA P8139-1mg Sigma-Aldrich, UK 
Phorbol 12-myristate 
13-acetate 
Sucrose s0389 Sigma-Aldrich, UK   
DMSO D4540-100ml Sigma-Aldrich, UK  Dimethyl Sulphoxide 
Collagenase CLSPA 
LS005275 
Worthington Biochemical 
Corporation UK 
  
Table 2.1Table of  additional reagents, 
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2.2 Participants and ethical approval (human studies).   
Venous blood was taken from healthy participants recruited into the studies ‘T cell 
differentiation and function’ (ERN_10-0728) and ‘Immune mechanisms in the ocular 
microenvironment’ (06/Q2702/63). These studies were approved by the life and health 
science ethical review committee, University of Birmingham (UoB). All participants were 
UoB staff or students and sampling was performed in a designated phlebotomy room within 
the University research laboratories. 
Age  
Group    
(yrs) 
Gender 
Total (n)  
♂  ♀ 
19-21 0 2 2 
21-30 5 10 15 
31-40 7 2 9 
Total (n) 12 14 26 
 
Table 2.2 Age and gender of healthy blood 
donors recruited from the University of 
Birmingham. 
Cerebrospinal fluid (CSF) samples obtained via lumbar puncture and matched peripheral 
blood samples were taken from patients consented into the study ‘Pathogenic and regulatory T 
cells in relapsing-remitting multiple sclerosis’ (ERN_10-0762). All samples were pre-
diagnostic and representative of patients attending neurology clinics at the Queen Elizabeth 
Hospital Birmingham. Samples were sourced via the Human Biomaterials Resource Centre, 
UoB. In some experimental objectives, patients with a multiple sclerosis (MS) diagnosis were 
further categorized according to the clinical course of the disease (Table 2.4). However, for 
others this was not possible due to insufficient sampling and all MS patients were assigned to 
one cohort (Table 2.3). Healthy control blood samples for these experiments were 
representative of staff and students at UoB. A description of these controls is included in table 
(Table 2.3) alongside the patient demographic.  
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Group 
(n) 
Sample 
(B/CSF) 
Age                           
(median and range) 
Diagnosis 
HC (9) B 27 (22-36) Healthy control (no diagnosis) 
MS (8) B/CSF 44.5 (24-63) 
Clinically isolated syndrome (1), relapsing 
remitting multiple sclerosis (3), primary 
progressive multiple sclerosis (4)  
OND 
(18) 
B/CSF 47.5 (21-74) 
Primary headache disorder (5), idiopathic 
intracranial hypertension (2), normal 
pressure hydrocephalus (2), anxiety (1), 
chronic pain syndrome (1), Meniere's 
disease (1), motor axonal polyneuropathy 
(1), post-concussion syndrome (1), sensory 
neuropathy (1), sensory symptoms (1), 
undetermined (1) 
Table 2.3 Demographic of patients and healthy controls in the study of CD69 
expression by CD4 T cells. All diagnoses were assigned to patient samples post analysis. 
HC; healthy control, MS; multiple sclerosis, OND; other neurological disease, B; blood, 
CSF; cerebrospinal fluid.   
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Group (n) 
Sample 
(B/CSF) 
Age                        
(median and 
range) 
Diagnosis 
CIS (12) B/CSF 34.5 (22-50) Clinically isolated syndrome 
PP-MS (9) B/CSF 56 (48-62) Primary progressive multiple sclerosis 
RR-MS (20) B/CSF 39.5 (19-72) Relapsing remitting multiple sclerosis 
OND (51) B/CSF 43 (21-87) 
Anxiety (6), idiopathic intracranial hypertension (5), migraines (5), 
tension headaches (4), leukodystrophy (3), neuropathy (3), 
degenerative ataxia (2), non-epileptic attack (2), normal pressure 
hydrocephalus (2), post chemotherapy neuropathy (2), carpal tunnel 
syndrome (1), cervical spondylosis (1), chronic fatigue syndrome (1), 
convergence spasm (1), facial pain (1), fibromyalgia (1), 
gastrointestinal disturbances (1), hereditary spastic paralysis (1), 
inclusion body myositis (1), muscle tension headache (1),multi-
systems atrophy (1), previous TB meningitis (1), previous viral 
encephalitis (1), stroke (1), hydromyelia (1), vascular MRI changes 
(1), non-inflammatory visual disturbances (1). 
ONID (12) B/CSF 48.5 (24-83) 
Sarcoidosis (2), antiphospholipid syndrome (1), aseptic meningitis (1), 
asymmetric axonal neuropathy (1), autoimmune neuropathy (1), 
Bechet's syndrome (1), chronic inflammatory demyelinating 
polyneuropathy (1), compressive myelopathy (1), neurosarcoidosis 
(1), inactive neuromyelitis optica (1), viral neuroretinitis (1) 
 
Table 2.4 Demographic of patients in the study of the memory status of CD4 T cells in the blood and CSF.  All 
diagnoses were assigned to patient samples post analyses. OND; other neurological disease, ONID; other inflammatory 
neurological disease, B; blood, CSF; cerebrospinal fluid.   
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2.3 Isolation of human peripheral blood mononuclear cells (PBMC).   
Blood was extracted from the median cubital vein of healthy donors. This was transferred into 
a 50ml falcon tube containing heparin sodium at 5IU/ml blood. Blood from diagnostic patient 
samples (both inflammatory and non-inflammatory) was collected directly into BD 
Vacutainer® K2EDTA Tubes (containing 1.8mg EDTA/ml blood). All subsequent cell 
culture work with blood products was performed in a class II safety cabinet under sterile 
conditions. Blood was diluted at a 1:1 ratio with RPMI culture medium and layered over 7ml 
of Ficoll-Paque Plus gradient into a 25ml universal tube. Tubes were centrifuged at 400g with 
brake 0 for 30min. The PBMC buffy coat was extracted and transferred to a tube containing 
RPMI supplemented with 10% heat inactivated fetal calf serum (HIFCS). Cells were washed 
twice in RPMI 10% HIFCS at 300g/21°C/10min and counted using a haemocytometer. After 
a final wash cells were resuspended at 1x10
6
 cells per 50µl of RPMI 10% HIFCS for cell 
culture or in a volume appropriate for subsequent cell separation techniques.  
2.4 Preparation of human CSF-derived cellular material. 
Human CSF fluid was centrifuged at 300g/4°C/4min in 1.5ml Eppendorf tubes. The 
supernatant was aspirated and the cell pellets resuspended in RPMI 10% HIFCS for cell 
culture or PBS 2% BSA for flow cytometry. Where multiple Eppendorf’s were required the 
cells were pooled and centrifuged again before being resuspended in an appropriate volume.  
2.5 Separation of human T cell subsets by magnetic-activated cell 
sorting (MACS).   
Where human PBMC-derived populations were separated by MACS the volumes indicated 
are appropriate for 10
7 
 starting cells. For experiments where higher cell counts were required 
reagent volumes were scaled up accordingly. In all MACS experiments the MACS buffer was 
degassed through storage at 2-4ºC for 12h and kept ice cold throughout the procedure. 
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2.5.1 Positive selection of CD4+ T cells from PBMC (MACS). 
For the isolation of CD4
+
 T cells freshly isolated PBMC were counted and washed at 
300g/4°C/10min in cold PBS. The cell pellet was resuspended in 80µl of MACS buffer. 20µl 
of anti-human CD4 microbeads were added and the suspension thoroughly agitated. Cells 
were refrigerated for 15min at 2-8 ºC to allow CD4
+
 cell binding to the anti-CD4 antibody 
conjugated magnetic beads. The cell suspension was washed in 2ml of MACS buffer at 
300g/4°C/10min to remove unbound microbeads. Up to 10
8
 cells were resuspended in 500µl 
of buffer and applied to a MS separation column [130-042-201, Miltenyi Biotech], which was 
positioned on a MiniMACS™ Separator in a magnetic field. Bead-bound CD4+ cells were 
magnetically retained on the column whilst the unlabelled CD4
-
 fraction passed through and 
was collected for later purity analysis. The column was washed three times with 500µl of 
MACS buffer to remove unbound cells. It was then removed from the MiniMACS™ 
separator and the labelled CD4
+
 cell fraction flushed off the column into a fresh tube using a 
plunger. CD4
+ 
and CD4
- 
cell fractions were washed in MACS buffer at 300g/4°C/10min and 
again in RPMI 10% HIFCS. The purity of the cell
 
fractions was analysed by flow cytometry 
following surface staining for CD4. CD4
+
 cell populations with a purity >95% were counted 
and used in subsequent cell culture and cDNA preparations (for purities see Chapter 3 Figure 
3.26). 
2.5.2 Negative selection of CD4 memory T cells from PBMC by MACS. 
A memory CD4
+
 T cell isolation kit was used to purify CD4
+
CD45RA
- 
T cells from PBMC 
for gene expression analysis. PBMC were counted, washed in cold PBS at 300g/4°C/10min 
and resuspended in 40μl of MACS buffer/107 cells. Non-CD4 memory T cells were labelled 
with a cocktail of biotin conjugated antibodies against  
CD8/CD14/CD16/CD19/CD36/CD56/CD45RA/CD123/TCRγδ/glycophorin A for 10min at 
2-8ºC. After a washing step, 30μl of buffer and 20μl of magnetic anti-biotin microbeads (per 
10
7
 cells) were added to the cell suspension and refrigerated for an additional 15min at 2-8 ºC. 
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Excess antibody and microbeads were removed by washing the cells in 2ml MACS buffer at 
300g for 10min. Labelled PBMC were resuspended in 500μl of MACS buffer and applied to 
an LS separation column [130-042-401, Miltenyi Biotech] on a MiniMACS™ Separator in a 
magnetic field. Unlabelled CD4
+
CD45RA
- 
cells were collected in the column effluent. These 
cells were passed through the column for a second time to increase their purity and were 
collected into a fresh tube. The mixed non-T cell and naïve T cell fraction was collected by 
removing the column and flushing the cells out in 1ml MACS buffer using a plunger. Cell 
fraction were washed in MACS buffer 300g/4°C/10min, followed by a second wash in RPMI 
10% HIFCS. Analysis of purity was assessed by flow cytometry following surface staining 
for CD4 and CD45RA (shown in results chapter 3 Figure 3.27). CD4
+
CD45RA
- 
memory cells 
were then counted and held on ice prior to cDNA preparation.  
2.5.3 The separation of regulatory and helper CD4+ T cell subsets by MACS. 
CD4
+
 Treg (CD25
hi
) were separated from non-Treg CD4
+
 T cells in a two-step MACS isolation 
process. Firstly CD4
+
 T cells were enriched from PBMC by depleting non-CD4
+
 T cells. 
PBMC were prepared by washing the cells in cold PBS at 300g/21°C/10min. Cells were 
resuspended in 90μl of MACS buffer (per 107 cells) and non-CD4+ T cells were labelled with 
10μl of biotin conjugated antibody cocktail against 
CD8/CD14/CD15/CD16/CD19/CD36/CD56/CD123/TCRγδ/glycophorin A. Following 5min 
of refrigeration at 2-8 ºC 20μl of anti-biotin microbeads were added and cells refrigerated for 
a further 10min. Excess antibody and microbeads were removed by washing the cells in 2ml 
MACS buffer at 300g/4°C/10min. PBMC were resuspended in 500μl of MACS buffer and 
applied to a buffer rinsed LS separation column [130-042-401, Miltenyi Biotech] on a 
magnetic MidiMACS™ Separator. Unlabelled CD4+ cells were collected in the column 
effluent and washed at 300g/4°C/10min in MACS buffer. Enriched CD4
+
 cells were 
resuspended in 90μl of MACS buffer and labelled with 10μl of anti-CD25 magnetic 
microbeads.
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Figure 2.1 Diagram demonstrating the principles of positive and negative selection of T cell subsets from peripheral blood mononuclear 
cell cultures by magnetic activated cell sorting (MACS).  
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Cells were refrigerated for 15min at 2-8 ºC to label the CD25
hi
 CD4
+
 Treg population. After a 
washing step, cells were resuspended in 500μl of MACs buffer and applied to a MS column 
on a magnetic MiniMACS™ Separator. Labelled CD25hi Treg were retained on the column 
whereas the CD25
int
 non-Treg fraction was collected in the column effluent. The non-Treg 
fraction was passed over the column again to remove contaminating Treg and the column 
washed 3 times with 500μl of MACS buffer. The Treg fraction was eluted by removing the 
column and flushing 1ml of buffer through with a plunger. The Treg and non-Treg cell fractions 
were washed in MACS buffer (300g/4°C/10min) and again in RPMI 10% HIFCS. Cells were 
counted and resuspended in RPMI 10% HIFCS for subsequent cell culture. The purity of the 
cell
 
fractions was analysed by flow cytometry following surface staining for CD3, CD4, CD8, 
CD25 and CD127 (for purities see Chapter 3, Figure 3.20A, Figure 3.20B).  
2.6 Fluorescence activated cell sorting (FACS) of human peripheral 
blood mononuclear cells. 
Multiple T cell populations were purified from freshly isolated human PBMC by FACS (see 
Table 2.5). PBMC were washed in PBS 2% BSA at 300g/4°C/4min and resuspended 1ml. 
The wash step was repeated and the cell pellet resuspended in a cocktail of fluorescently 
conjugated anti-T cell monoclonal antibodies (mAb) diluted in PBS 2% BSA (250µl 
mAb/25x10
6 
PBMC). The cells were refrigerated at 2-8°C for 15min to allow mAb binding. 
This step was performed under constant rotation to prevent cell clumping. 1ml of PBS 2% 
BSA was added to dilute unbound mAb and the cells washed at 300g/4°C/4min. Labelled 
PBMC were resuspended in <500µl RPMI 10% HIFCS and held in sealed polystyrene tubes 
on ice. FACS was performed by a MoFlo high speed cell sorter [Beckman Coulter] using 
Summit
®
 v4.3 software. Hoechst 33258 nuclear stain was added so dead cells could be gated 
out of the FACS process. The dye was diluted in RPMI 10% HIFCS to a working 
concentration of 0.5µg/ml and added to the cell suspensions 10min prior to sorting. T cell 
populations were sorted directly into FACS tubes or Eppendorf’s rinsed in RPMI 10% HIFCS 
Chapter 2  61 
 
with a residual volume of ~200µl. The purities of sorted populations were verified by flow 
cytometry on a Dako-Cyan flow cytometer [Beckman Coulter]. 
No. FACS steps 
required 
Figure* 
T cell 
markers 
FACS sorted T 
cell subsets 
1 
3.13 
CD4,CD8, 
CD45RA,CCR7 
Tnaive 
Tcm 
Teff 
3.14     
3.15 
CD4,CD8, 
CD45RA, 
CCR7, CD62L 
Tcm CD62L
hi
 
Tcm CD62L
lo
 
Teff CD62L
hi
 
Teff CD62L
lo
 
3.16 
CD4,CD8, 
CD69 
CD4 CD69
hi
 
CD4 CD69
lo
 
3.19 
CD4,CD8, 
CD45RA, 
CCR7, CD56, 
TCRγδ  
Tcm 
Teff 
CD4 Lin
+ 
(CD8
+
/CD56
+
/TCRγδ+) 
3.21 
CD4, CD45RA, 
CCR7, CD25, 
CD127 
Tcm Thelper 
Tcm Treg 
Teff Thelper 
Teff Treg 
3.23 
CD4,CD8, 
CD45RA, 
CCR7, PD-1 
Tcm PD-1
hi
 
Tcm PD-1
lo
 
Teff PD-1
hi
 
Teff PD-1
lo
 
2 
3.27     
3.29     
3.31 
Pre cell culture 
CD4, CD45RA, 
CCR7 
Teff 
Post cell culture 
CD4, CD69 
Teff CD4
int
CD69
lo
 
Teff CD4
lo
CD69
hi
 
 
  
Table 2.5 List of T cell subsets purified by FACS. The corresponding 
surface receptors used to identify each phenotype are listed. The table is 
indicative of experiments where both a single FACS procedure was 
required (white), and where cells were sorted and then resorted 
following cell culture (grey). *FACS was associated with experiments 
shown in the figures indicated (Chapter 3 of this investigation).  
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2.7 Human cell culture. 
All in vitro assays were performed in 96-well culture plates in a total volume of 200µl RPMI 
10% HIFCS. When freshly isolated PBMC were cultured 1x10
6 
cells were applied to each 
well. Where T cell populations were separated by MACS or FACS prior to culture the cell 
number was dependent on the cell recovery. In such instances a minimum of 1x10
5 
and a 
maximum of 1x10
6 
purified T cells were cultured per well. Cultures in RPMI 10% HIFCS 
alone acted as a negative control for stimulation assays (see below) and were also used for 
independent T cell phenotyping experiments. 
2.7.1 In vitro stimulation assays. 
To induce T cell activation PMA and ionomycin was added to PBMC or T cell cultures at a 
final concentration of 50ng/ml and 750ng/ml respectively (unless otherwise indicated). 
Alternatively, T cell activator Dynabeads
®
 were added to cultures for direct engagement of 
CD3 and CD28.  Prior to culture, Dynabeads
® 
were washed by adding an appropriate volume 
of beads to an Eppendorf containing 1ml of PBS and placing it next to a magnet. The 
magnetic Dynabeads
®
 were retained by the magnetic field whilst the supernatant was 
removed and the beads were resuspended in RPMI 10% HIFCS. The washed Dynabeads
® 
were added to cell cultures in a 1:1 bead to cell ratio.  
In both PMA/ionomycin and Dynabeads
® 
stimulation assays cells were cultured at 5% 
CO2/37ºC/6 hours (unless otherwise indicated). For experiments where cytokine expression 
was to be subsequently analysed exocytosis was blocked with Brefeldin A [Sigma-Aldrich, 
UK]. This was added 3 hours prior to the end of the culture at a final concentration of 2µg/ml.  
2.7.2 Addition of recombinant cytokines to in vitro stimulation assays. 
Where indicated the recombinant human cytokines rhIL-2, rhIL-7 and rhIL-15 [Immunotools] 
were added for the duration of some PMA/ionomycin stimulation assays. Cytokines were 
diluted in RPMI 10% HIFCS to a concentration of 50IU/ml (IL-2), 20IU/ml (IL-7), 80IU/ml 
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(IL-15) and were applied alone or in combination. Unstimulated cultures (-PMA/ionomycin) 
and cytokine free cultures were included to control for the effect of both the stimulation and 
cytokine.   
2.7.3 Proteasome inhibition in in vitro stimulation assays. 
The proteasome inhibitor Velcade
®
 (Bortezomib) was added to PMA/ionomycin stimulated 
cultures to inhibit proteolytic degradation. The inhibitor was added for the complete 6 hour 
culture duration and was titrated at a concentration between 1-1000ng/ml. A vehicle control 
(DMSO) was used to control for the effect of the inhibitor. 
2.8  Analysis of gene expression in human CD4 T cell subsets. 
2.8.1 Isolation of mRNA from CD4 T cell subsets. 
mRNA was isolated from human CD4 T cell subsets that had undergone prior enrichment by 
MACS (section 2.5) or FACS (section 2.6). A μMACS mRNA isolation kit [130-075-201, 
Miltenyi Biotech] was used to purify the mRNA from these T cell populations. All buffers, 
microbead reagents and separation columns referred to in this section are included as part of 
this kit.   
Cells were counted and washed in cold PBS at 300g/4ºC/8min. The supernatant was 
completely aspirated and cell pellets resuspended in 1ml of lysis/binding buffer. Cells were 
vortexed for 5min to ensure complete cell lysis. The lysate was transferred to a fresh 
Eppendorf and the DNA content sheered by repeatedly passing the material through a 21G 
needle into a 1ml syringe. Foaming of the lysate was eliminated by centrifugation at 
13,000g/4ºC/1min. To remove cell debris the lysate was applied to a lysate clear column 
which was inserted over a collection tube and centrifuged at 13,000g/4ºC/3min. mRNA was 
labelled by dispersing 50μl of Oligo(dT) Microbeads into the clear lysate by repeatedly 
pipetting the liquid up and down. A μMACS column was prepared by placement onto a 
thermoMACS
TM
 separator on a MACS multistand [Miltenyi Biotech]. The column was rinsed 
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with 100ml of lysis/binding buffer and the bead-labelled lysate applied, thus allowing labelled 
mRNA to be magnetically retained whilst non-mRNA material passed through. The column 
was washed twice with lysis/binding buffer and four times with wash buffer to remove 
contaminating rRNA and DNA. From here the purified mRNA retained on the column was 
converted to cDNA using a μMACS one-step cDNA kit [130-091-902, Miltenyi Biotech] as 
described in section 2.8.2. 
2.8.2 cDNA synthesis from purified mRNA. 
Purified mRNA held on a μMACS column was converted into cDNA using a µMACS one-
step cDNA kit [130-091-902, Miltenyi Biotech]. All buffers and reagents described in this 
section were supplied in this kit and were used at the volumes indicated below.   
The μMACS column held on the thermoMACS separatorTM was washed twice with 
equilibration/wash buffer to rinse the bound mRNA. 20µl of resuspension buffer was added to 
preformed aliquots of lyophilized enzyme and the solution added to the column. The 
thermoMACS separator
TM 
was set to 42ºC and the column incubated for 1h to allow the 
reverse transcription of mRNA to cDNA. 1µl of sealing solution was applied to the top of the 
column matrix to prevent evaporation. Following incubation the column was rinsed twice 
with 100µl of equilibration/wash buffer. 20µl of cDNA release solution was then added to the 
column and incubated for a further 10min at 42ºC. Newly transcribed cDNA was then eluted 
from the column into an Eppendorf in 50µl of cDNA elution buffer. cDNA was stored at -
80ºC in preparation for gene expression analysis.  
2.8.3 Quantitative real time polymerase chain reaction (qPCR). 
qPCR was performed on cDNA samples prepared in section 2.8.2 for relative analysis of gene 
expression. All assays were performed in triplicate in a 384 well plate, with a total reaction 
volume of 5µl per well. Taqman
®
 gene expression assays [Life Technologies] were used to 
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measure amplification of both a target gene and control gene in the same reaction (all 
measured genes are listed in Table 2.6). 
Target 
gene 
Primer/probe 
set 
Conjugate  
Associated 
Function 
CD69 Hs00934033_m1 FAM 
Activation/Immune 
response 
IFNγ Hs00989291_m1 FAM 
LCK Hs00178427_m1 FAM 
TCR Signalling PRKCQ Hs00989970_m1 FAM 
VAV1 Hs01041613_m1 FAM 
PRKAA1 Hs01562315_m1 FAM Metabolism 
Control 
gene 
Primer/probe 
set 
Conjugate  
Associated 
pathways 
GAPDH Hs99999905_m1 VIC Metabolism 
 
 
In each well 0.35µl of target gene primer/probe and 0.35µl of control gene primer/probe were 
added to 2.5µl of fast start universal probe master (X2) [Roche] and 1.8µl of cDNA. Where 
required the concentration of cDNA was diluted with RNAse free water [Ambion
®
] prior to 
its addition to the reaction mix. Plates were centrifuged briefly and sealed with plastic film 
before performing the qPCR reaction. cDNA amplification was performed by a 
Lightcycler
®
480 II instrument [Roche] with parameter for thermal cycling as indicated in 
Table 2.7.   
 
 
Table 2.6 Taqman gene expression assays from Life 
Technologies. Table shows the target and control genes 
examined in this investigation.  
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 Stage Cycles 
Temp 
(°C) 
Time 
(h:min:sec) 
Ramp 
(°C/sec) 
Preincubation 1 95 00:10:00 4.4 
Amplification 50 
95 00:00:15 4.4 
60 00:01:00 2.2 
72 00:00:01 4.4 
Melt curve 1 
95 00:00:10 4.4 
40 00:00:30 2.5 
80 Hold 0.06 
Cooling 1 40 00:00:10 2 
 
 
 
2.8.4 Relative gene expression analysis. 
Amplification curves resulting from qPCR reactions were analysed using Lightcycler
®
480 
SW1.5 software. For each qPCR reaction an amplification cycle threshold (Ct) was measured 
for the target and control gene. The difference in cycle threshold between the Cttarget and the 
Ctcontrol was measured and the mean value attained from the technical triplicates. The fold 
change (fc) in expression between the target and control gene for each sample was then 
calculated using the equation below.  
fc = 2^
-(Cttarget - Ctcontrol) 
 
Variation in fold change between cell populations of interest was then analysed as a function 
of relative gene expression.  
Table 2.7 Thermal cycling conditions for the 
amplification of cDNA. Table indicates the cycling 
program of a Lightcycler®480 II instrument.  
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2.9  Animals.  
All animal procedures were performed at the biomedical services unit, University of 
Birmingham in accordance with the Animals (Scientific Procedures) Act 1986. The housing 
and use of animals in this study was licenced by the UK Home Office (project licence 
30/2720) and was approved by the university ethics committee. All procedures in this 
investigation were performed on tissue harvested post mortem. Schedule One culling of rats 
and mice through exposure to increasing concentrations of CO2 gas was performed by the 
investigator (personal licence No. PIL 70/25469). Adult male Sprague Dawley rats (150-200g 
weight) [Harlan Laboratories, UK] were housed in the biomedical services unit for a 
maximum of 3 weeks prior to culling. Male and female C57BL/6 mice (8-16 weeks) were 
sourced from in house stock colonies, and were kindly provided by Dr Robert Barry. All 
animals were monitored daily by staff at the biomedical services unit.    
2.10 Post mortem tissue preparation (mouse and rat). 
2.10.1 Collection of cerebrospinal fluid (CSF).  
For CSF collection the rat or mouse was laid prone with the head secured in a stereotactic 
frame post mortem. The head was then lifted and stabilised with the nose pointing down 
leaving the body suspended at a ~135° angle. An incision was made at the base of the cranium 
down the midline and the muscle tissue and fascia teased apart with forceps. This exposed the 
atlanto-occipital membrane through which a glass micropipette was inserted avoiding the 
arteris dorsalis spinalis vessels. For mouse experiments this process was performed under a 
dissection microscope. CSF was drawn through the micropipette from the underlying cistern 
magna by gently pulling on an attached 1ml syringe. Approximately 50-150µl of CSF per rat 
and 10-20µl per mouse was placed in an Eppendorf containing 100µl RPMI 10% HIFCS. 
CSF from 3-4 rats or 4-6 mice was pooled into the same tube and held on ice for subsequent 
analysis. 
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2.10.2 Cardiac puncture and vascular perfusion. 
Blood was collected from both mice and rats via cardiac puncture. An incision was made 
down the midline of the animal and the thoracic cavity opened by piercing the diaphragm and 
then cutting upwards through the ribcage with scissors.  The ribs were opened to expose the 
heart and it was freed from its surrounding fascia. For blood collection a 25mm gauge needle 
was inserted into the right atrium and blood drawn into a 1ml or 5ml syringe for mouse and 
rat respectively. Blood was transferred into a heparinised Eppendorf and held at 2-8°C. 
In all animal experiments it was important that dissected tissue was free of blood 
contamination. Therefore a whole body vascular perfusion was performed to flush blood out 
of the circulation. A pipette tip attached to a saline drip line was inserted into the left ventricle 
and the right atrium punctured with scissors. PBS was allowed to flow from the drip into the 
left ventricle and circulate throughout vasculature, with the effluent leaving the animal via the 
punctured atrium. The flow of PBS was controlled via the drip line and the animal perfused 
until the atrial effluent was free of blood and ran clear. In some instances a solution of 0.5% 
w/v of Evans blue dye in PBS was perfused. This solution was made by dissolving powdered 
dye in PBS prior to the perfusion process.  
In instances where fixation of tissue was required following PBS perfusion the animal was 
also perfused with 4% PFA solution. This was continued until the limbs and neck of the 
animal became rigid and stiff indicating successful fixation. 
2.10.3 Preparation of rodent peripheral blood leukocyte and splenocyte cultures.  
Peripheral blood collected via cardiac puncture (section 2.10.2) was treated with a red cell 
lysis buffer (ACK lysis buffer). 10ml of ACK lysis buffer was added per 1ml of whole blood 
and held for 3min at room temperature. The lysis buffer was diluted in 40ml PBS and the 
remaining leukocyte cells washed at 300g/21°C/8min.  
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Preparation of splenocyte cultures also required red blood cell lysis. Rodent spleen was 
harvested and transferred to a culture dish (3.5cm diameter) in 1ml RPMI 10% HIFCS. The 
spleen was cut into small pieces with a scalpel and transferred to a 70µm cell strainer held 
over a 50ml falcon tube. The pieces were crushed through the strainer using the plunger end 
of a  syringe. The tissue was washed through the strainer with 20ml of RPMI 10% HIFCS and 
centrifuged at 300g/21°C/8min. The cell pellet was resuspended in 10ml of ACK lysis buffer 
for 3min to haemolyse the red blood cells. The lysis buffer was diluted in 40ml PBS and the 
cells washed at 300g/21°C/8min. Following red cell lysis both splenocyte and peripheral 
blood leukocytes were resuspended in RPMI 10% HIFCS for subsequent cell culture or PBS 
2% BSA for flow cytometry. 
2.10.4 Neural tissue dissection. 
Rodent brain was dissected following the vascular perfusion process (section 2.10.2). The 
head was decapitated and the craniofacial tissues removed with scissors and serrated forceps. 
The skull was peeled back in pieces with bone cutting implements [Fine Science Tools Inc.] 
to expose the brain. The whole brain was detached from the facial and optic nerves and 
separated from the head by snipping the olfactory bulb. A spatula was used to scoop the brain 
into a 50ml falcon tube containing RPMI 10% HIFCS or 4% PFA and stored on ice. 
Choroid plexus (CP) was dissected from rat and mouse brain (Figure 2.2) under a dissection 
microscope (Nikon SMZ1270). During the process the brain was bathed in ice cold PBS to 
keep the tissue hydrated. CP was dissected from the lateral and fourth ventricles and 
transferred to wells of a 24-well plate containing 100μl cold RPMI 10% HIFCS. Non-CP 
debris was removed from the preparations prior to tissue digestion (see section 2.10.4). 
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Figure 2.2 Dissection of rodent choroid plexus tissue. Choroid plexus (CP) was dissected 
from the lateral and fourth ventricles of freshly harvested rat and mouse brain. A. Diagram 
shows a dorsal view of mouse brain indicating the two incision points to gain entry into the 
lateral ventricles. Incisions were made in both cerebral hemispheres approximately 1mm 
parallel to the longitudinal fissure. CP was located suspended within the ventricular cavity. 
The cerebellum was also peeled upwards to reveal the 4th ventricle CP. B. Image captured 
from a dissection microscope view showing the use of forceps to open the incision point 
above the left lateral ventricle. The ventricle was located approximately 1mm deep into the 
cerebral hemisphere. C. Diagram shows a sagittal view of a mouse brain and shows the 4th 
ventricle located beneath the cerebellum (top panel). The cerebellum was lifted with forceps 
to reveal the CP suspended from the roof of the ventricle (bottom panel). The CP was 
extracted by gripping one end with forceps and gently pulling toward the contra lateral side 
cerebellum until it became fully detached.  
 
DORSAL VIEW SAGITTAL VIEW 
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2.11 Enzymatic digestion of rodent brain and choroid plexus tissue. 
This section describes the enzymatic digestion of murine brain tissue prior to the extraction of 
associated lymphocytes. Where rat whole brain tissue was used, the same concentration of 
enzyme was applied to the tissue but the reagent volume was increased threefold.  
Whole mouse brain was transferred into a 5cm petri-dish containing 2ml of fresh RPMI 
medium without serum. The brain was teased apart into small pieces using a sterile scalpel 
and tweezers. The tissue and liquid was transferred into a gentleMACS
™
 C tube [130-09-237, 
Miltenyi Biotech] and made up to 5ml with RPMI medium. A gentleMACS
™
 dissociator 
machine [130-093-235, Miltenyi Biotech] was used to mechanically disrupt the tissue 
structure in three stages. Firstly, the C tube was attached to the gentleMACS
™
 dissociator and 
the program m_brain_01 applied to begin tissue homogenisation. The C tube was removed 
and 20IU/ml of collagenase CLSPA enzyme [Worthington Biochemical Corporation, UK] 
applied to the tissue. The tissue was incubated at 37°C/5% CO2/15min on an angled rotator 
[MACSmix
™
 tube rotator, Miltenyi Biotech]. The tissue was dissociated for a second time by 
running the m_brain_02 program on the gentleMACS
™ 
machine. 0.5mg/ml of DNAse I 
enzyme [Roche, UK] was added to the tissue followed by a further 37°C/5% CO2/15min 
incubation under continuous rotation. This incubation step was repeated following a final 
tissue dissociation process by running program m_brain_03 on the gentleMACS
™
. The 
collagenase and DNAse I enzymes were then diluted by transferring the cell suspension to a 
new 50ml falcon and filling the tube with RPMI 10% HIFCS. The cells were washed at 
300g/21°C/10min and resuspended in 20ml of RPMI 10% HIFCS. To remove cellular debris 
the suspension was passed through a 70µm cell strainer into a fresh tube using the plunger end 
of a 5ml syringe. The resulting cell suspension was then washed in RPMI 10% HIFCS at 
300g/21°C/10min in preparation for the extraction of associated leukocytes (section 2.12). 
CP was also digested enzymatically with 20IU/ml of collagenase CLSPA and 0.5mg/ml of 
DNAse I enzyme. However due to the size of the tissue it was not possible to perform 
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mechanical digestion using the gentleMACS
™ 
system. Therefore, freshly isolated CP from 
multiple animals was pooled into a 3.5cm culture dish containing 1ml RPMI medium. The 
tissue was gently teased apart with forceps under a dissection microscope to dislodge the cells 
from the associated membranes. The remaining CP tissue and free cells were transferred to an 
Eppendorf in a 1ml volume and incubated with enzyme as described above.  
2.12 Magnetic-activated cell sorting (MACS) of rodent brain cell 
suspensions.   
Antibody conjugated microbeads [Miltenyi Biotech] were used to purify leukocyte subsets 
from the enzymatically digested rodent brain suspensions described in chapter 2.11 (the 
principles of MACS are shown in Figure 2.1). Due to the very high starting cell numbers for 
these experiments the reagent volumes were scaled up to be appropriate for starting cell 
equivalent of 10
8 
cells.    
2.12.1 Isolation of CD45+ cells from murine brain by MACS. 
Microbeads targeting the murine CD45 receptor were used to enrich CD45
+ 
leukocytes from 
murine brain. The brain cell suspension was washed in PBS at 300g/21°C/10min and 
resuspended in 900µl of MACS buffer. 100µl of anti-CD45 microbeads [130-097-153, 
Miltenyi Biotech] were thoroughly mixed into the suspension and the cells refrigerated for 
15min at 2-8°C. Excess microbeads were removed by washing the cells in 10ml of MACS 
buffer at 300g/21°C/10min. The cell pellet was resuspended in 1ml of MACS buffer and 
applied to a LS column [130-042-401, Miltenyi Biotech] on a MidiMACS™ Separator in a 
magnetic field. CD45
+
 cells were retained on the column whilst unlabelled cells were washed 
through with 3x1ml of MACS buffer. The CD45
+ 
cells were eluted in 1ml MACS buffer by 
forcing the liquid through with a column plunger. This process was then repeated by passing 
the eluted fraction over a second MS column [130-042-201, Miltenyi Biotech] to further 
purify the CD45
+ 
cells. Once eluted from the second column the cells were washed MACS 
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buffer at 300g/21°C/10min and resuspended in RPMI 10% HIFCS for cell culture or PBS 2% 
BSA for flow cytometry.  
2.12.2 Isolation of T cells from rat brain by MACS. 
Pan T cell microbeads targeting the rat OX-52 antigen (CD6) were used to purify T cells from 
rat brain cell suspensions. The brain cell suspension was washed in PBS at 300g/21°C/10min 
and resuspended in 800µl of MACS buffer. 200µl of pan T cell microbeads [130-090-320, 
Miltenyi Biotech] were added and the cells refrigerated for 15min at 2-8°C. The cells were 
then washed in MACS buffer at 300g/21°C/10min in preparation for magnetic separation. The 
magnetic separation process was analogous to that used to purify mouse brain cell 
suspensions as described in section 2.12.1. 
2.12.3 Rodent cell culture. 
Rodent splenocyte, peripheral blood, CSF and brain derived cells were resuspended in RPMI 
10% HIFCS and stimulated for 3 hours with 50ng/ml PMA and 750ng/ml ionomycin as 
described in section 2.7.1. Unstimulated (RPMI 10% HIFCS only) controls were performed 
for all samples except CSF-derived cultures due to their low cellularity. Following 
stimulation, cultures were washed in PBS 2% BSA and analysed by flow cytometry (section 
2.14).  
2.13 Immunofluorescence imaging 
2.13.1 Fixation and cryopreservation of murine tissue. 
Murine brain and spleen were fixed in situ by cardiac perfusion of 4% PFA solution. The 
organs were then harvested and immersed in 4% PFA for 3 hours. The fixed tissues were 
rinsed in PBS and dehydrated through immersion in 10% sucrose solution. Following 12h of 
refrigeration the sucrose concentration was increased to 20% then 30% for two additional 12h 
periods. The tissue was then thoroughly dried and embedded in Tissue Tek
™
 Cryo-OCT 
freezing medium (OCT). For this procedure a plastic Cryomold
™
 was placed on crushed dry 
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ice and filled with OCT. The tissue was immersed in the freezing medium before it froze and 
hardened. The frozen blocks of tissue were stored at -80°C prior to sectioning.  
Serial sections of brain and spleen tissue were cut from frozen OCT blocks by a cryostat 
[OFT5000, Bright Instruments] at 20µm thickness. Sections were not mounted on to slides 
immediately, but were floated in wells of a 24-well plate filled with cryopreservation medium 
(see section 2.1 for cryopreservative composition). Approximately 150 sections were taken 
per mouse brain (predominantly from the midbrain region) and stored at -20°C. To mount the 
sections onto microscope slides they were individually extracted from the cryopreservation 
plate with a ‘hooked’ spatula instrument and washed through floatation in a 5cm culture dish 
filled with ice cold PBS. Microscope slides were partially immersed in the PBS and the 
sections carefully guided in to position with a paint brush. Slides were laid flat and air dried at 
room temperature for a minimum of 3 hours prior to immunofluorescence staining.  
2.13.2 Immunofluoresence staining of murine brain and spleen sections. 
All buffers described in the immunofluorescence staining procedure are listed in table 2.8. 
Rinsing and wash steps were performed by immersing the slides in glass coplin jars filled 
with the appropriate buffer, then gently shaking the jar on a plate shaker for 3min. This was 
repeated three times by tipping out the buffer with the slides held in place and refilling the jar 
with buffer.  Monoclonal antibodies used for staining are described in Figure 2.3 alongside a 
schematic diagram of the immunostaining procedure. 
Reagent Composition 
Rinsing buffer PBS, 0.05% Tween 20 
Blocking buffer 1 PBS, 0.05% Tween 20,10% donkey serum 
Primary mAb buffer PBS, 0.05% Tween 20, 0.5% BSA 
Blocking buffer 2 PBS, 0.05% Tween 20, 10% rabbit serum 
Secondary mAb buffer PBS, 0.05% Tween 20, 0.5% BSA, 1.5% rabbit serum 
Blocking buffer 3 PBS, 0.05% Tween 20, 10% donkey serum 
Tertiary mAb buffer PBS, 0.05% Tween 20, 0.5% BSA, 1.5% donkey serum 
 Table 2.8 Buffers required for the immunofluorescence staining of 
murine brain sections.  
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Firstly, each section on the slides was circled with a hydrophobic pen [S2002, Dako] and the 
ink allowed to dry. The slides were rinsed 3 times in rinsing buffer and the excess fluid 
removed. 100µl of blocking buffer 1 was added to the centre of each hydrophobic ring thus 
immersing encircled section. The slides were incubated at room temperature for 30min in a 
darkened humidified chamber. The blocking buffer was then tapped off and the slides dried 
before adding 100µl of primary mAb cocktail (pre-diluted in primary mAb buffer). The 
sections were refrigerated in a slide box overnight at 4°C. The slides were then washed 3 
times in rinsing buffer and blotted dry. 100µl of blocking buffer 2 was added to each spot and 
incubated for 30min at room temperature in the dark.  The excess blocking buffer was 
removed and 100µl of secondary antibody (prediluted in secondary mAb buffer) added to 
each section. Slides were incubated for 1 hour in a dark humidified chamber at room 
temperature, and then washed with rinsing buffer. This procedure was repeated for tertiary 
mAb staining, with a pre-block step using blocking buffer 3 and antibodies diluted in tertiary 
mAb diluting buffer. After the final staining step slides were washed 3 times in PBS and dried 
at room temperature. Slides were mounted by adding one drop of Prolong
®
 Gold anti-fade 
reagent with DAPI to the centre of each section and placing a coverslip over the top. The 
mounting medium was allowed to dry for a minimum of 12 hours at room temperature. The 
slides were then sealed with nail varnish and stored at 2-8°C.  
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Figure 2.3 Immunofluorescence staining of murine tissue sections.  A. Schematic 
diagram summarising the staining procedure. B. Table of monoclonal antibodies 
indicating the steps in the staining procedure and associated blocking stages. C. Table of 
isotype controls for primary antibodies. *Antibody conjugated with Alexa Fluor® 647 in 
house.  
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2.13.3 Image analysis 
Epifluoresence microscopy was performed on a Leica DM6000780 widefield microscope 
using Leica Application Suite Advanced Fluorescence (LAS AF) software. This software 
allowed for the tiling of images, where multiple fields were electronically stitched together to 
represent a larger field of view.  
Confocal imaging was performed using a Zeiss LSM780 microscope with Zen 2010 software. 
Image analysis was performed offline using Zeiss LSM software. Isotype control staining was 
performed for each brain region independently, with a staining intensity above the isotype 
threshold used to indicate positive staining for CD3
+
, CD4
+
 and CD3
+
CD4
+
 subsets.  
For comparative analysis of T cell subset frequencies in various regions of murine brain, 5-12 
images were captured in the meninges, cerebral cortex, periventricular and choroid plexus 
regions. The number of CD3
+
, CD4
+
 and CD3
+
CD4
+
 cells were counted in each field of view, 
and average cell count per field of view (133475µm
2
) was calculated for each region. This 
value was multiplied to give a representative cell count per mm
2
 of brain tissue (see equation 
below). 
1mm
2
 = 1000000µm
2
 
Field of view = 365µm x 365µm = 133475 µm
2
     Conversion factor = 1000000/133475 = 
7.492 
Average cells per field of view x 7.492 = Cells per mm
2
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2.14 FLOW CYTOMETRY (rodent and human) 
2.14.1 Surface receptor immunofluorescence staining of T cell subsets for flow 
cytometry. 
With the exception of staining prior to fluorescence activated cells sorting (FACS) 
experiments (see section 2.6) staining of all freshly isolated and cultured cells was performed 
in 96-well plates. The cells were centrifuged at 300g/4ºC/4min and the culture supernatant 
flicked away. The cell pellets were briefly vortexed and resuspended in 50µl of a mAb 
cocktail diluted in PBS 2% BSA (see table 2.9 and 2.12 for list of mAb). Cells were stained 
on ice in the dark for 15min to allow the antibodies to bind to their respective surface 
receptors. Excess antibody was removed by washing cells twice at 300g/4ºC/4min in 150µl 
PBS 2% BSA. For immediate analysis by flow cytometry cells were transferred to an 
appropriate polystyrene tube in PBS 2% BSA (300µl final volume) and held at 2-8ºC. 
Alternatively, cells were fixed prior to intracellular staining (see next section 2.14.2). 
2.14.2 Cell permeabilisation and intracellular cytokine staining.  
In instances where intracellular staining of cytokine was required, cells were fixed with 50µl 
of Reagent A from the Catlag cell permeablisation kit. Following a 15min fixation in the dark 
at room temperature (~21°C) cells were washed with 150µl PBS 2%BSA (300g/4ºC/4min). 
Cell pellets were resuspended in a cocktail of mAb diluted in 50µl of permeabilisation 
Reagent B (see table 2.11 and 2.12).  The plates were incubated for 15min in the dark at room 
temperature to allow mAb to bind intracellular epitopes. Cells were washed twice in 150µl 
PBS 2%BSA (300g/4ºC/4min) to remove excess antibody. For immediate analysis cells were 
resuspended in total volume of 300µl PBS 2%BSA. Alternatively cells were stored in 100µl 
of PBS 2%BSA at 2-8ºC.  
 
 
Chapter 2  79 
 
2.14.3 Anti-human monoclonal antibodies for flow cytometry. 
Surface Markers Fluorochrome Company Product No. Dilution 
Annexin V* FITC eBioscience BMS147F1 1/20 
CCR7 Alexa Fluor® 488 Biolegend 353206 1/20 
CD3 
APC-eFluor
®
 780 eBioscience 47-0038-42 1/100 
V500 BD Bioscience 561417 1/20 
CD4 PE-Cy7 Biolegend 317414 1/160 
CD8 
Viogreen Miltenyi Biotech 130-096-902 1/20 
APC eBioscience 17-0086-42 1/20 
CD25 PerCP-Cy5.5 Biolegend 302026 1/20 
CD27 APC-Cy7 Biolegend 302816 1/20 
CD45RA PE-TR BD Bioscience 562298 1/400 
CD45RO PE-TR BD Bioscience 562299 1/40 
CD56 APC eBioscience 17-0567-42 1/40 
CD62L PECY5 Biolegend 304808 1/20 
CD69 
APC-Cy7 Biolegend 310914 1/40 
PE Biolegend 310906 1/40 
CD127 FITC eBioscience 11-1278-42 1/20 
PD-1 PE Biolegend 329906 1/20 
TCRγδ APC Biolegend 331212 1/20 
 
 
Isotype control Fluorochrome Company Product No. Dilution 
Irrelevant IgG1κ PE Biolegend 400111 1/320 
Irrelevant IgG2a PE Biolegend 400311 Variable 
Irrelevant IgG1 PE ebioscience 12-4301-82 Variable 
 
 
 
Table 2.9 Monoclonal antibodies against human T cell surface receptors.  
*phosphatidylserine is the cell surface target for Annexin V.  
Table 2.10 Isotype control reagents for the staining of human T cells.  
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Intracellular 
Markers 
Fluorochrome Company Product No. Dilution 
CD69 APC-Cy7 Biolegend 310914 1/20 
IL-2 PE eBioscience 12-7029-82 1/4000 
IL-4 PE eBioscience 12-7049-42 1/80 
IL-5 PE eBioscience 500904 1/80 
IL-9 PE eBioscience 12-7098-71 1/40 
IL-10 PE eBioscience 12-7108-82 1/160 
IL-13 PE BD Bioscience 559328 1/40 
IL-17A PE eBioscience 12-7179-42 1/160 
IL-17F PE eBioscience 12-7169-41 1/160 
IL-21 PE eBioscience 12-7219-42 1/400 
IL-22 PE eBioscience 12-7229-42 1/400 
GM-CSF PE eBioscience 12-7319-42 1/80 
IFNɣ PE eBioscience 12-7349-82 1/200 
TNFα PE BD Bioscience 554507 1/160 
 
 
 
 
 
 
 
 
 
Table 2.11 Monoclonal antibodies against human markers tested by intracellular 
staining.   
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2.14.4 Anti-rodent monoclonal antibodies for flow cytometry. 
Mouse Surface 
Markers 
Fluorochrome Company Product No. Dilution 
CD3 PE-Cy7 eBioscience 25-0031-82 1/20 
CD4 PerCP-Cy5.5 eBioscience 45-0042-82 1/80 
CD8 V500 BDBiosciences 560776 1/40 
CD44 APC-eFluor780 eBioscience 47-0441-82 1/160 
CD45.2 FITC eBioscience 11-0454-82 1/40 
CD62L PE eBioscience 12-0621-82 1/160 
CD69 APC Biolegend 104517 1/20 
 
 
    
Rat Surface 
Markers 
Fluorochrome Company Product No. Dilution 
CD3 Alexa Fluor® 488 Biolegend 201405 1/20 
CD4 Alexa Fluor® 647 Biolegend 201513 1/20 
CD45RC PE Biolegend 204007 1/40 
     Rat Intracellular 
Markers 
Fluorochrome Company Product No. Dilution 
IFNɣ V450 BDBiosciences 559498 1/20 
 
 
2.14.5 Simultaneous staining of a receptors surface and intracellular pool 
(human only).  
In some experiments the surface and intracellular pools of the CD69 receptor were examined 
in the same CD4 T cell population. This was achieved by staining with two anti-CD69 mAb 
of the same clone each conjugated to different fluorochromes. One anti-CD69 conjugate was 
included in the surface mAb staining protocol (as described in section 2.14.1), whilst the other 
was included in an intracellular staining panel (section 2.14.2). Surface staining was 
performed on ice and all reagents were kept cold to limit endocytosis of the surface receptor 
Table 2.12 All anti-mouse and anti-rat monoclonal antibodies for flow cytometry 
Chapter 2  82 
 
pool. In these experiments the cytokine IFNγ was used as a control for cell stimulation and the 
intracellular expression of CD69. 
2.14.6 Indicators of cell death and apoptosis. 
For flow cytometry experiments where no fixation step for intracellular staining was required, 
dead cells were excluded from the analysis by addition of a Sytox
®  
nuclear stain. Sytox
® 
blue 
was diluted from reconstituted stock PBS 2%BSA. The diluted Sytox
® 
blue was added to flow 
cytometry tubes containing stained cells at a final dilution of 1/800 in PBS 2%BSA. The tubes 
were vortexed and held in the dark on ice for a maximum of 10min prior to the running of 
samples on the flow cytometer. Dead cells were indicated by a strong positive signal in the 
appropriate violet laser channel (maximum excitation and emission spectra at 444nm and 
480nm). 
For studies specifically measuring the degree of apoptosis in cell cultures, following surface 
staining (see chapter 2.14.1) cells were resuspended in 300ul of 1X Annexin binding buffer 
and stained for 10min with AnnexinV at room temperature. Cells were then washed 
(300g/4ºC/4min) and resuspended in 300ul Annexin binding buffer, and analysed by flow 
cytometry within 1 hour. Sytox
® 
blue dye was added 10min prior to the running of samples on 
the flow cytometer.  
2.14.7 Flow cytometry analysis. 
Multi-colour flow cytometry for both human and rodent samples was performed on a Dako-
Cyan flow cytometer (Beckman Coulter). Digital and manual correction for spectral overlap 
was performed using Summit
®
 v4.3 software. Single colour staining of onecomp ebeads were 
used to set the fluorescence parameters of each mAb to be compensated. All flow cytometry 
and FACS data was analysed using the Summit v4.3 program.  
Chapter 2  83 
 
2.15 Statistics  
Statistical analysis was performed using GraphPad Prism
®
 6 software. Non-parametric 
statistical testing was applied to human datasets, whereas parametric tests were appropriate 
for comparative analysis of rodent samples. There were not enough data points to test for 
normal distribution in most rodent experiments. Parametric testing was justified as the 
median and mean values were found to be numerically similar in these cases. In all tests 
statistical inferences were considered significant at the level p<0.05 (confidence interval 
95%) and below. 
  
 
 
 
 
 
 
CHAPTER 3  
RESULTS 
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3 INVESTIGATION OF HUMAN PERIPHERAL BLOOD   
CD4
+
 T CELLS THAT FAIL TO PRODUCE EFFECTOR 
CYTOKINE. 
3.1 Rationale.  
A characteristic function of CD4
+
 T helper cells is the ability to produce cytokine in response 
to a cellular or molecular change in the local environment. The cytokine secreting potential of 
a cell population can be revealed through ex vivo stimulation which triggers relevant 
signalling pathways that drive cytokine-related gene expression. A combination of the protein 
kinase C activating phorbol myristate acetate (PMA) and ionomycin (to elevate intracellular 
calcium) is a common non-physiological stimulus notable for its potency and polyclonal 
properties
[365,366]
. During stimulation the expression of cytokine on an individual cell basis is 
detectable by preventing protein secretion during cell culture with an endocytic block
[367]
. 
Monoclonal antibodies are used to label T cell surface markers and intracellular cytokine (the 
latter following cell membrane permeabilisation)
[368]
 and subsequent analysis by flow 
cytometry is a powerful tool for measuring the number of cytokine-producing cells and the 
relative amount of cytokine expressed per cell.  
Preliminary studies have used such techniques to investigate cytokine secretion by CD4
+ 
T 
cells in the peripheral blood and CSF of healthy volunteers. In these studies a variable 
proportion of memory CD4
+
 T cells (CD3
+
CD4
+
CD45RA
-
) expressed one of seven common 
effector cytokines (IFNγ, TNFα IL-17, IL-21, IL-22, IL-10, IL-5) following PMA/ionomycin 
stimulation. In addition to analysing patterns of cytokine expression it was noted that a large 
proportion of CD4
+
 T cells did not express any of the cytokines measured and thus their 
effector function was unaccounted for. It was considered whether the cytokine secreting 
potential of all peripheral CD4
+
 T cells could be revealed by extending the panel to include 
additional markers or whether a population of cytokine
-ve
 cells would persist. The aim of this 
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work is to characterise a population of CD4
+
 T cells with no apparent cytokine function, 
beginning with an extensive analysis of cytokine expression by CD4
+ 
T cells in the blood.  
I subsequently identified a population of memory CD4
+
 T cells that showed true 
hyporesponsiveness to PMA/ionomycin stimulation (as defined by atypical activation marker 
expression and absent cytokine production). The inability of such cells to activate ex vivo may 
be indicative of either; 1) previous activation events in vivo, 2) a modulated differentiation 
pathway resulting in deactivation of inflammatory response genes, or 3) an atypical response 
to PMA/ionomycin stimulation (e.g. defective PKCθ signalling). In this investigation flow 
cytometry and gene expression analysis are used to examine these potential scenarios. As T 
cell hyporesponsiveness can be indicative of anergy, senescence or exhaustion the CD4
+
 T 
cell population identified in this chapter is also examined for characteristics associated with 
these distinctive cellular states.  
Further understanding the cellular processes that underpin the T cell hyporesponsiveness has 
significant implications related to multiple areas of T cell biology, including mechanisms 
underpinning the maintenance of self-tolerance, understanding the impairment of adaptive 
immune responses in senescence and the ability to produce robust anti-vaccine or anti-tumour 
T cell responses.  
3.2 Strategy for detecting CD4+ T cells that don’t make cytokine by flow 
cytometry. 
3.2.1 Stimulation assay optimisation for the maximum detection of cytokine. 
Preliminary studies had defined a cytokine
-ve
 CD4
+
 T cells as those that did not make any 
IFNγ, TNFα IL-17, IL-21, IL-22, IL-10 or IL-5. As it was possible that this defined cytokine-
ve
 population expressed cytokines not included in this list this was tested by extending the 
panel to include other notable T cell effector cytokines. Thirteen T cell cytokines in total were 
chosen (IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, GM-CSF, IFNγ, 
TNFα) to give a more robust definition of ‘cytokine-ve’. However, the secretion kinetics of all 
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these cytokines are not identical and so the point where maximal expression is detectable by 
flow cytometry is variable. Therefore, to begin the investigation a stimulation assay time 
course was performed. This could ascertain an optimal stimulation time point where the 
expression of the most cytokines would be maximal but they all could be detected (Figure 
3.1).  
Peripheral blood mononuclear cells (PBMC) were stimulated for 2-24 hours with 
PMA/ionomycin and the percentage of cytokine
+ve
 cells within the CD4
+ 
T cells compartment 
(CD3
+
CD4
+
 lymphocytes) was measured at five time points by flow cytometry. As 
unstimulated CD4
+ 
T cells do not produce cytokine the threshold for a cytokine
+ve
 signal was 
set at a fluorescence intensity above level observed in unstimulated cultures.  As anticipated 
the cytokine producing T cells were predominantly in the memory CD45RA
-
 compartment 
with the exception of IL-2.  Figure 3.1 shows five representative examples where the 
percentage of cytokine producing memory cells was recorded over time. Cytokine expression 
was detectable within 2h from all cytokines tested with maximum expression peaking 
between 6-8h with the exception of TNFα where expression peaked at 4h (data not shown). 
Based on this finding it was decided to test for true cytokine
-ve
 cells following a 6h 
PMA/ionomycin stimulation in subsequent experiments.  
3.2.2 Single fluorochrome intracellular staining strategy for detection of 
multiple cytokines. 
At the time of these experiments it was not possible to test one cytokine per fluorochrome 
using the flow cytometry machines available due to an insufficient number of fluorescence 
channels. As an alternative strategy all thirteen cytokines were stained simultaneously using 
specific anti-cytokine antibodies conjugated to the same fluorochrome. This approach could 
clearly distinguish between cytokine
+ve
 and cytokine
-ve
 cells without being concerned with 
what cells expressed what cytokine in the positive fraction.   
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Figure 3.1 Cytokine secretion kinetics in the CD4
+
 memory T cell compartment. 
Peripheral blood mononuclear cells were stimulated for 2-24 hours with PMA/ionomycin. 
Cultures were surface stained for CD3,CD4,CD45RA, stained intracellularly for 
expression of IL-4, IL-5, IL17A, IL-21 and IFNγ, then analysed by flow cytometry. A-E. 
The percentage of CD3
+
CD4
+
CD45RA
-
 T cells that express each cytokine (right hand 
panel). Adjacent plots represent expression at the 6h time point (left hand panel). Each 
cytokine was measured once using PBMC from 1 healthy donor.   
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Pooling multiple anti-cytokine antibodies required optimisation to minimise the background 
staining whilst retaining a detectable positive signal for all cytokines. This optimisation 
reduced the risk of background signals from one antibody overlapping the signal for another, 
thus avoiding contamination of the cytokine
-ve
 population. Each anti-cytokine antibody was 
titrated individually to identify a dilution giving the maximum signal to noise ratio (Figure 
3.2A-N). This was measured quantitatively by dividing the median fluorescence intensity 
(MFI) of cytokine
+ve
 cells by the MFI of the cytokine
-ve
 cells in the memory CD4
+
 T cell 
fraction (Figure 3.2A-N right hand panel). However, the dilution with the most favourable 
MFI cytokine
+ve
/MFI cytokine
–ve
 ratio was not always taken forward. In some cases where the 
absolute background was considered too high (such as with IL-2 (Figure 3.2B) and IFNγ 
(Figure 3.2M)) the dilution factor was increased to further reduce the non-specific signal. This 
ensured that cytokines expressed at a very low level (for example IL-9 and IL-21 (Figure 3.2E 
and 3.2J respectively)) were not obscured by the background noise. Once the most favourable 
dilution for each antibody was established all cytokine antibodies were pooled together in 
subsequent experiments.  
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Figure 3.2 Optimisation of intracellular cytokine staining protocol. PBMC were 
stimulated for 6h with PMA/ionomycin. Cells were stained for T cell surface markers and 
intracellularly for the expression of thirteen cytokines, then analysed by flow cytometry. A. 
Gating strategy for analysis of cytokine expression by CD3
+
CD4
+
CD45RO
+
 memory T cells. 
B-N (left). The median fluorescence intensity (MFI) of cytokine
+
 (purple) and cytokine
- 
(cyan) CD4 memory T cells for each cytokine tested (shown numerically on representative 
flow cytometry plots). B-N (right). Graphs show the MFI cytokine
+
/MFI cytokine
-
 ratio at 
increasing dilution of anti-cytokine monoclonal antibody. Chequered bars indicate the final 
dilution selected for subsequent experiments (corresponding plots are shown left).  Each 
cytokine was tested once using PBMC from 1 healthy donor.  
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3.3 Phenotypic analysis of cytokine negative CD4+ T cell in human 
peripheral blood. 
Experiments were performed to quantify the percentage of cells that were ‘cytokine-ve’. 
PBMC cultures were stimulated for 6 hours with PMA/Ionomycin, stained intracellularly for 
cytokine and analysed by flow cytometry. The gating threshold for cytokine
-ve
 cells was set at 
the background level in unstimulated cultures where cytokine was not expressed (Figure 
3.3A). Although background staining was high when all thirteen antibodies were pooled a 
distinct cytokine
-ve
 population in both the naïve (CD45RO
-
) and memory (CD45RO
+
) CD4
+
 T 
cell subsets were detected. In five independent experiments the median percentage of 
cytokine
-ve
 cells in the total population was 36.1% (27.7-41.2 IQR) (Figure 3.3C). However, 
this was heavily biased by a high frequency of naïve cytokine
-ve
 cells which appeared as a 
double peak in the negative population. This double peak may be explained by contamination 
of the cytokine
-ve
 population with cells expressing a low level of IL-2. When naïve (Tnaive 
(CD45RO
-
CCR7
+
)), central memory (Tcm (CD45RO
+
CCR7
+
)) and effector memory (Teff 
(CD45RO
+
CCR7
-
)) CD4
+ 
T cells were analysed independently the median percentage of the 
Tcm and Teff populations that failed to secrete cytokine were similar (18.0% (12.2-22.3) and 
14.5% (12.2-17.5) respectively (Figure 3.3B, Figure 3.3D)). It was also noted that the 
cytokine expression by those cells that did secrete cytokine was higher in the Teff population 
than in the Tcm subset as indicated by an elevated MFI (Figure 3.3B). Together these findings 
indicate that; 1) a significant percentage of memory CD4
+
 T cells lack a cytokine secretion 
profile even when tested for thirteen T cell cytokines, 2) the frequency of these cytokine
-ve
 
cells is similar between the Tcm and Teff populations, 3) on an individual cell basis Teff cell 
cytokine expression is more potent than their Tcm counterparts. 
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Figure 3.3 Analysis of CD4 T cells that do not produce cytokine following in vitro 
stimulation. CD3
+
CD4
+
 T cells from PBMC cultures were stained intracellularly for 13 
combined cytokines
±
. The absence of cytokine expression was analysed by flow cytometry. 
A. Representative plots showing cytokine expression by CD4
+
 T cells with and without 
stimulation. B. Histograms show the percentage of cytokine negative cells in the naïve 
(CD45RO
-
CCR7
+
), central memory (CD45RO
+
CCR7
+
) and effector memory subsets 
(CD45RO
+
CCR7
-
). C-D. Graphs show the median percentage of cytokine negative cells in 
the total CD4 population (C) and in individual subsets (D). *p<0.05 depicts statistical 
significance, ns=no significance at p<0.05 (Friedman’s statistical test followed by Dunn’s 
multiple comparisons analysis). Data is representative of measurements from n=5 healthy 
donors. Cytokine
ǂ
; IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, GM-
CSF, IFNɣ, TNFα. 
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3.4  Do cytokine-ve CD4+ T cells activate in response to PMA/ionomyin 
stimulation? 
It was then questioned whether cytokine
-ve
 cells were completely ignorant to stimulation or 
were readily activated but devoid of any cytokine gene expression. CD69 is a transmembrane 
glycoprotein that is rapidly upregulated in response to T cell activation (reportedly within 1h 
in in vitro assays
[42]
). In the peripheral blood the majority of CD4
+
 T cells do not express 
CD69 at the surface (less than 10% of circulating CD4
+
 T cells
[369,370]
). Therefore, CD69 
upregulation was measured to determine whether cytokine
-ve
 cells were activated by 
PMA/ionomycin stimulation. 
3.4.1 Isotype control testing for CD69 staining protocols. 
Matched isotype control staining for a specific CD69 antibody was performed following 6h 
culture of PBMC with and without PMA/ionomycin (Figure 3.4). Although the MFI of CD69 
staining in unstimulated cultures was not perfectly matched to the corresponding isotype 
control the values were very similar in measuring at 3.6±0.4 and 3.1±0.4 respectively 
(mean±SEM) (Figure 3.4A, Figure 3.4B). It was decided that the threshold for CD69 
upregulation could be gated as expression greater than the gate set upon the unstimulated 
control cultures. This would ensure consistency between experiments and allow permissive 
internal control for subtle changes in staining intensity between different days.  However, the 
isotype control staining did increase marginally (5.2±1.4 mean±SEM) in stimulated cultures 
which was perhaps due to a slight elevation in cell autofluorescence induced by cell 
stimulation. In contrast, the specific CD69 staining reflected the significant upregulation of 
CD69 by CD4
+
 T cells in the stimulated cultures (629.7±228.0 mean±SEM).  
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Figure 3.4 Isotype control staining for CD69 expression by CD4 T cells. Peripheral 
blood mononuclear cells were cultured with and without PMA/Ionomycin for 6h. The 
CD3
+
CD8
-
CD4
+ 
T cell fraction was analysed by flow cytometry for expression of CD69. 
A. Representative flow cytometry plots with numbers indicating the median fluorescence 
intensity (MFI) of specific CD69 staining (bottom panel) and matched isotype control 
staining (top panel) in unstimulated and stimulated CD4
+
 T cells. B. Graph shows the 
mean±SEM MFI of CD69 staining for the specific antibody and the isotype control 
(irrelevant IgG1κ) group. Data is representative of n=3 healthy donors measured across 3 
independent experiments. 
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3.4.2 Expression of CD69 by CD4+ T cells that do not produce cytokine. 
The CD4
+
 T cell population was identified by flow cytometry as CD4
+
CD8
-
 cells within the 
lymphocyte forward and side scatter gate. Due to variation in the frequency of cytokine
-ve
 
cells in different T cell subsets Tnaïve (CD45RO
-
) and Tmemory (CD45RO
+
) populations were 
analysed independently (gating strategy is shown in Figure 3.5A). The expression of CD69 by 
CD4
+
 Tnaive and Tmemory was similar in unstimulated cultures (Figure 3.5B) but this was not so 
in cultures stimulated with PMA/ionomycin. In the Tnaive subsets both the cytokine
-ve
 and 
cytokine
+ve
 populations readily upregulated CD69 with only 0.6% and 0.02% of cells left in 
the unstimulated control gate respectively (Figure 3.5C). In contrast, whereas cytokine
+ve
 
Tmemory cells also readily upregulated CD69 23.3% of the cytokine
-ve
 population did not.  Not 
only did this Tmemory subpopulation not upregulate CD69 but these cells also failed to 
completely downregulate CD4
+
 to the level of CD69
hi
 cells (Figure 3.5C), despite this being a 
well-documented phenomenon associated with PMA/ionomycin induced activation
[371,372]
. 
Although there was a partial decrease in the CD4
+
 MFI in the CD69
lo
 fraction (as indicated in 
Figure 3.4A) this population was clearly distinguishable from its activated counterpart and 
appeared incompletely responsive to the stimulation.   
The observation that almost a quarter of memory cytokine
-ve
 CD4
+ 
T cells did not show signs 
of activation with PMA/ionomycin stimulation was striking. It suggested that there may be 
differential biological processes occurring that was reflected in their hyporesponsiveness in 
these in vitro assays. Additional questions were also raised regarding the physiological 
significance of this population and why it might be maintained in vivo. At this point, the CD4
+
 
T cell population with a CD4
int
CD69
lo
 phenotype following stimulation was given the 
definition of ‘non-responsive’, as opposed to the ‘responsive’ cell fraction with a 
CD4
lo
CD69
hi
 phenotype. These cells are investigated in depth in the remainder of this chapter.  
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Figure 3.5 Analysis of cell populations unresponsive to stimulation in purified naive, 
central memory and effector memory CD4
+
 cell cultures. Peripheral blood mononuclear 
cells (PBMC) underwent fluorescence activated cell sorting (FACS) to purify naive 
(CD45RO
-
) and memory (CD45RO
+
) CD4
+
CD8
-
 T cells. Purified populations were 
stimulated for 6h with PMA/Ionomycin. The expression of activation marker CD69 and a 
combined panel of 13 cytokines
±
 were analysed by flow cytometry. A. Gating strategy for 
FACS purification of PBMC. B. Flow cytometry plots showing CD4 and CD69 expression 
by naïve (orange) and memory (cyan) sort fractions. C. (top panel) The percentage of 
cytokine
-ve
 cells by naïve and memory fractions following stimulation. C. (bottom panel) 
Expression of CD4 and C69 in the cytokine
–ve  
and cytokine
+ve  
populations in each subset. 
Numbers are representative of the percentage of cells failing to respond to the PMA 
stimulation in n=2 experiments. A membrane viability dye (Sytox) was used to exclude 
dead cells from the analysis. 
± 
IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, 
IL-22, GM-CSF, IFNɣ, TNFα.  
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3.5 Validation of the in vitro model for the analysis of ‘non-responsive’ 
CD4
+
 T cells 
3.5.1 Longitudinal analysis of CD69 upregulation in response to in vitro 
stimulation. 
It was necessary to test the kinetics of CD69 upregulation to confirm that the observed non-
responsive CD4
int
CD69
lo
 population was not a transient phenotype. For initial assays, purified 
CD4
+
 cells were cultured for 1-6 hours with PMA/ionomyin and the percentage of non-
responsive cells in the Tnaive  (CD45RA
+
) and Tmemory (CD45RA
-
)  populations recorded hourly 
(Figure 3.6B left panel, Figure 3.6C). For these experiments CD4
+
 T cells were purified from 
PBMC using magnetic activated cell sorting technology (MACS system from Miltenyi 
Biotech). Anti-CD4
+
 magnetic microbeads were used to separate CD4
+
 cells onto a magnetic 
column which were then eluted independent of the CD4
-
 fraction. Flow cytometry was used to 
measure the percentage purity of each fraction with the purity of the CD4
+ 
fraction measured 
at 99.1% of the recovered material (Figure 3.6A).  
Between 1-3 hours of stimulation there was a rapid upregulation of CD69 by the majority of 
CD4
+
 T cells in both the naïve and memory populations. By the 4h time point the frequency 
of the non-responsive population had begun to stabilise and there was relatively little change 
in the percentage of non-responsive cells between the 5-6h time points. In keeping with 
previous experiments, the percentage of non-responders in the Tmemory subset was greater than 
in the Tnaive population although their absolute frequency was notably diminished. 
In parallel with this assay it was investigated whether the non-responsive phenotype was 
present using a more physiological stimulus than PMA/ionomycin. For this purpose anti-
CD3/anti-CD28 monoclonal antibody coated Dynabeads
® 
were added to the CD4
+
 T cell 
cultures. Use of Dynabeads
®
 simulates antigenic stimulation by activating signal transduction 
directly through the TCR and co-stimulatory CD28 molecules. This is more equivalent to 
what occurs physiologically than PMA/ionomycin stimulation.  
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Figure 3.6 Longitudinal expression of CD69 by naïve and memory CD4
+
 T cell subsets 
during polyclonal and T cell receptor stimulation. CD4
+
 T cells were isolated from PBMC 
and stimulated for 1-6h with PMA/ionomycin or CD3/CD28 conjugated beads. A. The 
percentage purity of the CD4
+
  and CD4
-
 cell fractions (ungated). B. Expression of CD69 by 
naïve (orange) and memory (cyan) CD4
+
 subsets was analysed by flow cytometry. Numbers 
represent the percentage of each subset that failed to upregulate CD69 at each time point 
(shown graphically for each stimulus in C. and D.). Data is representative of n=1 experiment.  
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Consistent with the PMA/ionomycin stimulation assay, the percentage of non-responsive cells 
decreased with increased CD3/CD28 incubation time (Figure 3.6B right panel, Figure 3.6D). 
Between 4-6h of stimulation the non-responsive population stabilised, thus indicating the 
reproducibility of the non-responsive phenotype with a more physiological stimulant. 
However, although the trend between the two stimulations was comparable the frequency of 
hyporesponsive cells in the CD3/CD28 assays was greater than was observed with 
PMA/ionomycin stimulation (Figure 3.6D). Due to this numerical disparity it could not be 
concluded whether the PMA/ionomycin and CD3/CD28 induced a phenotypically identical 
non-responsive population from this experiment alone.  
In a separate experiment PBMC were cultured in PMA/ionomycin for up to 26h to examine 
the non-responsive population over an extended stimulation period. Here the frequency of 
non-responsive CD3
+
CD4
+
CD8
-
 T cells was consistent at 6h and 12h (Figure 3.7A, Figure 
3.7C). The percentage of non-responsive cells increased by approximately a third in overnight 
cultures (20h time point) but there was little change at 26h (Figure 3.7C). However, gating on 
true non-responsive cells was challenging at later time points due to considerable cell death 
and debris in the cultures. An altered forward and side scatter of the total lymphocyte 
population (indicating a decrease in cell size and granularity) was further evidence of 
PMA/ionomycin-induced cell death (data not shown). Therefore, cell viability of the non-
responsive and responsive CD4
+ 
T cell fractions was measured more directly by use of a 
Sytox
® 
viability dye (Figure 3.7B, Figure 3.7D). There was considerable cell death in both the 
non-responsive and responsive populations when exposed to PMA/ionomycin for 12h or 
more. However, the frequency of viable cells (Sytox
-ve
) in the non-responsive population was 
notably diminished comparative to the responsive phenotype. This was particularly striking in 
cultures over 6h with a negligible frequency of viable cells following 20h of stimulation.  
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Figure 3.7 Maintenance of the CD4
int
CD69
lo
 T cell phenotype during prolonged ex vivo 
stimulation. Peripheral blood mononuclear cells were stimulated for 6-26 hours with 
PMA/ionomycin. A,C. At each time point measured the CD3
+
CD8
-
CD4
+
 T cell fraction was 
analysed for the percentage of CD4
+
 T cells that did not respond to PMA ionomycin 
stimulation (CD4
int
CD69
lo
) by flow cytometry. B,D. The percentage of live cells (sytox
-ve
) in 
the non-responsive and responsive CD4
+ 
T cell populations was measured at each time point. 
Flow cytometry plots and graphs are representative of n=1 experiment.   
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Together this data indicated that although the non-responsive CD4
+ 
T cell population persists 
in longer term cultures cell viability is severely compromised with prolonged stimulation. 
With regards to studying the molecular biology of the hyporesponsive phenotype 
PMA/ionomycin exposure greater than 6h was shown to jeopardise the viability and retrieval 
of the cells for subsequent analysis. A more detailed examination of apoptosis markers in a 
more completely defined non-responsive phenotype is described later in this chapter (Section 
3.9).    
3.5.2 The effect of PMA and ionomycin dosage on the frequency of non-
responsive CD4
+
 T cells.   
To assess whether the concentration of PMA/ionomycin added to the PBMC cultures was 
affecting CD69 upregulation by CD4
+
 T cells PBMC were stimulated for 6 hours with PMA 
and ionomycin at a range of concentrations (0-1500ng/ml) (Figure 3.8). CD4
+
 T cells were 
analysed by flow cytometry (gating shown in Figure 3.8A and Figure 3.8B) for the percentage 
of unresponsive cells under each condition. When stimulated with ionomyin alone the 
population of cells that did not upregulate CD69 was substantial, with over 50% of cells 
remaining within the gate set on unstimulated cells at concentrations below 75ng/ml (Figure 
3.8B, Figure 3.8C).  At a higher dosage of ionomycin the percentage of non-responsive cells 
did decrease but not comparative to the frequency observed in the presence of PMA. This 
showed that the predominant stimulatory effect in the cultures was PMA although the 
maximum dose (1500ng/ml) did not result in more CD4
+
 cells responding and the non-
responsive population was still present at this high concentration. Interestingly, all doses of 
PMA tested followed the same trend with respect to the induced frequency of non- responders 
with the exception of the 750ng/ml test, which may represent a technical anomaly (Figure 
3.8C). It appeared that it was the combinatorial effect of PMA and ionomycin concentration 
that had the greatest effect on the frequency of non-responsive cell in a dose  
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Figure 3.8 Effect of PMA and ionomycin concentration on the unresponsiveness of CD4
+
 
T cells in in vitro cultures. Peripheral blood mononuclear cells were stimulated for 6h with 
increasing concentrations of PMA and ionomycin. The CD3
+
CD4
+
 T lymphocyte population 
was analysed for the failure to upregulate CD69 when stimulated under each condition. A. 
Flow cytometry gating strategy for analysis of CD69 by CD4
+
 T cells. B. Representative plots 
show upregulation of CD69 and downregulation of CD4
+
 when cells are stimulated with 
either PMA or ionomycin alone. Numbers represent the proportion of unresponsive cells as a 
percentage of CD4
+
 T cells (gated). C. Graph shows the percentage of CD69
lo 
(non-
responsive) CD4
+
 T cells in each culture condition. Data is representative of n=1 experiment.
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dependent manner, with the highest non-responder frequency measured between 10-100ng/ml 
ionomycin in combination with 7.5-1500ng/ml PMA (Figure 3.8C). In order to minimise 
AICD and preserve maximum cell viability in the 6h cultures it was decided to proceed using 
a concentration of 50ng/ml of PMA, which is midrange of what is reported for intracellular 
cytokine staining
[373–375]
. This was used in conjunction with a high concentration of 
ionomycin (750ng/ml) to ensure all cells with the potential to respond upregulated CD69 
within the culture period.  
3.6 Changes in the ‘non-responsive’ CD4+ T cell population as a 
consequence of inter- and intra- donor variability. 
3.6.1 The effect of age and gender variation on the frequency of the non-
responsive CD4
+
 T cells. 
The frequency of the non-responsive CD4
+
 T cell population was measured in multiple 
healthy individuals to establish a range of inter-donor variability. 26 PBMC samples were 
stimulated for 6h with PMA/ionomycin (50ng/ml and 750ng/ml respectively) and the CD4
+
 T 
cell population analysed for the non-responsive
 
cell frequency by flow cytometry. For these 
and all subsequent flow cytometry experiments CD4
+
 T cells were defined as CD3
+
CD8
-
CD4
+
 
lymphocytes (Figure 3.9A). The CD8
-
 gate was added in conjunction with CD3
+
 definition to 
minimise the percentage contamination of the non-responsive CD4
+
 population. Results 
showed that the median frequency of the non-responsive population in the total cohort was 
1.2% (0.65-1.9 IQR). The range of the non-responsive cell frequency was notable, with clear 
differences in frequency of non-responsive cells between individuals even when assays were 
conducted in parallel (Figure 3.9B). No significant difference in the percentage of non-
responsive cells was observed when the cohort was separated into male and female groups 
(Figure 3.9C) with median frequencies measured at 1.5% (0.8-2.2 IQR) and 1.2% (0.5-1.6 
IQR) respectively. 
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Figure 3.9 Age and sex demographic of CD4
+
 T cells unresponsive to in vitro stimulation 
in a healthy cohort.  PBMC were cultured for 6h with and without PMA/Ionomyin and the 
CD4
+ 
T cell population analysed for the absence of CD69 upregulation by flow cytometry. A. 
Typical gating strategy for analysis of CD69 expression by CD4
+ 
T cells. B. Representative 
flow cytometry plots showing CD69 expression in unstimulated and stimulated cultures. Data 
is representative of two donors from the same experiment, and demonstrates the donor 
variability in the population unresponsive to stimulation (CD4
int
CD69
lo
 – with gate set at 
fluorescence intensity of unstimulated cells). C. Median percentage of unresponsive cells in 
male and female donors. D. The median percentage unresponsive grouped by age of 
participant. ns = no significance at p<0.05 (Mann Whitney U statistical test). Data is 
representative of samples taken from n=26 healthy donors.  
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In addition to separation by gender subjects were categorised into three age groups (18-20yrs, 
21-30yrs, 31-40yrs) and their corresponding non-responsive cell frequencies were compared. 
There was a small increase in the median frequency of non-responsive cells between the 21-
30yr and 31-40yr age categories. Regrettably the number of younger participants in the 18-
20yr age group meant that this category could not be used meaningfully in the analysis.   
It is also acknowledged that as all of the participants in this study were below the age of 
40yrs, any age-related findings are not representative as the wider local population as a whole. 
3.6.2 Longitudinal analysis of non-responsive CD4+ T cell frequency in 
individual healthy participants.  
There are numerous environmental factors that may influence the phenotype and functionality 
of an individual’s CD4+ T cells. The stability of the non-responsive CD4+ T cell population 
was assessed by recording its frequency in four donors that were tested repeatedly over a 24 
month period (Figure 3.10).  It was found that the frequency of the non-responsive population 
in peripheral blood was not always consistent when an individual was repeatedly tested. In 
three of the four participants there were notable spikes where the population would increase 
or decrease significantly (Figure 3.10B-D). However, such changes did not correspond with 
those observed in other donors, and there was no discernible relationship between frequency 
of the non-responsive cells and seasonal timing of the measurements. It was therefore 
recognised that the unresponsive population is not stable and other physiological influences 
may play a significant role in the failure of these cells to upregulate CD69.   
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Figure 3.10 Longitudinal analysis of the unresponsive population identified in CD4
+
 T 
cells in four healthy participants. Peripheral blood mononuclear cells from four healthy 
donor was cultured with PMA/Ionomycin for 6h. The percentage of live CD4
+ 
T cells 
(CD3
+
CD8
-
CD4
+
) that failed to upregulated CD69 when stimulated (the non-responsive 
population) was analysed by flow cytometry. This analysis was performed at varying time 
points over a 24 month period in four healthy donors. A-D. Graphs show the changes in the 
percentage of total CD4
+ 
T cells failing to upregulate CD69 over time, and thus intra-donor 
variability of the non-responsive population.  
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3.7 Phenotypic analysis of the memory subset distribution within the 
non-responsive CD4
+
 T cell population. 
3.7.1 Subset analysis of the non-responsive CD4+ T cell population in cultures of 
peripheral blood mononuclear cells.  
To begin establishing a surface receptor profile of non-responsive CD4
+
 T cells the population 
was induced through 6h of PMA/ionomycin stimulation and analysed for the distribution of 
Tnaive (CD45RA
+
CCR7
+
), Tcm (CD45RA
-
CCR7
+
) and Teff (CD45RA
-
CCR7
-
) subsets (Figure 
3.11A) within the population. Using flow cytometry the initial approach to gating each subset 
could be described as a ‘forward gating’ strategy, with analysis based on this design revealed 
that the non-responsive population was predominated by a Tcm phenotype (65.7% 61.2-69.9 
(median and IQR)) (Figure 3.11C).   
Reanalysis of the same data set was performed at a later date where the Tnaive, Tcm, and Teff 
populations were independently examined for the percentage of non-responsive cells in each 
subset (reverse gating shown in Figure 3.11B). As with the previous analysis the Tnaive subset 
had a very low frequency of non-responsive cells. In contrast to previous findings, a similar 
percentages of non-responsive cells were found in both the Tcm and Teff subsets with median 
values of 6.3% (2.3-11.9 IQR) and 4.8% (4.0-12.5 IQR) respectively (Figure 3.11D). It was 
striking how alternative analyses could produce such contrasting results as this reanalysed 
data set was more consistent with the non-responsive population being a more heterogeneous 
memory phenotype as opposed to predominantly central memory. As findings from the 
alternative gating strategies were conflicting, it was considered whether the percentage 
representation of each subset within the total CD4
+
 T cell population was influencing the 
analysis of the non-responsive phenotype. Therefore, the representation of Tnaive, Tcm and Teff 
subsets within the total CD4
+
 T cell population was analysed by flow cytometry (Figure 3.12). 
Results showed that the Tnaive cells were the most heavily represented subset, with a median 
percentage of 60.6% (45.3-65.0 IQR). 30.9% (25.9-65.0 IQR) of the CD4
+
 population were a 
Tcm phenotype and only 7.9% (5.6-10.6 IQR) were Teff cells.  
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Figure 3.11 Alternative gating strategies for analysis of CD4
+
 T cells unresponsive to in 
vitro stimulation. Peripheral blood mononuclear cells were stimulated for 6h with 
PMA/ionomyin and CD3
+
CD8
+
CD4
+
 T cells analysed by flow cytometry for absence of 
CD69 upregulation. A, C. Forward gating strategy – analysis of the CD4+ T cell subset 
distribution with the CD69
lo 
population following stimulation. B, D. Reverse gating strategy 
– identifies the percentage of each CD4+ T cell subset that is CD69lo following 
stimulation.*p<0.05 **p<0.01, ***p<0.0001, ns=no significance at p<0.05 (Friedman 
statistical test, followed by Dunn’s multiple comparisons analysis). Data was collected from  
n=8 healthy donors. 
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Figure 3.12 Distribution of naïve, central memory and effector memory populations in 
human peripheral blood CD4
+
 T cells. Peripheral blood mononuclear cells were rested for 
6h in complete medium, stained for lymphocyte cell surface markers and analysed by flow 
cytometry. A. Gating strategy for identification of CD4
+
 T cell populations. CD4
+ 
T cells 
were defined by CD3
+
CD8
-
CD4
+
 expression by cells within a live lymphocyte gate (doublets 
and dead cells were excluded from the analysis). Expression of CD45RA and CCR7 were 
used to determine subset distribution within the CD4 gate. B. Median percentage frequency of 
naive (Tnaive (CCR7+CD45RA
+
)), central memory (Tcm (CCR7
+
CD45RA
-
)), and effector 
memory (Teff (CCR7
-
CD45RA
-
)) CD4 T cells in healthy blood donors. Data is representative 
of n=10 healthy donors measured independently.  
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As the non-responsive population are shown to be a memory phenotype it became clear that 
when applying the ‘forward gating’ phenotypic analysis it appeared that this population was 
predominated by Tcm cells simply because Tcm predominate the memory pool in the blood. 
Based on these findings the ‘reverse gating’ strategy is the more appropriate analysis, as 
measuring the prevalence of non-responsive cells within each subset removes any bias due to 
each subset’s overall representation. Together these findings in PBMC cultures indicate that 
the non-responsive population is a memory CD45RA
-
CCR7
+/- 
phenotype, as both Tcm and Teff 
subsets show similar proportions of non-responsive cells post stimulation.   
3.7.2 Refinement of the phenotypic analysis of non-responsive CD4+ T cells 
through pre-stimulation fluorescence activated cell sorting.  
By gating on CD4
+ 
T cell subsets in PBMC cultures there was a possibility that the surface 
marker expression of the cells could change during the culture period or be influenced by the 
stimulation. Additionally, the non-responsive population could potentially be influenced by 
other non-CD4
+ 
T cells or any soluble mediators secreted into the culture milieu. To alleviate 
these factors a fluorescence activated cell sorting (FACS) approach was used to purify Tnaive, 
Tcm, and Teff populations from PBMC prior to the 6h stimulation process. For these 
experiments PBMC were separated by FACS according to the gating strategy shown in Figure 
3.13A. Following FACS the Tnaive, Tcm, and Teff populations were stimulated for 6h with 
PMA/ionomycin and analysed for the percentage non-responsive cells (Figure 3.13B). As 
anticipated the proportion of the Tnaive cultures that failed to downregulate CD4
+
 and 
upregulate CD69 was minimal (median 0.3% 0.1-0.4 IQR) as shown in Figure 3.13C. In 
contrast to results produced in PBMC cultures the frequency of the sorted Tcm that did not 
respond was also low (median 2.5% 0.6-5.7 IQR). In addition, results indicated that the 
proportion of non-responsive Teff cells was significantly higher than in the Tcm subset (median 
34.2% 16.9-47.4 IQR). Although there was notable variability in the percentage of  
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Figure 3.13 Analysis of cell populations unresponsive to stimulation in purified naive, 
central memory and effector memory CD4
+
 T cell cultures. Peripheral blood mononuclear 
cells underwent fluorescence activated cell sorting (FACS) to purify naive (Tnaive 
(CCR7
+
CD45RA
+
)), central memory (Tcm (CCR7
+
CD45RA
-
)), and effector memory (Teff 
(CCR7
-
CD45RA
-
)) CD4
+
 T cells. Purified populations were stimulated for 6h with 
PMA/Ionomycin and the expression of activation marker CD69.analysed by flow cytometry. 
A. Gating strategy for FACS purification of PBMC. B. Flow cytometry plots showing CD69 
upregulation in response to PMA/ionomycin from each population. Plot numbers represent 
the percentage of cells failing to upregulate CD69, which is also presented graphically in C. 
D. The median fluorescence intensity of CD69 expression by those cells responsive to 
stimulation. C-D. ns; no significance at p<0.05, *p<0.05 (Wilcoxon matched-pairs sign rank 
test) Data is representative of n=6 healthy donors measured in 3 independent experiments. 
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non-responsive Teff cells finding from these experiments suggest the non-responsive 
phenotype are more of a CCR7
-
 Teff phenotype than CCR7
+
 Tcm (Figure 3.13C).  
As a further analysis of CD69 expression in these sorted populations, the MFI of CD69 in the 
responding cell fraction was also measured (Figure 3.13B, Figure 3.13D). The responding 
cells from the sorted Tnaive cultures displayed the highest CD69 MFI, showing that this 
population expressed the most receptor on a per cell basis. The expression of CD69 by the 
responding Teff cells was significantly lower with the Tcm responder CD69 MFI measured as 
an intermediary (Figure 3.13D). This result indicates that upregulation of CD69 following 
stimulation is progressively reduced as CD4
+
 T cells differentiate.  
3.7.3 Analysis of CD62L expression in activated CD4+ T cell cultures.  
There was some disparity between the memory phenotype of the non-responsive population 
observed from PBMC cultures (both CCR7
+
CD45RA
-
 and CCR7
-
CD45RA
-
) and where 
subsets were sorted prior to stimulation (predominantly CCR7
-
CD45RA
-
). Therefore, 
alternative markers associated with Tcm and Teff phenotypes were investigated to further 
characterise the memory status of non-responsive cells.  
Both CCR7 and L-selectin (CD62L) are classically associated with Tnaive and Tcm CD4
+
 T cell 
populations but are not expressed by the Teff subset
[57]
. Therefore differential CD62L 
expression in CD45RA
-
 memory populations was used in conjunction with CCR7 to look for 
changes in ‘responsiveness’ between phenotypes. As the ectodomain of CD62L is readily 
shed in the presence of PMA/ionomycin this posed a problem in terms of analysing the 
receptor post-stimulation. CD62L ectodomain cleavage requires MMP enzyme activity
[376]
. 
Therefore, an attempt was made to prevent shedding in initial experiments through addition of 
an indirect MMP inhibitor [TAPI-2, Enzo Life Sciences] to PBMC cultures (as described in 
[377]
). However, even at high concentrations of the MMP inhibitor the expression of CD62L 
by stimulated CD4
+
 T did not match the level seen in unstimulated cultures (data not shown). 
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Due to the incomplete inhibition of shedding and consideration for the indirect effects of the 
MMP inhibitor an alternative strategy was approached where memory T cells with differential 
expression of CD62L were sorted by FACS prior to stimulation (Figure 3.14). CD4
+
 Tcm and 
Teff (based on a CCR7 and CD45RA definition) were separated into their CD62L
hi
 and 
CD62L
lo
 compartments (Figure 3.14A). As anticipated the Tcm CD62L
hi
 and Teff CD62L
lo 
were the dominant populations in each phenotype. However, small atypical Tcm CD62L
lo
 and 
Teff CD62L
hi
 populations were also identifiable. Interestingly, these cells with an inversed 
relationship of CCR7/CD62L expression had the highest frequency of non-responsive cells 
when stimulated with PMA/ionomycin (Figure 3.14B, Figure 3.14C). This trend was 
reproduced when each population was stimulated with anti-CD3/anti-CD28 Dynabeads
®
, 
although here the Tcm CD62L
lo
 population showed the greatest percentage non-responsiveness 
with only a marginal proportion of these cells upregulating CD69 at all (Figure 3.14D, Figure 
3.14E). These finding suggest that changes in CD62L expression within CCR7
+ 
and CCR7
- 
memory populations can predict the absence of CD69 upregulation to an exogenous stimuli. 
However, this combination of markers alone is insufficient to identify a pure non-responsive 
population prior to stimulation.  
3.7.4 Analysis of CD27 expression as a measure of differentiation status in 
CD4
+
 T cell cultures. 
As CD4
+
 T cells differentiate they progressively lose expression of the surface receptor 
CD27
[378,379]
. As Tcm have a higher CD27 expression than Teff this marker was used to 
investigate whether the non-responsive CD4
+
 T cell population represented cells close to 
becoming terminally differentiated. For these experiments, Tcm (CCR7
+
CD45RA
-
) and Teff 
(CCR7
-
CD45RA
-
) subsets with CD62L
hi/lo
 expression were separated into four populations by 
FACS as previously described in Figure 3.14A. Each population was cultured for 6h with 
PMA/ionomycin and the percentage of CD27
lo 
cells measured in the non-responsive and 
matched responsive groups by flow cytometry (Figure 3.15A, Figure 3.15B). 
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Figure 3.14 Differential CD62L expression may predict unresponsiveness in CD4
+
 
memory T cell populations. Central (CD45RA
-
CCR7
+
) and effector (CD45RA
-
CCR7
-
) 
memory CD4
+ 
T cells with high and low CD62L expression were separated by 
fluorescence activated cells sorting (fraction purities are shown in A). Cells were 
stimulated for 4h with PMA (B,C) or CD3/28 beads (D,E) and analysed for the absence 
of CD69 upregulation.  B,D. Representative flow cytometry plots showing CD69 
expression post stimulation. C,E. Graphs show the median percentage of unresponsive 
cells per population. *p<0.05, ns; no significance at p<0.05 (Friedman’s statistical test 
followed by Dunn’s multiple comparisons analysis). Data is representative of n=2 (D,E) 
and n=4 (B,C) healthy donors in 4 independent experiments.  
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Figure 3.15 The association of CD27 expression and CD69 upregulation following in 
vitro stimulation. Central (CD45RA
-
CCR7
+
) and effector (CD45RA
-
CCR7
-
) memory 
CD4
+ 
T cells with high and low CD62L expression were separated by fluorescence 
activated cells sorting. Populations were stimulated with PMA/Ionomycin or CD3/CD28 
beads. A. Representative flow cytometry plots showing the percentage of CD27
lo
 cells in 
populations responsive (CD4
hi
CD69
lo
) and non-responsive (CD4
int
CD69
hi
) to stimulation. 
B,C. Graphs shows the median percentage CD27
lo
 population in each subset following 
PMA (B) and CD3/CD28 (C) stimulation. Data is representative of n=2-3 healthy donors 
in 3 independent experiments.
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In every sorted subset the percentage of CD27
lo
 cells in the non-responsive fraction was 
greater than in the corresponding responsive fraction. However, the trend suggested that the 
frequency of the CD27
lo
 cells correlated with the differentiation status of the population 
measured (i.e. increasing CD27
lo
 frequency from Tcm CD62L
hi 
through to Teff CD62L
lo
), as 
opposed to differentiating between the non-responsive versus responsive groups specifically 
(Figure 3.15B). These findings were recapitulated in the same system when PMA/ionomycin 
stimulation was substituted for anti-CD3/anti-CD28 Dynabeads
®
 activation (Figure 3.15C). 
Together these findings suggest that expression of CD27 is associated with a particular state 
of memory and not specifically linked to the non-responsive phenotype.  
3.8 The non-responsive CD4+ T cell population does not represent cells 
recently activated in vivo.  
It was considered whether the CD4
int
CD69
lo
 non-responsive population represented memory 
cells recently activated in vivo. PBMC were purified by FACS to separate resting CD4
+
 T 
cells (CD69
lo
) from those recently activated (CD69
hi
) (Figure 3.16A). A small but discernible 
population of recently activated cells were identified but their expression of CD69 was not as 
high as cells artificially stimulated with PMA (Figure 3.16A, Figure 3.16B). When these cells 
were removed by FACS a population of non-responsive cells remained, indicating that non-
responsive cells are not recently activated in vivo. In support of this the resting sorted 
population significantly upregulated CD69 when stimulated but the CD69 expression of 
recently activated cells did not change (Figure 3.16B). Therefore, these cells did not fall 
within the parameters of a CD4
int
CD69
lo 
gate following stimulation. In addition a substantial 
proportion of the recently activated cells died during the stimulation assay (Figure 3.13C, 
Figure 3.16D). The fact that recently activated cells only represent a very small fraction of 
total CD4
+
 T cells (<1.2% in these experiments) and the majority of those die during culture 
(median death 82.0% (76.7-87.4 IQR)) is further evidence against their contribution to the 
non-responsive population.  
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Figure 3.16 Contribution of CD4
+
 T cells activated in vivo to the unresponsive 
population observed following in vitro stimulation. Fluorescence activated cell sorting 
was used to separate recently activated (CD69
hi
) CD4
+ 
T cells from those at rest (CD69
lo
). 
Populations were stimulated for 6h with PMA/Ionomycin and analysed for expression of 
CD69. A Flow cytometry plots showing the median fluorescence intensity (MFI) of sorted 
CD4
+ 
T cell fractions with and without PMA stimulation (also shown graphically in B). C 
Plots show the percentage of surviving cells (purple) in stimulated cell cultures. D Graph 
shows the mean percentage of cell death of each culture. *p<0.05, ns; no significance at 
p<0.05 (Mann Whitney U statistical test. Data is representative of n=2-3 healthy donors in 
2 independent experiments).  
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Never-the-less for subsequent experiments where in vivo activated cells were observed in 
unstimulated cultures they were excluded from the CD69
lo
 gate to make certain that they did 
not contribute to subsequent analysis. 
3.9 The propensity of non-responsive and responsive CD4+ T cells to 
undergo apoptosis 
As the non-responsive CD4
+
 T cell population could not be maintained in cultures over 12h 
the population’s viability and resistance to apoptosis was reassessed. PBMC were cultured for 
6h with PMA/ionomycin and the CD4
+
 T cell population analysed for surface expression of 
phosphatidylserine residues. Annexin V binds to these residues and can be measured by flow 
cytometry in conjunction with a cell membrane permeability dye
[380]
 (Sytox® blue). 
Therefore, combinatorial expression of Annexin V and Sytox is able to distinguish early 
apoptotic (AnnexinV
+
Sytox
-
) and late apoptotic/necrotic (AnnexinV
+
Sytox
+
) cells from the 
viable population.  
As anticipated there was very little apoptosis in the 6h cultures without PMA/ionomycin 
(Figure 3.17A) but strong evidence of apoptosis in the simulated cultures (Figure 3.17B, 
Figure 3.17C). The CD4
int
CD69
lo 
non-responsive population had a greater percentage 
frequency in early apoptosis than their responding CD4
lo
CD69
hi
 counterparts but this was not 
statistically significant (Figure 3.17C). In contrast, there was significantly more late 
apoptosis/necrosis within the non-responsive population when compared to responsive cells 
as represented by median (IQR) values of 13.0% (5.8-22.9) and 3.3% (0.7-7.9) respectively 
(Figure 3.17B, Figure 3.17C). This trend suggests that although the majority of non-
responsive cells are viable they are susceptible to apoptosis and have a lower survival rate 
than responsive CD4
+
 T cells. 
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Figure 3.17 Analysis of  apoptosis markers expressed by CD4
+
 T cells following 
PMA/Ionomycin stimulation. PBMC were cultured for 6h ± PMA/ionomycin stimulation. 
CD4
+ 
T cells (defined by CD3
+
CD8
-
CD4
+
 expression) activated by PMA stimulation 
(CD4
lo
CD69
hi
), and the population which failed to respond (CD4
int
CD69
lo
) were analysed for 
expression of apoptotic markers. A. Representative plots showing CD4
+ 
T cells in early 
(AnnexinV
+
Sytox
-
) and late (AnnexinV
+
Sytox
+
) apoptosis in unstimulated cultures. B. 
Evidence of early and late apoptotic marker expression by unresponsive and responsive CD4
+ 
T cells following stimulation. C. Graph shows the median percentage of unresponsive and 
responsive CD4
+ 
T cells in early and late apoptosis. *p<0.05 depicts statistical significance ns; 
no significance at p<0.05 (Friedman’s statistical test followed by Dunn’s multiple 
comparisons analysis). Data is representative of n=4 healthy donors measured in 2 
experiments.  
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3.10 Investigation of the lymphocyte lineage of the non-responsive CD4+ 
T cell population. 
3.10.1 Is the non-responsive CD4+ T cell population derived from a non-T helper 
cell lineage? 
 To ensure that the non-responsive population represented classical T helper cells it was 
assessed whether they expressed markers associated with three less prevalent cell types. The 
three non-classical T cell lineages chosen were gamma delta T cells, natural killer like T cells 
(NKT-like) and CD4
+
CD8
+
 double positive T cells that express both TCR co-receptors. To 
represent each of these lineages in the analysis PBMC were additionally stained for TCRγδ, 
CD56 and CD8. As the question was not concerned with which one of these lineages the non-
responders might be TCRγδ, CD56 and CD8 were stained using the same fluorochrome. Cells 
with a positive signal in this channel were collectively termed Lin
+ve
 and analysis of this 
mixed group was performed alongside Tcm and Teff subsets of the ‘Lin
-ve’ Thelper population 
(gating strategy is shown in Fig3.18A). 
The aim of initial experiments was to calculate the maximum potential contribution of Lin
+ve 
cells to the non-responsive population based on their frequency and subset distribution in the 
blood. Results from flow cytometry performed on unstimulated PBMC cultures indicated that 
collectively Lin
+ve
 cells represented less than 2% of CD4
+
 T cells (median 1.8% (1.1-2.2 
IQR)) (Figure 3.18B). This small mixed population was distributed more evenly across the 
Tnaive, Tcm, and Teff subsets than conventional TCRαβ Thelper cells. However, the Tnaive/Tmemory 
ratio was inverted with the most Lin
+ve
 cells being an Teff phenotype (median 39.8% (31.5-
43.7 IQR)) (Figure 3.18B). Using the data on the percentage frequency and subset distribution 
of the Lin
+ve
 cells it was estimated what their maximum contribution to the non-responsive 
population would be if every cell in each subset did not respond (Figure 3.18D). This 
theoretical data was superimposed on matching data showing the actual percentage of each 
subset that did not respond in these experiments (Figure 3.18D). 
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Figure 3.18 Investigation of the theoretical contribution of non-T helper CD4
+
 lineages 
to the non-responsive CD4
+
 T cell population. Flow cytometry was used to quantify the 
proportion of CD4
+ 
T cells in peripheral blood that collectively expressed either CD56, 
TCRγδ or CD8, in order to estimate their potential contribution to the previously identified 
non-responsive population (gating strategy is shown in A.). B. The median frequency of this 
mixed population was compared to the proportion of CD4
+ 
T cells with a central memory 
(Tcm; CCR7
+
CD45RO
+
), and effector memory (Teff; CCR7
-
CD45RO
+
) phenotype. C. The 
percentage distribution Tnaive (CCR7+CD45RO
-
), central memory Tcm (CCR7
+
CD45RA
-
), 
and effector memory Teff (CCR7
-
CD45RA
-
) within the mixed CD56/TCRγδ/CD8 population 
was also quantified. D. Graph represents the theoretical maximum contribution of mixed 
lineage cells to each non-responsive fraction if every cell failed to upregulate CD69 when 
stimulated. Calculation is based on data representative of n=6 healthy donors measured in 3 
independent experiments.  
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The frequency of the mixed Lin
+ve 
population suggests that these cells would not substantially 
contribute to the non-responsive fraction of each memory subset even if every Lin
+ve
 cell was 
hyporesponsive.  
To add more direct evidence to this finding Lin
+ve
 cells were purified by FACS alongside 
conventional Tcm and Teff memory CD4
+
 T cells (for gating strategy see Figure 3.19A). Each 
population was cultured with and without PMA/ionomycin and the percentage of non-
responsive cells measured by flow cytometry (Figure 3.19B, Figure 3.19C). Stimulation 
caused the expression of the Lin
+ve
 markers to downregulate on some cells of the sorted 
fraction (Figure 3.19B middle panel) but it was impossible to identify which of the three 
markers was responsible. The proportion of the sorted Lin
+ve
 cells with the CD4
int
CD69
lo
 non-
responsive phenotype was similar to the sorted conventional Teff population, with median 
values measured at 26.8% (18.7-38.1 IQR) and 26.8% (5.5-69.1 IQR) respectively. Despite 
this the majority of the Lin
+ 
population did respond which implies their contribution to the 
non-responsive population was even lower than was initially estimated. In addition, 
PMA/ionomycin induced cell death was substantially greater in the Lin
+ 
population than other 
subsets, further indicating that these cells cannot substantially contribute to the non-
responsive phenotype (Figure 3.19D). 
3.10.2 Do non-responsive CD4+ T cells display characteristics associated with a 
regulatory T cell phenotype? 
It was investigated whether the non-responsive population had a Treg phenotype by separating 
Treg from non-Treg then examining their responsiveness to PMA/ionomycin. In initial 
experiments, MACS technology (Miltenyi Biotech) was used to purify CD4
+
 T cells and then 
separate this population into Treg and non-Treg components based on expression of CD25. The 
percentage purity of the CD4
+
 isolation and the distribution of Treg within that population was 
measured by flow cytometry (Figure 3.20A left panel). In the second MACS step CD25
int
 
cells (non-Treg) were depleted of CD25
hi 
(Treg) cells through a negative selection process and   
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Figure 3.19 Expression of CD69 by non T helper CD4
+
 lineages following 
PMA/Ionomycin stimulation. Fluorescence activated cell sorting was used to purify a mixed 
CD4
+
 non-T helper cell population (CD56/TCRγδ/CD8) and two T helper memory subsets 
(Gating shown in A). B. The mixed lineage population was cultured for 6h ± PMA and 
analysed for expression of CD3, CD4 and CD69. C. The percentage of cells unresponsive to 
stimulation was compared to that observed in T helper memory subsets. D. The cell death in 
stimulated cultures was measured by the percentage of CD3
+
 cells that were positive for the 
dead cell dye sytox.  Data is representative of the median and IQR values from n=2-3 healthy 
donors measured across 2 experiments. ns = no significance (Friedman statistical test, 
followed by Dunn’s multiple comparisons analysis).  
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the purity of these fractions was measured (Figure 3.20A right panel). CD25
hi
 alone is an 
incomplete definition of a Treg population and this was reflected in the poor purities achieved 
through the second separation. Although there was approximately a five-fold enrichment of 
Treg in the CD25
hi
 fraction based on a CD25
hi
CD127
lo
 definition there was 70% contamination 
with non-Treg CD4
+
 T cells. The depletion of Treg from the non-Treg fraction was also poor 
(Figure 3.20A right panel). Never-the-less, samples from the total CD4
+
 isolation along with 
the Treg and Treg-depleted fractions were stimulated with PMA/ionomyin and analysed for the 
presence of the non-responsive population. The Treg population was found to have more non-
responsive cells than the Treg-depleted fraction (Figure 3.20B, Figure 3.20C). Reciprocally, 
removal of Treg caused a small reduction of non-responsive cells in the Treg-depleted fraction 
when compared to total CD4
+
 population (Figure 3.20B, Figure 3.20C). This data suggests 
that Treg which fail to upregulate CD69 may significantly contribute to the non-responsive 
population. Despite such findings it was noted that the majority of Treg upregulate CD69 
readily. Therefore if Treg
 
do contribute to the non-responsive population it may be a distinct 
sub-population Treg as opposed to the population as a whole.  
Based on the significance of IL-2 in Treg function and maintenance it was then questioned 
whether addition of exogenous IL-2 cytokine to Treg cultures would perturb the non-
responsive population. Recombinant IL-2 was added to the total CD4
+
, Treg and Treg-depleted 
cultures at the beginning of each stimulation assay. It was found that addition of IL-2 had no 
effect on the non-responsive population in any of the cultures (Figure 3.20D). This finding 
suggests that lack of CD69 upregulation is not related to IL-2 deficiency in the culture milieu 
and consequential insufficient signalling through the IL-2 pathway.  
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Figure 3.20 CD69 expression by Treg and non-Treg CD4
+
 T cell populations in response 
to in vitro stimulation. CD4
+ 
T cells were isolated from PBMC and then separated into Treg 
(CD25
hi
) and non-Treg (CD25
int
) compartments in a two-step magnetic activated cell sorting 
process. Populations were stimulated for 6h with PMA/ionomycin ± the cytokine IL-2, then 
analysed for the absence of CD69 upregulation. A. Representative flow cytometry plots 
showing purity of the CD4
+ 
isolation and Treg/non-Treg separation based on a CD25 and 
CD127 gating definition. B. Example plots showing CD4
int
CD69
lo
 and CD4
lo
CD69
hi
 
populations in each subset. C. The median percentage non-responsive cells (CD4
int
CD69
lo
) in 
each subset and the interquartile range. D. The effect of IL-2 addition on lack of CD69 
upregulation in stimulated cultures. Data is representative of n=2 healthy donors measured 
independently.  
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Although informative these findings were attained on a background of poor CD4
+
 Treg and 
non-Treg purities using MACS separation. In the following experiments this was substituted 
for FACS to give a more complete Treg definition using both CD25 and CD127 (for gating 
strategy see Figure 3.21A). As mainly cells within the memory CD4
+
 T cell compartment 
contributed to the non-responsive population only Tcm and Teff populations were separated 
into their Treg and non-Treg constituents. These four FACS-separated populations were 
cultured for 6h with PMA/ionomycin and the percentage of non-responsive cells measured by 
flow cytometry (Figure 3.21B, 3.21C). Consistent with other experiments the frequency of 
non-responsive cells was considerably higher than when the same population was analysed by 
gating from a PBMC culture. Results indicated that the Teff Treg-depleted non-responsive 
population was considerably more prevalent than in corresponding Tcm cultures (Figure 
3.21C). The Treg cultures from both subsets had a comparable frequency of non-responsive 
cells that were more prevalent than in subset-matched non-Treg assays. The MFI of CD69 in 
the responding population (CD69
hi
) of each fraction was also measured and indicated that 
responding Treg had lower CD69 expression than their non-Treg counterparts in both the Tcm 
and Teff subsets. This shows that Treg do not upregulate CD69 in response to PMA/ionomycin 
to the same extent as non-Treg cells and supports initial findings that Treg contribute to the non-
responsive population. 
3.11 Characteristics associated with hyporesponsiveness in the non- 
responsive CD4
+
 T cell population. 
3.11.1 Expression of PD-1 by stimulated CD4+ T cell subsets.  
Up to this point no combination of T cell homing receptors, indicators of differentiation status 
or lineage markers measured could define the non-responsive population specifically. With 
reference to their lack of activation it was considered whether these cells might have 
characteristics consistent with T cell exhaustion. PD-1 expression is associated with T cell 
exhaustion in the context of chronic overstimulation, such as in the tumour microenvironment  
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Figure 3.21 Analysis of an unresponsive phenotype in regulatory verses non-regulatory 
CD4
+
 T cell subsets. Treg (CD25
hi
CD127
lo
) and non-Treg (CD25
int
CD127
int
) populations in 
central and effector memory CD4
+
 T cell subsets were purified by fluorescence activated cell 
sorting (Gating is shown in A.). The four populations were cultured for 6h with 
PMA/ionomycin and analysed for the absence of CD69 upregulation. B. Representative flow 
cytometry plots showing the proportion of each population which responded to the 
stimulation (CD69
hi
) and that failed to upregulate CD69. C. Graphical representation of the 
percentage of each sorted subset that failed to upregulate CD69. D. The CD69 median 
fluorescence intensity (MFI) of cells responsive to stimulation (CD69
hi
). Data representative 
of n=2 healthy donors in n=1 experiment. 
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where engagement with PD-L1 can render cells hyporesponsive
[196,197]
. Therefore, PD-1 
expression was measured by flow cytometry as a candidate marker for the non-responsive 
phenotype. To establish a baseline of PD-1 expression by CD4
+
 T cells flow cytometry was 
performed on freshly isolated PBMC cultures gated on CD3
+
CD8
-
CD4
+
 lymphocytes (Figure 
3.22A, Figure 3.22B). The vast majority of the Tnaive CD4
+
 subset did not express PD-1 but in 
the memory (CD45RO
+
) subset there was more varied expression of the receptor. As for 
memory cells there was no clear definition between PD-1
lo
 and PD-1
hi
 populations a gating 
threshold was set where PD-1
hi
 expression was defined as staining intensity above the level of 
the Tnaive population. Although significantly more memory cells were PD-1
hi 
(38.2% (37.4-
51.3) (median and IQR)) it was noted that the MFI in the PD-1
lo
 fraction was slightly elevated 
compared to the Tnaive population. This may indicate that all memory CD4
+
 T cells express 
PD-1 to a varying degree and the increase in its expression is progressive rather than phasic. 
It was then investigated whether PD-1
hi
 memory T cells less readily downregulated CD4
+
 and 
upregulated CD69 than their PD-1
lo
 counterparts following PMA/ionomycin treatment. 
PBMC cultures were stimulated and the PD-1
lo
 and PD-1
hi 
memory T cell populations 
examined for the percentage of unresponsive cells. Tnaive cells which upregulate CD69 readily 
were included in the analysis as an internal control for the stimulation (Figure 3.22C, Figure 
3.22D).  As expected both memory populations had significantly more non-responsive cells 
than the control naïve subset. However, despite a slight increase in the non-responsive 
phenotype in the PD-1
hi
 fraction this was not statistically significant compared with PD-1
lo
 
cells (Figure 3.22C, Figure 3.22D).  
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Figure 3.22 PD-1 expression by CD4
+
 T cell subsets and the effect of differential 
expression on T cell activation. CD4
+ 
T cells from PBMC cultures were analysed for 
expression of PD-1 by flow cytometry. Additionally, cultures were stimulated for 6h with 
PMA/Ionomycin and upregulation of CD69 was measured. A. Representative flow cytometry 
plot showing PD-1 expression by naïve (orange) and memory (blue) CD3
+
CD8
-
CD4
+
 T cell 
subsets in freshly isolated PBMC samples. Numbers represent the percentage of PD-1
hi
 and 
PD-1
lo 
cells per individual subset. B. Graph shows the median percentage of PD-1
hi
 cells in 
each subset. Error bars represent the IQR. C. Expression of CD69 in naïve, and PD-1
hi/lo
 
memory T cells ± stimulation. D. The percentage of subsets identified in in C. that fail to 
upregulate CD69 following stimulation. ns= no significance at p<0.05, *p<0.05 (Friedman 
statistical test followed with Dunn’s multiple comparison analysis). **p<0.01 (Mann Whitney 
U statistical test). Data is representative of n=5-6 healthy individuals measured across 3 
experiments.  
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As work in PBMC cultures suggested that PD-1 status is not related to non-responsiveness an 
alternative approach using FACS was applied to substantiate these observations (Figure 3.23). 
Tcm and Teff CD4
+
 T cell subsets were separated into their PD-1
lo
 and PD-1
hi 
fractions by 
FACS (for gating strategy see Figure 3.23A).Each population was stimulated for 6h with 
PMA/ionomycin and analysed for the percentage of CD4
int
CD69
lo
 non-responsive cells 
(Figure 2.23B, Figure 2.23C). In the Tcm sorted subsets there were more non-responsive cells 
in the PD-1
hi
 fraction than in the PD-1
lo
 culture. In contrast, in the Teff subset where non-
responsive cells have been shown to be most prevalent differential PD-1 expression had little 
bearing on the frequency of the non-responsive population (Figure 3.23C).  
The MFI of CD69 expression was also analysed for the responding (CD4
lo
CD69
hi
) cell 
fraction. In the Tcm PD-1
hi 
culture the CD69 MFI of responding cells was lower than in the 
corresponding PD-1
lo
 culture. This is consistent with previous data in suggesting that the PD-
1
hi
 fraction is less responsive. However, the reverse of this trend was seen in the Teff 
population where the responsive PD-1
hi
 had a greater CD69 MFI, but there were no 
statistically significant differences attached to these observations. In conclusion, these 
findings support some association between PD-1
hi
 expression and diminished responsiveness 
to PMA/ionomycin in the Tcm subset. However, PD-1 expression is not related to the non-
responsive phenotype in the Teff subset and is an insufficient marker to define non-responsive 
CD4
+
 T cells prior to stimulation.  
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Figure 3.23 The relationship between PD-1 and CD69 expression in sorted CD4
+
 
memory T cell subsets. PD-1
hi
 and PD-1
lo
 CD4
+ 
memory T cell populations were purified by 
fluorescence activated cell sorting (gating strategy from the CD4
+ 
T cell stage forwards is 
shown in A.). Populations were cultured for 6h ± PMA and analysed for the absence of CD69 
upregulation (representative flow cytometry plots shown in B, graphical representation is 
shown in C.). D. The CD69 median fluorescence intensity (MFI) of cells responsive to 
stimulation. Data representative of n=2 healthy donors in n=1 experiment. 
B.
C.
A.
GATING
D.
Tcm Teff
0
20
40
60
80
PD-1lo
PD-1hi
PMA/Iono          +                                           +
%
 C
D
4
in
t C
D
6
9
lo
in
s
o
rt
e
d
 s
u
b
s
e
ts
Tcm Teff
0
200
400
600
800
1000
PD-1lo
PD-1hi
PMA/Iono          +                                           +
C
D
6
9
 M
F
I 
o
f
re
s
p
o
n
d
in
g
 p
o
p
u
la
ti
o
n
s
PD-1hiPD-1lo
Teff
Tcm
C
D
4
CD69
C
D
8
CD4
C
C
R
7
CD45RA
P
D
-1
CD4
P
D
-1
CD4
SORT SORT
SORT SORT
Chapter 3  133 
 
3.11.2 The effect of exogenous gamma chain cytokine on the non-responsiveness 
of CD4
+
 T cells. 
As examination of PD-1 expression did not conclusively link the non-responsive population 
to T cell exhaustion it was investigated whether these cells exhibited ‘anergic’ as opposed to 
‘exhausted’ characteristics. There are currently no positive markers that identify anergic T 
cells in vivo. However, the hyporesponsiveness elicited by anergic T cells can be reversed 
through the addition of exogenous IL-2 in in vitro cultures
[189,381]
. Prior work in my study had 
shown IL-2 did not influence the non-responsive population in stimulated Treg, and Treg-
depleted cultures. Never-the-less this line of investigation was extended with the addition of 
other common gamma chain family cytokines (IL-7 and IL-15) in combination with IL-2.  
PBMC were cultured for 6h with PMA/ionomycin in the presence of IL-2, IL-7, IL-15 and a 
combination thereof (Figure 3.24). The percentage of non-responsive cells in the CD3
+
CD4
+
 
T cell compartment was analysed by flow cytometry (Figure 3.24A). Addition of IL-2 to 
stimulated PBMC cultures again had no impact on the non-responsive CD4
+
 T cell population 
and its persistence suggests these cells are not anergic (Figure 3.24B). In separate experiments 
where all three cytokines were investigated there was a small decrease in the median non-
responsive frequency noted when IL-2 alone or the combination of IL-2, IL-7 and IL-15 was 
added to the cultures (Figure 3.24C). This trend was not statistically significant and there was 
no change in the non-responsive cell frequency when IL-7 and IL-15 were added alone. The 
overall effect of exogenous cytokine in this system was minimal and suggests anergy does not 
contribute to the hyporesponsiveness observed in these assays.  
3.11.3 Intracellular expression of CD69 in the non-responsive CD4+ T cell 
population.  
A documented mechanism behind the hyporesponsiveness of anergic T cells is the 
sequestration of T cell signalling components
[176,177,179]
. This is achieved via the targeting of 
signalling mediators for degradation and an accelerated rate of proteolysis through increased 
ubiquitin ligase activity
[172]
. To assess whether the non-responsive CD4
+
 T cell population 
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 Figure 3.24 CD69 expression by CD4
+
 T cells is not affected by presence of of γc chain 
cytokine in vitro. PBMC were cultured for 6h with PMA/Ionomycin ± IL-2, IL-7 and IL-15. 
CD4
+ 
T cells were analysed by flow cytometry for cells lacking CD69 expression. A. 
Representative plots showing CD69 expression by unstimulated (top panel) and simulated 
(bottom panel) CD4 T cells  (gated on CD3
+ 
 lymphocytes) with and without  combinatorial γc 
chain cytokine. B. Comparison of the percentage of T cells unresponsive to stimulation 
(CD4
int
CD69
lo
)  in the absence and presence of IL-2. C. In experiments independent to those 
shown in B. the absence CD69 upregulation in the presence of multiple cytokines was also 
tested.  
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demonstrated these characteristics staining for both surface and intracellular CD69 was 
performed consecutively. Surface and intracellular CD69 was labelled using different 
fluorochromes to identify whether non-responsive cells expressed CD69 intracellularly 
(Figure 3.25). A proteasome inhibitor (Velcade
®
) was then added to the PBMC cultures at 
increasing concentrations. By blocking proteasomal degradation it was proposed that any 
translated CD69 would accumulate in the cytosol. Therefore, it could be detected whether 
non-responsive cells translated CD69 protein that was targeted for lysosomal compartments 
before reaching the cell membrane.   
PBMC were cultured for 6h with PMA/ionomycin and the CD3
+
CD8
-
CD4
+
 T cell population 
analysed for surface and intracellular expression of CD69 (Figure 3.25A). When CD69 was 
stained intracellularly the background staining for CD69 was increased even in the absence of 
PMA/ionomycin (Figure 3.25A top panel). Due to this shift the gating of the intracellular non-
responsive population was based on intracellular staining from the unstimulated control 
culture. Although there was a slight reduction in the non-responsive cell frequency when 
CD69 was measured intracellularly compared to at the surface (0.4% difference in median 
frequencies) results suggested that the population of CD4
int
CD69
lo
 cells persisted (Figure 
2.25A middle panel, Figure 2.25C). This finding is based on the fact that not all cells were 
CD69
hi 
when stained intracellularly and thus the non-responsive population does not express 
CD69 protein in the cytosol. When the proteasome inhibitor was added to the cultures there 
was a small percentage increase of non-responsive CD4
+
 T cells at high concentrations 
(Figure 3.25C). This was unexpected as it was anticipated that by blocking protein 
degradation CD69 expression would increase and thus reduce the CD4
int
CD69
lo
 population. 
The CD69 MFI of the responding fraction also reduced with increasing concentrations of 
inhibitor (Figure 3.25D). In light of these observations the percentage of IFNγ+ cells was 
measured to control for the effect of the inhibitor and T cell activation. Increasing doses of  
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Figure 3.25  The effect of proteosome inhibition on CD69 expression by stimulated CD4
+
 
cells. PBMC were cultured with PMA/Ionomycin and increasing concentrations of Velcade 
(Bortezomib). The CD3
+
CD8
-
CD4
+
 T cell population was analysed for CD69 upregulation 
relative to unstimulated cultures. A.  Flow cytometry plots represent the percentage of CD4
int 
CD69
lo 
cells in each condition when staining for surface (left panel) and intracellular (right 
panel) CD69 expression.  B. Plots represent the percentage of IFNγ+ CD4+ T cells. C. Surface 
and intracellular analysis of  the CD4
int 
CD69
lo 
 population with increasing concentrations of 
inhibitor. D. Median (and range) fluorescence intensity (MFI) of surface CD69 expression 
and the median (and range) percentage of IFNγ+ CD4+ T cells within the responsive fraction. 
Data is representative of n=3 healthy donors.  
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proteasome inhibitor resulted in a decrease of IFNγ+ cells especially at high concentrations 
(Figure 3.25B, Figure 3.25D).This indicated that the proteasome inhibitor had more 
ubiquitous effects on CD4
+
 T cell activation than anticipated.  
3.12 Gene expression analysis of PMA/ionomycin-stimulated CD4+ T 
cell populations.  
3.12.1 Investigation of CD69 gene expression by the non-responsive CD4+ T cell 
phenotype. 
As no intracellular stores of CD69 protein were detected in the non-responsive population 
(Figure 3.25) it was investigated whether the root of this deficiency was a lack of CD69 
mRNA expression. For this investigation cDNA was prepared from mRNA isolates of the 
desired cell cultures. Multiplex real time PCR (qPCR) was then used to compare the 
expression of the CD69 gene to a housekeeping gene to normalise differences in the starting 
amount of cDNA material. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) was 
chosen as a housekeeping gene and was initially tested to confirm that the cycle threshold (Ct) 
value measured was directly proportional to the amount of material added. CD4
+
 T cells were 
isolated from PBMC using microbead MACS technology and the purity of the CD4
+
 
population was confirmed by flow cytometry (95.4% CD4
+
) (Figure 3.26A). A titration based 
on equivalent cell numbers from the CD4
+
 cell isolation cDNA prep was performed and the 
corresponding GAPDH qPCR amplification curves analysed for each Ct value (Figure 3.26B, 
Fig3.26C). Results showed that the Ct value was inversely proportional to the Log2 cell 
number added which was consistent with a doubling of cDNA material per amplification 
cycle. Therefore, the GAPDH primer was considered free of contaminants and suitable for use 
as a housekeeping gene in multiplex experiments.  
Work in this study had thus far failed to identify surface markers (or combination thereof) that 
could identify the non-responsive CD4
+
 T cell population prior to PMA/ionomycin 
stimulation. A complex cell sorting strategy was devised in order to isolate non-responsive  
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Figure 3.26 qPCR analysis of GAPDH gene expression in a cell number titration assay. 
CD4
+ 
T cells were purified from peripheral blood mononuclear cells by magnetic-activated 
cell sorting (MACs). cDNA was prepared from a known number of CD4
+ 
T cells and a 
dilution series performed to yield a quantity of cDNA from a calculated equivalent cell 
number. qPCR was performed to assess  the relative amount of GAPDH gene in each sample. 
A. Flow cytometry was used to confirm the purity of the CD4 MACS isolation. Plots 
represent the forward/side scatter profiles (top panel) and the percentage of CD4
+
 cells 
(bottom panel) in the separated CD4 negative and positive fractions. B. qPCR amplification 
curves showing the amplification of GAPDH for each cell equivalent amount of cDNA 
(legend indicates the number of CD4
+ 
T cells per PCR reaction). Technical replicate's 
(duplicate) curves are shown for each cell number. C. Graph showing the relationship 
between the cycle threshold (Ct) of GAPDH and the applied cell number (log2). Data is 
representative of n=2 technical replicates n=1 experiment.  
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cells at a purity sufficient for gene expression analysis (Figure 3.27A).  As work on sorted T 
cell subset had shown that non-responsive cells were predominantly an effector memory 
phenotype (Figure 3.13) CD4
+
CCR7
-
CD45RA
-
 cells were purified from PBMC by FACS. 
This population was stimulated for 4h with PMA/ionomycin and then separated into 
CD4
int
CD69
lo 
non-responsive and CD4
lo
CD69
hi
 responsive fractions by a second round of 
FACS (Figure 3.27A Figure 3.27B). Multiplex qPCR for CD69 and GAPDH was performed 
for both fractions in technical triplicates and the mean Ct analysed for n=5 donors (Figure 
3.27C).  Strikingly, when the fold change between CD69 expression and GAPDH expression 
was analysed (calculated by 2
^-ΔCt
) it showed that the non-responsive population had 
approximately double the fold change in CD69 gene expression compared with the responsive 
fraction (Figure 3.27D). Although the elevated CD69 gene expression in the non-responsive 
fraction was not statistically significant this trend was counter-intuitive, as it was expected 
that the highest CD69 mRNA expression would be found in the responding population which 
expressed the highest level of CD69 protein. Additionally, the non-responsive population had 
previously been shown to have no notable intracellular expression of the receptor and it was 
not anticipated that the population would display greater levels of message with no evidence 
of translation (Figure 3.25).  
In light of these findings CD69 gene expression was examined in unstimulated and stimulated 
total memory CD4
+
 T cell cultures. This way it could be assessed if the differential CD69 
expression between the sorted non-responsive and responsive Teff fractions was population 
specific or a consequence of PMA/ionomycin stimulation. For these experiments memory 
(CD45RA
-
) CD4
+
 T cells were purified from PBMC by MACS and the purity of the retrieved 
fractions confirmed by flow cytometry (Figure 3.28A). The memory T cells were cultured 
with and without PMA/ionomycin and cDNA prepared from the unstimulated and stimulated 
cultures. Multiplex qPCR was used to compare the expression of CD69 to the internal 
GAPDH control as previously described.  
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Figure 3.27 Analysis of CD69 gene expression by responsive and non responsive effector 
memory CD4
+
 T cells. CD4
+ 
effector memory (CD45RA
-
CCR7
-
) T cells were purified by 
FACS. Following PMA/Ionomycin stimulation these cells were re-sorted into responsive 
(CD4
lo
CD69
hi
) and non-responsive (CD4
int
CD69
lo
) populations. cDNA preparations from 
each population were then analysed by qPCR to relatively quantify expression of the CD69 
gene. A. Representative flow cytometry plots showing the purity of CD4
+ 
effector memory T 
cells following the pre stimulation separation. B. Plots show the purity of the non-responsive 
and responsive populations after the post stimulation separation. C. qPCR amplification 
curves show the specific amplification of the CD69 gene (top panel) and the matched control 
gene GAPDH (bottom panel) for each population. Technical replicate's (triplicate) curves are 
shown for each condition. D. Graph shows the median (And IQR) fold change (2^
-ΔCt
) 
between the CD69 and GAPDH gene for in responsive and non-responsive cells. ns= no 
significance at p<0.05 (paired student T test). Data is representative of n=5 independent 
experiments. 
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Figure 3.28 Analysis of CD69 gene expression by effector memory CD4
+
 T cells 
following ex vivo stimulation. Memory CD4
+ 
T cells (CD45RA
-
) were purified from PBMC 
by magnetic-activated cell sorting (MACs) and cultured with and without PMA/ionomycin. 
cDNA preparations were analysed by qPCR for expression of the CD69 gene relative to the 
control gene GAPDH. A. Flow cytometry was used to measure the purity of the MACS 
separation. Plots show the forward/side scatter profiles, the percentage of cells that are 
CD4
+
, and the percentage of CD4
+
 cells that are memory (CD45RA
-
) in the fractions 
produced following separation. B. qPCR amplification curves show the specific 
amplification of the CD69 gene (top panel) and the matched control gene GAPDH (bottom 
panel) for unstimulated and stimulated memory CD4
+ 
T
 
cell cDNA. Technical replicate's 
(triplicate) curves are shown for each condition. C. Graph shows the mean Ct value for 
GAPDH for each culture condition (cell numbers were equivalent). D. Graph shows the 
mean fold change (2^
-ΔCt
) between the CD69 and GAPDH gene expression in unstimulated 
and stimulated memory CD4
+ 
T cells. Data is representative of n=1 donor measured in 2 
technically replicated experiments.  
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It was found that the Ct values of GAPDH were the same for the unstimulated and stimulated 
cultures, thus confirming the same amount of genetic material had been applied to each assay 
(Figure 3.28B bottom panel, Figure 3.28C). However, the fold change in CD69 expression 
showed that the unstimulated culture had approximately seventeen times greater CD69 
expression than the matched stimulated culture (Figure 3.28D). This result confirmed that a 6 
hour PMA/ionomycin stimulation induces a reduction in CD69 gene expression in CD4
+
 
memory T cells. Additionally this suggests that incomplete downregulation of CD69 mRNA 
expression in the sorted non-responsive population is consistent with an inability of these 
cells to activate. 
3.12.2 Analysis of IFNγ cytokine gene expression.  
The expression of the cytokine IFNγ was also analysed at mRNA level in the purified non-
responsive and responsive populations defined in section 3.12.1. As with analysis of the 
activation marker CD69 the expression of IFNγ was also measured in purified unstimulated 
and stimulated total memory CD4
+
 T cell populations. Similarly, such experiments could 
reveal changes solely resulting from the effects of the stimulation and be informative in the 
analysis of the sorted non-responsive and responsive Teff
 
phenotypes. 
PMA/ionomycin stimulation induces some memory CD4
+
 T cells to produce IFNγ protein (as 
shown in Figure 3.1E, Figure 3.2M) but no protein production occurs in resting cells. 
Therefore it was expected that cDNA preparations from stimulated cultures would show 
greater levels of IFNγ mRNA. However, findings showed that expression of the IFNγ gene in 
stimulated cultures was barely within the detectable range by qPCR as indicated by a very 
high Ct value (Figure 3.29A). The relative fold change in IFNγ gene expression was also 
around 4.2x10
4
 times greater in unstimulated cDNA preps as compared to stimulated preps 
(Figure 3.29A). These findings suggests that unstimulated (resting) memory CD4
+
 T cells 
have greater stores of IFNγ mRNA than cells stimulated for six hours with PMA/ionomycin.  
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Figure 3.29 Analysis of IFNγ gene expression by effector memory CD4+ T cell 
populations. A. Purified CD4
+
CD45RA
-
 memory T cells were cultured with and without 
PMA/ionomycin for 6h. Expression of IFNγ (relative to the control gene GAPDH) was 
measured from unstimulated and stimulated cultures by qPCR. Data is indicative technical 
triplicate amplification curves in n=1 experiment. B. Expression of IFNγ was measured in two 
effector memory CD45RA
-
CCR7
-
 populations that did and did not respond to 
PMA/ionomycin stimulation (CD4
lo
CD69
hi
 and CD4
int
CD69
lo
 surface expression 
respectively). Data is indicative of technical triplicate amplification curves for n=3 donors. ns; 
no significance at p<0.05. A-B. qPCR amplification curves for IFNγ and GAPDH are shown 
for all populations investigated. Graphs (left) indicate the fold change (2^
-ΔCt
) between IFNγ 
and GAPDH expression for each population.  
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Similar to the analysis of CD69 mRNA levels the Teff non-responsive population had greater 
relative IFNγ expression comparative to the match responsive fraction (Figure 3.29B). This 
trend matched those observations from total memory CD4
+ 
T cell cultures (Figure 3.29A), 
although the difference in relative gene expression was nowhere near as profound (18 fold as 
opposed to 4.2x10
4
 fold). This was predominantly because IFNγ gene expression by the Teff 
responsive fraction was not diminished to the level observed in the stimulated memory 
culture. Together these results suggest that the behaviour of the non-responsive CD4
+
 T cells 
mirrors that of unstimulated cells, but in responsive (or stimulated) populations IFNγ mRNA 
expression is attenuated following exposure to PMA/ionomycin for 4 hours.  
3.12.3 Expression analysis of T cell receptor signalling genes.  
It was considered that the CD4
int
CD69
lo
 non-responsive phenotype may be induced through 
deficient intracellular signalling pathways triggered by PMA/ionomycin activation. Therefore, 
the expression of four key genes associated with T cell activation was measured to identify 
changes in the non-responsive population. The candidate genes included three T cell 
signalling genes (for LCK, PKCƟ, VAV-1) and one metabolic regulator (AMPK) which were 
measured independently by multiplex qPCR. 
To get a baseline expression from each gene qPCR was initially performed on unstimulated 
and stimulated CD4
+
 memory T cell cultures as described in Figure 3.28A. qPCR 
amplification curves were analysed for the Ct values of each gene and internal GAPDH 
control, then the fold change between these values calculated for each culture condition 
(Figure 3.30). The AMPK gene showed negligible amplification in qPCR reactions performed 
using cDNA preparations from both unstimulated and stimulated cultures. As its expression 
was beyond the detection range in such test cultures where there was ample input of genetic 
material this gene was excluded from subsequent analysis using sorted non-responsive cells 
(data not shown). 
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Figure 3.30 Expression of T cell receptor signalling genes in memory CD4
+
 T cells. 
Memory CD4
+ 
T cells (CD4
+
CD45RA
-
) were purified from peripheral blood mononuclear 
cells by magnetic-activated cell sorting (MACs). Cells were cultured for with and without 
PMA/ionomycin and cDNA prepared from each condition. qPCR analysis was performed to 
measure the gene expression of three T cell signalling associated genes (LCK, PKCθ, VAV-1) 
relative to the control gene GAPDH. A. qPCR amplification curves show the specific 
amplification of each signalling gene (left panel) and the matched control gene GAPDH 
(right panel) for unstimulated (blue) and stimulated (green) memory CD4
+ 
cell cDNA. 
Technical replicate's (triplicate) curves are shown for each cell number. B-D. Graphs show 
the fold change (2^
-ΔCt
) between the gene expression of each signalling gene and GAPDH in 
unstimulated and stimulated memory CD4
+ 
T cell cultures. Data is representative of n=1 
experiment.   
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The T cell receptor signalling-related genes were all shown to amplify exponentially in each 
PCR reaction albeit towards the lower end of the range of detection (Figure 3.30A). There 
was an increase in expression of all three signalling genes in the stimulated memory T cell 
cultures when compared to those cultures not exposed to PMA/ionomycin (Figure 3.30B-D). 
In the case of PKCƟ and VAV-1 the fold increase in gene expression between the 
unstimulated and stimulated cultures was relatively small, measuring in at 7-fold and 3.5-fold 
respectively (as calculated by 2
^-ΔCt
) (Figure 3.30C, Figure 3.30D). However, the difference in 
LCK gene expression was more substantial, with a 13.75-fold increase in expression 
following PMA/ionomycin treatment (Figure 3.30B). Together this data indicates that 
PMA/ionomycin stimulation itself increases mRNA expression of the three tested signalling 
components with LCK most influenced by the stimulation.  
When the three T cell signalling genes were measured in FACS sorted Teff non-responsive and 
responsive populations the trends observed in the stimulation control experiments were not 
recapitulated (Figure 3.31). Here there were minimal differences in the expression of LCK, 
PKCƟ and VAV-1 between each fraction, although the low expression of these genes 
combined with minimal starting material (restricted by the infrequency of the non-responsive 
population) rendered analysis of this data challenging. However, findings indicate that 
deficiencies in these genes are not responsible for the CD4
int
CD69
lo
 non-responsive 
phenotype as comparable expression levels were observed in the corresponding responsive 
fractions.  
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Figure 3.31 Expression of T cell receptor signalling genes in responsive and non 
responsive effector memory CD4
+
 T cells. Purified CD4
+
 effector memory T cells 
(CD45RA
-
CCR7
-
) were stimulated with PMA/Ionomycin. Cells were separated into 
responsive (CD4
lo
CD69
hi
) and non-responsive (CD4
int
CD69
lo
) populations by FACS. 
Expression of LCK, PKCθ and VAV-1 genes was examined relative to the control gene 
(GAPDH) by qPCR. A. qPCR amplification curves show the amplification of each signalling 
gene (left panel) and the control gene GAPDH (right panel) from each cDNA preparation. 
Technical triplicate amplification curves are shown for each population. B-D. Graphs show 
the fold change (2^
-ΔCt
) between the each signalling and control gene pair (and thus the 
relative gene expression) for both the non-responsive and responsive populations. Data is 
representative of n=3 paired non-responsive and responsive cell samples repeatedly measured 
in n=2-3 independent qPCR reactions. ns; no significance at p<0.05.  
Cycle
F
lu
o
re
s
c
e
n
c
e
Cycle
F
lu
o
re
s
c
e
n
c
e
Cycle
F
lu
o
re
s
c
e
n
c
e
Cycle
F
lu
o
re
s
c
e
n
c
e
Cycle
F
lu
o
re
s
c
e
n
c
e
Cycle
F
lu
o
re
s
c
e
n
c
e LCK
PKCθ
VAV-1
GAPDH
GAPDH
GAPDH
A.
LCK
PKCθ
VAV-1
B. D.
C.Non Responder Responder
0.00
0.01
0.02
0.03
0.04
0.05
0.06
ns
2
^
-
C
t L
C
K
Non Responder Responder
0.00
0.01
0.02
0.03
0.04 ns
2
^
-
C
t P
K
C

Non Responder Responder
0.00
0.01
0.02
0.03
0.04 ns
2
^
-
C
t V
A
V
-1
Non Responder
Responder
Non Responder
Responder
Non Responder
Responder
Chapter 3  148 
 
3.13 Discussion 
Although naive CD4
+
 T cells do express some effector cytokines when activated (most 
notably IL-2) the majority of T cell cytokines are produced by differentiated, antigen-
experienced memory populations
[382,383]
. This investigation identified a subpopulation of cells 
within the two main memory subsets (Tcm and Teff) which failed to produce any of thirteen 
effector cytokines when simulated in vitro (Figure 3.3). Findings suggest that a considerable 
proportion of the memory population has a function that cannot be accounted for following 
exposure to PMA/ionomycin. It may be assumed that these cells have some biological 
purpose or their persistence in vivo would be futile. A summary of the potential function and 
identity of these cells are explored below; 
1) Cells have an atypical cytokine profile - although the panel of cytokines tested in these 
experiments was extensive it remains possible that the ‘cytokine-ve’ cells express other 
effector molecules untested here.  Two notable examples of these include the Th1 and Th17-
associated cytokine lymphotoxin alpha (LT-α) and IL-25 which associated with Th2 
differentiation
[384,385]
. Given that flow cytometers now have more fluorescence channels 
available than at the time of these experiments there is more scope to expand the cytokine 
panel to include further markers in the future. 
2)  Cells have an atypical cytokine response to PMA/ionomycin – It is possible that the 
‘cytokine-ve’ population are fully functional cytokine producing cells but their cytokine gene 
expression is not driven by PMA/ionomycin-induced PKCƟ signalling. The nature of a 
stimulus can influence a cells cytokine profile in in vitro systems, which is shown by 
concurrently comparing the cytokine expression in response to multiple stimuli such as 
PMA/ionomycin, PHA and CD3/CD28 ligation
[373,386,387]
. For example, I. Olsen and L.M 
Sollid (2013) recently showed IL-17 and IFNγ production by T cell clones in response to 
PMA/ionomyin that only expressed IFNγ upon CD3/CD28 activation[373]. In in vitro systems 
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cytokine secretion kinetics (and thus the length of a stimulation assay) are also a consideration 
in revealing a populations total effector cytokine potential. Although the optimal time point 
for cytokine secretion was tested (Figure 3.1) it cannot be discounted that subpopulations of 
cells exhibit a delayed response beyond the measured duration. 
3) Cells are truly cytokine negative – If the ‘cytokine negative’ population defined here truly 
produce no effector cytokine it is reasonable to consider their alternative function or identity. 
It is possible that such cells are purely proliferative and may even represent cells in the 
earliest transition from Tnaive to Tmemory. A definition of Th0 is assigned to intermediary cells 
generated from activated Tnaive populations prior to Tmemory differentiation. However, in this 
model the Th0 phenotype is transient and shown to produce multiple cytokines associated 
with both Th1 and Th2 lineages
[112,388]
. More recently a highly proliferative population of stem 
cell-like memory T cells (TSCM) has been defined in both CD4
+
 and CD8
+
 T cell subsets
[64,65]
. 
These cells are also unsuitable candidates for the ‘cytokine-ve’ phenotype as they retain the 
naïve-like CD45RA expression and produce intermediate levels of IFNγ, IL-2 and TNFα[64].  
Plasticity between the differentiation pathways of CD4
+
 Thelper lineages is well described both 
in vitro and in vivo.  For example, cells derived from a Th17 lineage upregulate Th1-associated 
transcription factors and cytokines (notably IFNγ) under appropriate polarising 
conditions
[343,389]
.  It is conceivable that molecular mechanisms governing such shifts in 
cytokine expression such as transcriptional repression and epigenetic gene silencing
[390]
 can 
shut down a cell’s cytokine armoury entirely. Therefore, it cannot be discounted that  
cytokine
-ve
 cells may have expressed cytokine at some point in their history. The temporal 
aspect of cytokine expression and plasticity can be investigated through fate mapping 
experiments in mice and could be adapted for the purpose of this investigation
[122]
. 
Moving towards the more terminally differentiated end of the Tmemory spectrum it is possible 
that cytokine
-ve
 cells have become ‘anergised’ to the effects of stimulation or are quiescent 
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through processes related to immune senescence. As processes which result in cytokine 
expression are highly complex it was first investigated whether cytokine
-ve 
cells were capable 
of activating with PMA/ionomycin exposure at all. As no transcription of cytokine genes can 
occur without activation this was easily ascertained by measuring CD69 upregulation. A 
population of cytokine
-ve
 memory CD4
+
 T cells was identified that did not upregulate CD69 
and showed minimal downregulation of CD4 (a typical feature associated with PMA 
stimulation
[372]
). As PMA readily passes through phospholipid cell membranes and triggers 
PKCθ signalling from the inside of the cell[366] it is improbable that these cells had not 
encountered the stimulus in a 6h culture and their small decrease in CD4
+
 expression was 
indicative of this. Their hyporesponsiveness was striking and so the biology of these ‘non-
responsive’ cells was analysed in depth to ascertain what they represented. It is acknowledged 
that there was also a CD4
+
 cytokine
-ve
 population that did activate readily but these cells were 
not investigated further in this study. Potential characteristics of these cells are alluded to in 
the discussion of cytokine
-ve
 cell biology above. 
Based on initial analysis of PBMC cultures the non-responsive CD4
+
 T cell population had a 
Tcm (CD45RA
-
CCR7
+
) phenotype (Figure 3.11C). It was unexpected that a subpopulation 
with such quiescent-like characteristics would be found within the Tcm subset. However, this 
finding was refuted through retrospective examination of Tcm frequency in the blood. It 
appeared that Tcm cells were the main contributors to the non-responsive fraction because 
numerically they are represented almost 4 times greater than Teff cells in the blood (Figure 
3.12). This was confirmed by removing the Tcm/Teff population bias via an alternative gating 
strategy, which showed that non-responsive cells were a heterogeneous mix of Tcm and Teff 
phenotypes (Figure 3.11D). However, this heterogeneity was not recapitulated when T cell 
memory subsets were separated and stimulated independently. Here the Teff subset had by far 
the largest non-responsive population whereas there was minimal representation in purified 
Tcm cell cultures (Figure 3.13).  
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A possible explanation for this disparity is that Teff cells upregulated CCR7 expression in the 
PBMC cultures and made it appear like more Tcm did not respond. However, there is no 
published data suggesting that PMA/ionomycin stimulation induces CCR7 expression in the 
Teff population. An alternative explanation is that some Teff cells expressed CCR7 prior to the 
culture which also would have been undetectable in post-stimulation analysis. Since the 
CCR7/CD45 definition of memory was established by F. Sallusto et al (1999) subsequent 
studies have demonstrated that CCR7 expression by Teff cells is necessary for peripheral tissue 
egress and their re-entry into the circulation 
[57,95]
. Therefore the CCR7/CD45 isoform 
definition is not stringent and Teff cells can transiently express CCR7
[391]
. Experiments here 
where Tcm and Teff cells with varying expression of CD62L were stimulated independently 
supported this explanation as to why more non-responsive cells appeared to have a Tcm 
phenotype in PBMC cultures (Figure 3.14). Findings showed that a high proportion of the Tcm 
(CD62L
lo
) cell cultures were non-responsive. Given that Tcm are classically associated with 
both CCR7
+
 and CD62L
hi
 expression it is possible that this purified CD45RA
-
CCR7
+
CD62L
lo
 
population was highly non-responsive because it actually represents a CCR7
+ 
Teff subset. 
However, work examining the expression of CD27 on sorted Tcm and Teff CD62L
hi
/
lo
 sorted 
fractions counter argues this theory (Figure 3.15). CD27 expression is progressively lost 
during T cell differentiation
[379]
 so it was anticipated that CD27 expression by the Tcm CD62
lo 
population would be analogous to the Teff subset if they were truly CCR7
+ 
Teff cells. This was 
not the case and loss of CD27 correlated with the progressive loss of CCR7 and CD62L from 
Tcm to Teff. However, the non-responsive fractions did have reduced CD27 expression 
regardless of their concurrent phenotype indicating that these cells may have undergone more 
proliferation than their subset-matched responsive counterparts. This may not necessarily be 
antigen-driven as high levels of homeostatic proliferation in the Tcm subset can drive a 
conversion through to a CD27
lo
 phenotype
[392]
. CD27
lo
 expression is amongst the defining 
feature of senescent T cells which have reached the limit of their replicative potential
[393]
. 
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However, without additional markers of senescence such CD28
lo
 and CD57
hi
 expression it 
cannot be definitely established that the non-responsive population is representative of 
senescence T cells.  
Collectively evidence from this study suggests that the non-responsive population is a 
differentiated effector memory phenotype. This population did not belong to a non-classical 
Thelper lineage (such as NK-like cells, CD4
+
CD8
+
 lymphocytes and TCRγδ T cells) which may 
have contributed to their differential response to PMA/ionomycin. CD69 expression by CD4
+
 
T cells is shown to peak by 12 hours following PMA exposure
[394]
. Other studies report 
maximal CD69 expression by 6 hours in response to various stimuli
[42,395,396]
 which is 
consistent with data presented here and reflected in a stabilisation of the non-responsive 
population between 4-6h. The non-responsive population had no cytosolic stores of CD69 
receptor at this time point as the CD69
lo
 signal persisted when CD4
int
CD69
lo
 cells stained 
intracellularly (Figure 3.25). Expression of CD69 protein is dependent on translation of 
mRNA that is expressed de novo following activation
[397]
. The absence of CD69 expression 
by non-responsive cells is likely to be a consequence of deficient signal transduction upstream 
of gene transcription. This is supported by gene expression analysis which showed that CD69 
expression by non-responsive Teff cells was comparable to that of unstimulated memory cells 
that do not express CD69 protein (Figure 3.27-3.28). Surprisingly, the expression of CD69 
transcript was greater in non-responsive and unstimulated memory populations than in the 
corresponding responsive or stimulated fractions (Figure 3.27-3.28). However, published data 
measuring the kinetics of CD69 transcription from both peripheral blood lymphocyte and T 
cell cultures shows CD69 transcript is detectable at 30min but levels decline rapidly from 6-8 
hours
[397,398]
. Therefore, although the end point of this assay was at 4 hours it is possible that 
CD69 mRNA expression is already declining in the responding and stimulated Tmemory 
populations in this system. In these populations CD69 expression may dip below that seen in 
unstimulated cultures due to overuse or degradation of mRNA transcripts to a refractory level. 
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To confirm these theories the transcriptional kinetics of this system could be measured by 
performing a time course of CD69 mRNA expression in activated Teff cultures every 2h for a 
12h period. 
Surprisingly, expression of IFNγ at the message level followed the same trend as CD69 with 
the stimulated (and responsive) fractions showing diminished mRNA expression comparative 
with unstimulated (and non-responsive) cells (Figure 3.29). This is inconsistent with 
published findings and could not be explained by the cytokine’s expression kinetics. It is well 
reported that IFNγ message is undetectable in resting CD4+ T cells but levels rise immediately 
following activation
[387,399]
.  IFNγ mRNA expression is shown to be monophasic and 
persistent for over 72h in response to various polyclonal and antigen specific stimuli
[400]
.  
However, PMA/ionomycin is underrepresented as a method of stimulation in such studies and 
alternative stimuli such as phytohemagglutinin and anti-CD3/CD28 are more frequently 
reported. In Tmemory populations W. Lai et al (2011) show that NF-κB interaction with the 
IFNG gene promotor rapidly drives IFNγ expression to high levels[399]. This T-bet 
independent process underpins the rapid recall responses of memory CD4
+
 cells in a manner 
reminiscent of innate immune cell responses. However, others maintain that IFNγ induction is 
T-bet dependent, as is supported by significant levels of Tbet nuclear localisation pre-
activation
[401]. It is hard to relate the analysis of IFNγ expression from my investigation to 
either of these scenarios and my results remain unexplained. From a technical perspective it 
was considered whether PMA/ionomycin stimulation caused changes in the control gene 
GAPDH and aberrantly influenced the gene expression calculations. However, experiments 
where unstimulated and stimulated cells were compared confirmed that PMA/ionomycin 
exposure did not affect GAPDH expression (Figure 3.28). Despite this, it would be beneficial 
to repeat this analysis perhaps with the inclusion of an alternative control gene such as β-actin 
to reassess findings related to IFNγ gene expression.  
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The frequency of non-responsive cells was highly variable between donors; particularly in the 
Teff compartment (Figure 3.9, Figure 3.13). Non-responsive cell frequency was unrelated to 
gender which suggests that the population is not influenced by levels of androgens, oestrogens 
or progestogens. However, a small increase in non-responsive cell frequency was noted with 
increasing age, although the age range tested was limited. If the non-responsive population are 
senescent their frequency would be expected to increase with age, so measuring their 
frequency in an elderly population may be informative. In addition to these variables the 
distribution and function of memory T cells is known to be affected by physical activity. 
Strenuous exercise can reduce the Th1-associated cytokine responses of circulating CD4
+
 T 
cells to PMA/ionomycin and this decrease correlates to levels of plasma epinephrine
[402]
. 
CD4
+
 T cells express beta adrenergic receptors (notably the β2 isoform) which can transduce 
signalling upon the binding of serum catecholamines
[403]
 and levels of these increase during 
exercise or stress
[404]
. It is shown that circulating T cells increase during exercise which is 
followed by a paradoxical decrease on activity cessation achieved via their redistribution into 
the peripheral tissue 
[405]
. This is partially attributed to the effect of glucocorticoid changes on 
chemokine receptors associated with homing
[406]
. Serum cortisol also fluctuates with time of 
day as part of natural circadian rhythm and also alters distribution of lymphocyte populations 
and their activity
[407]
. In this investigation the time of blood sampling and activity levels of the 
donors were controlled variables so the significance of such effects is questionable in this 
system. However, to directly negate the influence of cortisol and adrenomedullary hormones 
upon non-responsiveness serum levels could be measured directly and correlated to the 
population’s frequency.  
There are other potential causes of the intra-donor variability in non-responsive cell 
frequency. Infection can have implications for T cell functionality that persist long after that 
infection is resolved. There is significant work in the literature describing a refractory period 
exhibited by activated CD4
+
 T cells
[408–410]
. C.T Duthoit et al (2004) have documented that in 
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both in vitro and in vivo adoptive transfer models once stimulated with antigen, CD4
+
 T cells 
are resistant to restimulation for a considerable period and may acquire suppressive 
functionality during this inactive phase
[410]
. However, my work suggested that the non-
responsive population is not recently activated in vivo as the population persisted when those 
cells with physiological expression of CD69 were removed (Figure 3.16). That said, the 
expression of CD69 in T cell activation is phasic and it cannot be discounted that these cells 
have undergone in vivo activation some days previous and have subsequently lost CD69 
expression. In in vitro cultures CD69 expression can be maintained for up to 72h whereas 
others show CD69 expression decreases to baseline between 24-72h in experiments using 
PBMC
[42,411]
. Therefore, the T cell hyporesponsiveness defined in my study may be due to a 
previous activation event and account for the variability in their frequency.  
Like CD69, CD25
 
expression is also elevated on activated CD4
+
 T cells as well as its 
association with Treg biology. Initial experiments here examining whether the non-responsive 
population had a Treg phenotype were based on a CD25
hi
 phenotype alone (Figure 3.20). The 
CD25
hi 
population had a greater proportion of non-responsive cells so it could be questioned 
whether these cells were true Treg or actually activated conventional CD4
+
 T cells. Work in 
mouse models suggests that IL-2 is essential for the functionality and maintenance of the Treg 
population
[156,412,413]
. In mouse models animals deficient in the IL-2 signalling pathway (IL-
2Rβ-/-) lack CD25hi Treg and CD25
hi
 Treg adoptively transferred IL-2Rβ
-/-
 knockout mice 
cannot successfully expand
[414]
. In other studies addition of IL-2 to Treg cultures from CD69
-/- 
mice is shown to restore activation of the TCR pathway via phosphorylation of STAT5
[415]
. 
Addition of exogenous IL-2 did not perturb the non-responsiveness of the CD25
hi 
population 
in my investigation which may suggest these cells are not a true Treg phenotype. However, the 
poor purities of the Treg and non-Treg fractions in these experiments made subsequent analysis 
difficult to interpret.  
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The proportion of cells with a non-responsive phenotype in the Teff subset was comparable in 
the Treg and non-Treg populations when these subsets were defined by CD25 with CD127 
expression (Figure 3.21). Although Treg were marginally less responsive than non-Treg in this 
system they do not numerically predominate the non-responsive population due to their low 
frequency in the blood. Therefore, the non-responsive population is a mix of CD25
int
CD127
int
 
and CD25
hi
CD127
lo 
subsets and this implies that Teff are more non-responsive irrespective of 
their CD25/CD127 status. It is not possible to determine what the contribution of iTreg or 
effector nTreg is to the non-responsive populations described here as these subsets are 
phenotypically similar in terms of their CD25 and CD127 expression. However, it would be 
interesting to investigate whether the non-responsive cells in the non-Treg compartment 
actually represent more atypical Treg such as Tr1. Tr1do not putatively express CD25 at rest 
and although surface markers to identify this rare subset are not firmly established candidate 
examples include CD49b and LAG-3 together with low FOXP3 expression
[416]
. 
Historically Treg biology has been synonymous with the T cell tolerance and anergy but 
endogenous anergic T cells have not been identified ex vivo. In in vitro studies a feature of 
anergic T cells is the reversal of hyporesponsiveness through addition of exogenous IL-
2
[189,381]
. In my investigation the presence of IL-2 did not reverse the non-responsive 
phenotype (Figure 3.20, Figure 3.24). IL-2 signalling reverses anergy through restoring the 
activity of AP-1
[381]
. As AP-1 deficiency (via lack of co-stimulation) is a key feature of 
anergy this suggests that the non-responsive phenotype is not anergic by the classical 
definition. The fact that the population was induced following anti-CD3/CD28 signalling 
where adequate co-stimulatory signalling was provided supports this assumption (Figure 3.6, 
Figure 3.14-3.15). However, an alternative form of hyporesponsiveness that is distinctive 
from ‘anergy’ is defined in the literature as ‘adaptive tolerance’ by Schwartz R. H et al and is 
not reversible by IL-2 signalling
[188,190]
. In adaptive tolerance cells are less responsive with 
respect to effector cytokine production and require the persistence of stimuli to remain 
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tolerised
[190]
. It is possible that the non-responsive phenotype is more consistent with adaptive 
tolerance than anergy although interrogation of their biochemical signalling pathways would 
be required to support this. Currently such work would be challenging given the populations 
low frequency and the inability to purify them without prior stimulation.  
A feature shared between anergy and adaptive tolerance is the incomplete degradation of 
IκBα[190]. In anergised or tolerised cells release of NF-κB for nuclear translocation is 
prevented and its downstream effects are lost. It was suspected that this phenomenon was 
reproduced when a proteasome inhibitor was added to stimulated 6h cultures in this study 
(Figure 3.25). At high concentrations of this proteasome inhibitor Bortezomib (Velcade
®
) the 
non-responsive cell frequency was elevated and the expression of CD69 and IFNγ by 
responding cells decreased. This may indicate inhibition of the proteolytic degradation of 
IκBα amongst other NF-κB regulators and this is previously described in the context of 
Bortezomib as a therapy for multiple myeloma
[417]
. Such findings were a collateral effect of 
my assay design as it was intended to assess whether non-responsive cells had increased 
proteasome trafficking of activation-associated proteins. This is a feature associated with 
anergy via increased activity of ubiquitinase enzymes
[172]
. However, given the proteasome 
inhibitors effects on T cell activation this could not be appropriately measured in this system 
and this question requires an alternative strategy for investigation.  
An additional mechanism of peripheral T cell tolerance is the deletion of self-reactive cells by 
apoptosis
[418]
. The induction of anergy and apoptosis are distinctive phenomenon on a 
signalling level and here I show that the non-responsive population was highly prone to the 
latter fate (Figure 3.17). PMA/ionomycin stimulation induced a considerable degree of cell 
death in both the non-responsive and responsive CD4
+
 T cell populations particularly in 
cultures over 12 hours (Figure 3.7). This may be unsurprising as the effects of 
PMA/ionomycin stimulation are irreversible and excessive stimulation causes activation-
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induced cell death (AICD). Compared with PBMC based assays the degree of T cell apoptosis 
did not reduce when subsets were purified prior to stimulation (Figure 3.19D). This suggests 
that the induction of apoptosis was a T cell intrinsic phenomenon and was not influenced by 
non-T cell subsets or soluble mediates released into PBMC cultures.  
PMA/ionomycin exposure may be considered a cellular stressor given the metabolic 
requirements of the T cell response that it invokes
[419]
. It can be speculated that the non-
responsive state is induced by abnormal metabolic processes as a result of activation. AMPK 
(5' AMP-activated protein kinase) is shown to activate the p38MAPK pathway in response to 
cellular stress, low glucose or DNA damage
[420,421]
. Therefore, in my investigation expression 
of AMPK was measured in stimulated cultures as a measure of metabolic regulation. AMPK 
was also a suitable candidate for analysis as the non-responsive population had demonstrated 
an increased fragility and diminished CD27 expression. A. Lanna et al (2014) show that 
increased AMPK induces p38 activation and is associated with CD27
-
CD28
-
 senescent CD4
+
 
T cells
[422]
 . This is attributed to DNA damage in senescence and is reproducible through 
inducing DNA damage in more undifferentiated cells. The authors demonstrated the presence 
of unphosphorylated AMPK protein by western blot in primary CD4
+
 T cells
[422]
. However, in 
my investigation no AMPK expression by memory CD4 T cells was detected by qPCR 
irrespective of PMA/ionomycin exposure. It cannot be distinguished whether this result 
reflects a genuine instability of AMPK mRNA at the message level, absence of constitutive 
transcription or accelerated degradation. A failure of the AMPK gene primers cannot be 
discounted in these experiments as no positive control for AMPK was tested.  
The homeostatic cytokines IL-7 and IL-15 have an important role in the maintenance of the 
memory CD4
+
 T cell population
[423,424]
. Addition of IL7, IL-15 or IL-2 to stimulation assays 
could neither reverse nor assist the survival of non-responsive cells (Figure 3.24). Even when 
removing the stimulus at 6 hours and allowing the cells to rest the population could not be 
maintained for over 24 hours irrespective of homeostatic cytokine.  With acknowledgement to 
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the fragility of the population it was speculated whether it represented a collection of dying 
cells and thus a non-physiological by-product of the in vitro system. However, this can be 
refuted on a number of levels. Firstly, the non-responsive population was a homogeneous 
memory phenotype. If it represented apoptotic cells more heterogeneity and the inclusion of 
Tnaive cells may have been expected. Secondly, with consideration to morphological changes 
that occur in early apoptosis those cells that were apoptotic in vivo would not fall within a 
viable lymphocyte gate in flow cytometry experiments after 6 hours of culture. Lastly, when 
dead cell exclusion dyes were used in these assays the majority of non-responsive cells were 
viable indicating that failure to upregulate CD69 was not a consequence of cell death. In 
summary, although the non-responsive population is more prone to apoptosis this is an effect 
of their lack of response to PMA/ionomycin as opposed to a cause of it. Therefore, 
PMA/ionomycin is revealing a set of cellular characteristics that are distinctive in this 
population and require further investigation.  
Anti-CD3/CD28 Dynabead
® 
stimulation also revealed a hyporesponsive population analogous 
to that revealed by PMA/ionomycin (Figure 3.6, Figure 3.14-3.15). However, non-responsive 
cells in these assays did not downregulate CD4 and were more frequent in analysis of both 
Tnaive and Tmemory populations. The latter may be explained by the methodology of stimulating 
T cells with CD3/CD28 coated beads, as unlike with PMA/ionomycin it cannot be guaranteed 
that every cell in the culture has engaged the stimulus. Therefore, the non-responsive 
population in these assays is likely to be contaminated with unstimulated cells. Despite this 
discrepancy in frequency the similarities in CD69 kinetics, lack of CD69 upregulation and 
analogous differentiation status is supporting evidence that the non-responsive population can 
be induced physiologically and has relevance in vivo.  
Studying the non-responsive population and their intracellular signalling was associated with 
various challenges in this investigation partially due to low cell counts and the inability to 
maintain them in long-term cultures. It would have been favourable to examine 
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phosphorylation events in PMA/ionomycin-induced signalling pathways by western blot but 
there were insufficient cell numbers to do this. From a gene expression perspective the desired 
approach was to perform a T-cell receptor-specific gene array to analyse differential 
expression of 96 genes between responding and non-responsive Teff populations. Recovered 
cDNA preparations were again insufficient in quantity for this extensive analysis. Due to 
these technical barriers an alternative approach was adopted where the expression differentials 
of three candidate T cell signalling genes (for LCK, PKCƟ, VAV-1) were measured 
independently by multiplex qPCR (Figure 3.30-3.31). PKCƟ is the main target for PMA 
binding and PKCƟ expression is an absolute requirement for CD69 upregulation[365,425], so it 
was considered whether PKCƟ deficiency was responsible for the non-responsive state. 
Conversely, PKCƟ activation drives AICD through caspase-8 induced FAS/FASL related 
interaction
[426]
 so it’s over expression may be driving apoptosis in the non-responsive state. 
LCK was investigated due to the minimal downregulation of CD4 in the non-responsive 
population. In appropriately activated cells PMA induces CD4 downregulation via the 
uncoupling of CD4 to p56
lck
 (protein product of the LCK gene) through PKCθ-driven 
phosphorylation of Ser
408
 and Ser
415
 on the CD4 cytoplasmic tail
[427,428]
. This leads to 
increased clathrin-mediated endocytosis of the CD4 receptor and its diversion away from the 
endosomal membrane recycling pathways once internalised
[372]
. With regards to the activity 
of VAV-1 this guanosine nucleotide exchange factor is required for PKCƟ translocation to 
the immunological synapse in T cell activation
[429]
. In other reports phosphorylation of VAV-
1 is a prerequisite for calcium flux which is an integral requirement for complete T cell 
activation
[430,431]
. VAV-1 expression was also investigated as the ubiquitin ligase Cbl-b 
negatively regulates VAV-1 activity and this relationship is a proposed mechanism of T-cell 
tolerance
[180]
.  
PMA/ionomycin induced increased expression of all three signalling genes comparative to 
baseline with LCK most notably upregulated (Figure 3.30). This may imply that a feedback 
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loop operates to stabilise these mRNA’s or increased their transcription following 
PMA/ionomycin-induced activation.  There were no such differences in expression observed 
between the purified non-responsive and responsive fractions (Figure 3.31). This was 
unexpected although the non-responsive and responsive populations did not exactly match the 
control cultures in terms of memory phenotype which may have contributed to this 
inconsistency. However, the data suggests that differential expression of LCK, PKCƟ and 
VAV-1 does not contribute to the differential response to PMA/ionomycin seen in these 
assays. Despite this, some involvement of these signalling components cannot be discounted 
as changes in their phosphorylation status or localisation were not measured in these assays.  
Although informative the expression analysis of the non-responsive population was not 
completed in this investigation. To move experiments forward the requirement for a concise 
definition of surface markers to identify the non-responsive population is essential. Currently 
experiments are limited by the inability to purify the population without revealing the 
phenotype through PMA/ionomycin stimulation. This stimulation ultimately induces cell 
death and the material recoverable through post-stimulation sorting strategies is limited. 
cDNA amplification techniques could be applied to future studies to boost the amounts of 
genetic material obtainable from purified non-responsive cells. Through this a more wide 
scale gene array approach could reveal a detailed surface receptor profile associated with the 
non-population to take forward subsequent strategies. 
CHAPTER SUMMARY 
This work identified a subpopulation of CD4
+
 cells whose phenotype was revealed through a 
hyporesponsiveness to PMA/ionomyin and anti-CD3/CD28 stimulation. These cells were 
characterised by the surface expression of CD4
int
CD69
lo
CCR7
+/-
CD45RA
-
CD62L
lo
CD27
lo
 
which suggests they are a highly differentiated memory phenotype. However, their PD-1 
expression was associated with their memory status and not their hyporesponsiveness per se, 
indicating that these cells are not ‘exhausted’ by means of the classical definition. 
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PMA/ionomycin is routinely used universally to reveal the cytokine potential of T cells and 
here I demonstrate that a notable proportion of Teff cells are programmed to be driven towards 
apoptosis by this stimulus. This investigation highlights that the effect of PMA/ionomycin on 
T cells is not equivocal even within a particular subset and subsequent analysis should thus be 
treated with caution.  
The non-responsive population did demonstrate features associated with in vivo adaptive 
tolerance as opposed to clonal anergy, meaning further understanding of this population’s 
biology is highly relevant to these fields. It would be of interest to investigate the clonality of 
the population and access whether they were driven to an irreversibly hyporesponsive state 
through chronic viral infection. This work may also have implications in tumour immunology, 
with respect to the evasion of cancerous cells from the immune system through chronic 
antigen presentation to T cells.  It could be argued that these cells must activate in response to 
some stimulus but the relevant signals required to facilitate activation are yet to be identified. 
 
  
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
RESULTS 
CHARACTERISATION OF CEREBROSPINAL 
FLUID DERIVED CD4
+
 T CELLS IN HEALTH AND DISEASE. 
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4 CHARACTERISATION OF CEREBROSPINAL FLUID 
DERIVED CD4
+
 T CELLS IN HEALTH AND DISEASE. 
4.1 Rationale. 
Many studies have described the cellular components of CSF in various neuroinflammatory 
patient cohorts
[248,271,432]
. Despite such work there has been little focus upon CSF cells in the 
context of human health until relatively recently. CD4
+
 T cells are now recognised as the 
predominant CSF leukocyte subset in both the absence and presence of disease and are largely 
a central memory phenotype in humans (CD45RO
+
CCR7
+
)
[247,288]
. However, fundamental 
aspects of CSF CD4
+
 T cell biology are under defined. These include the specificity of 
homeostatic CD4
+
 T cell migration from blood to CSF under resting conditions and the 
anatomical localisation of these cells within the fluid and associated stromal compartments. 
Analysis of ‘normal’ human CSF is restricted as the sampling procedure is highly invasive 
and cannot be performed ethically in healthy individuals. Therefore to study normal CSF it is 
often modelled in patients who lack inflammatory disease but require this procedure for 
diagnostic or therapeutic purposes. An alternative system is to model normal CSF and its 
associated compartments in naïve rodents that do not have any underlying pathology. At 
present there are minimal publications that make use of this method to investigate homeostatic 
CNS migration. In this chapter T cell subsets associated with unchallenged mouse and rat 
CNS are characterised by their surface marker expression and anatomical distribution within 
the brain. Such work compliments a comparative analysis of peripheral blood and CSF-
derived T cells from a patient cohort without inflammatory disease. In parallel with this 
investigation inflammation-driven changes to CD4
+
 T cell populations are measured in 
patients with multiple sclerosis and other neuroinflammatory pathologies.   
Hypotheses applicable to this work are that in man central memory (CCR7
+
CD45RO
+
) CD4
+
 
T cells are enriched in the CSF through selective recruitment from the blood and this trend is 
upheld through the analogous central memory population in mouse (CD44
hi
CD62L
hi
). 
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Additionally, CD4
+
 T cells associated with unchallenged mouse CNS are localised to the 
choroid plexus regions which is described as the primary location of CD4
+
 T cell migration 
into brain in many publications
[253,271,433]
 . As it is proposed that the glia limitans limits T cell 
entry into the brain parenchyma in the absence of inflammation
[257]
 it is hypothesized that no 
CD4
+
 T cells will be associated with the parenchymal compartments in this study. 
4.2 Validation of the immunofluorescence protocol for detection of CD4+ 
T cells in mouse CNS tissue. 
Experiments were performed to identify CD4
+
 T cell niches in unchallenged murine brain. 
Confocal microscopy was the appropriate analytical tool for this exercise, but given that the 
anticipated frequency of CD3
+
CD4
+
 T cells in brain was extremely low it was important to 
establish that these cells were reliably detectable. The staining and imaging process was 
validated by imaging sections of murine spleen, which were treated identically to CNS 
preparations and acted as a positive control for the immunofluorescence procedure (Figure 
4.1). Figure 4.1A shows isotype control images of murine spleen stained with irrelevant IgG 
and with the nuclear counterstain DAPI. Imaging parameters applied to the isotype control 
staining were used to set the threshold of specific positive staining for CD3, CD4 and B220 
(Figure 4.1B). In these experiments T cell zones of the spleen were clearly identified by co-
localisation of CD3
+
 and CD4
+
 staining. In addition, images showed B220
+
 cells within B cell 
areas which were largely distinct from CD3 or CD4 staining. These experiments demonstrated 
the ability to detect CD4
+
 T cells in this system. 
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Figure 4.1 Confocal imaging of T and B cell areas in murine spleen tissue. C57BL/6 mice 
were intra-cardially perfused post mortem with PBS and fixative. Brain tissue was harvested 
for confocal analysis of infiltrating CD4
+
 lymphocytes (CD3
+
CD4
+
). As a positive control for 
each brain imaging experiment spleen were also harvested, sectioned and stained for CD3 and 
CD4 using the same protocol. Spleen was also stained with B220 to differentiate between T 
and B cell areas of the tissue. A. Single colour and composite confocal images of the isotype 
control staining performed on spleen sections. B. Confocal images of specific lymphocyte 
staining taken under the same parameters as the isotype controls shown in A. A nuclear 
counterstain (DAPI) was used in both isotype control and specific staining experiments. Data 
is representative n=2 independent experiments with 6-10 images taken per experiment.
   
IgG2bDAPI
IgG2a
IgG
DAPI IgG IgG2b IgG2a
CD4CD3
DAPI CD3 CD4 B220
DAPI
B220
A.
B.
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Isotype control parameters set on spleen sections could not be applied to the imaging of brain 
sections due to differences in the intensity of non-specific staining and background 
autofluorescence. Therefore single colour isotope control staining for CD3 and CD4 was 
performed on brain sections to set the threshold for a positive signal (Figure 4.2). The 
autofluoresence of different anatomical areas of the brain was variable and confirmed by 
imaging the sections without performing any staining (data not shown). Therefore, regional 
isotype control staining was performed in multiple brain areas and specific staining was 
indicated in accordance with the corresponding isotype parameters. 
4.3 Image analysis of CD4+ T cells in murine choroid plexus tissue 
Imaging of murine CP was performed on lateral ventricle CP located within sections of the 
midbrain region. The CP structure was occasionally pressed against the wall of the ventricles 
due to effects of the sectioning procedure, but more often it was observed free hanging into 
the ventricular space. The tissue was clearly recognisable through the organisation of its 
distinctive large cuboidal epithelium layers arranged in elongated villous projections (Figure 
4.3).  Embedded within the CP tissue positively stained CD3
+
, CD4
+
 and CD3
+
CD4
+
 cells 
were observed (Figure 4.3). Co-localisation of CD3 and CD4 positive staining indicated the 
presence of CD4
+
 T cell associated with the tissue. However, this was only just detectable 
above the level of the background autofluorescence.  
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Figure 4.2 Isotype control imaging for lymphocyte staining in CNS. C57BL/6 mice were 
intra-cardially perfused post mortem with PBS and fixative. Harvested intact brain tissue was 
fixed frozen, sectioned and stained for CD3 and CD4 with a nuclear counterstain (DAPI). 
Single colour isotype control staining was performed to set the fluorescence intensity 
threshold of specific positive staining. A. Representative image of brain outer cortex showing 
the level of background staining from a CD3 isotype control. B. Representative image of the 
periventricular region of the midbrain (ventricle is shown left bottom corner of frame), 
showing isotype control staining for CD4. Images are representative of 3-5 images taken in 
n=3 independent experiments.  
  
DAPI CD3
CD4
DAPI CD3
DAPI DAPI CD4
A.
B.
DAPI 
DAPI 
IgG (CD3 isotype) 
IgG2b (CD4 isotype) 
DAPI IgG 
DAPI IgG2b 
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Figure 4.3 Confocal imaging of CD3
+
 and CD4
+
 cells associated with murine choroid 
plexus tissue. C57BL/6 mice were intra-cardially perfused post mortem with PBS and 
fixative. Harvested in tact brain tissue was fixed frozen, sectioned at 20μm thickness and 
stained for CD3 and CD4. Midbrain sections were mounted using medium containing DAPI 
(nuclear stain) and confocal images were captured of the choroid plexus tissue at a x40 
objective magnification. A,B. Images show single stained (red arrows) CD4
+
 cells in the 
choroid plexus tissue. C. Images show a single stained CD3
+
 cell (red arrow) and co-localised 
staining by a CD3
+
CD4
+
 T cell (white arrow).  Positive staining was set as an intensity above 
the threshold of single stained matched isotype controls. Images shown are of representative 
of n=2 experiments were n=6-8 images captured at this magnification per experiment. 
 
 
  
DAPI CD3 CD4 DAPI CD3 CD4A.
B.
C.
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4.4 Quantification of CD4+ T cells in unchallenged murine CNS by 
confocal microscopy. 
The frequency of CD4
+
 T cells associated with CP was then measured with respect to other 
regions of the brain.  Figure 4.4 shows nuclear staining performed on a whole mouse coronal 
brain section. This image represents multiple images captured on an epifluorescence 
microscope that are digitally reconstructed to recreate a map of the brain section. The 
associated extracted regions show the four brain areas selected for analysis of lymphocyte 
infiltration. As epifluorescence microscopy was found to be insufficient for this purpose, the 
meninges, cortex, periventricular, and CP regions were analysed individually by confocal 
microscopy (Figure 4.5A-D)). In these experiments, multiple images were taken of each 
region and the CD3
+
, CD4
+
 and CD3
+
CD4
+
 cells counted in each field of view. The average 
frequency of each phenotype per field of view was recorded and these values were 
recalculated to represent the frequency of each cell type per mm
2
 of tissue (Figure 4.6). 
Results showed representation of all three phenotypes was extremely low with no evidence 
for any positive cells embedded within the cortex parenchyma (Figure 4.5B, Figure 4.6). 
CD3
+ 
and CD4
+ 
single positive cells had the greatest representation in the meninges and these 
populations tended to be clustered together rather than dispersed across multiple captured 
images (Figure 4.6A). A very low frequency of CD3
+ 
cells were also identified in the 
periventricular and CP regions (Figure 4.6A), whereas CD4
+ 
cells were restricted to the 
meninges and CP (Figure 4.6B). It is likely that a CD3
+
CD4
-
 signal represented the presence 
of CD8
+
 T cells but direct staining for CD8 was not performed to confirm this. CD3
+
CD4
+ 
cells were only identified in the CP and periventricular regions, albeit at a lower frequency 
than the single positive cells (Figure 4.6C). This result showed that CD3
+
CD4
+ 
T cells were 
predominantly associated with the CP and ventricular system in these experiments. 
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Figure 4.4 Imaging strategy for identification of CNS-associated CD4
+
 T cells. C57BL/6 
mice were intra-cardially perfused post mortem with PBS and fixative. Harvested in tact brain 
tissue was fixed frozen, sectioned at 20μm thickness and stained for CD3 and CD4. Sections 
were mounted using medium containing DAPI (nuclear stain). Four brain regions were 
selected to quantify the frequency of lymphocytes in each area. A. Image shows nuclear 
staining (DAPI) of a whole midbrain coronal section. Image represents multiple fields 
captured by an epifluorescence microscope that are digitally reconstructed to produce the 
complete image. Four selected brain regions for subsequent analysis are shown (B-E). B-E. 
Images show enlarged extracted regions from areas indicated in A. and demonstrate nuclear 
staining in the regions later analysed for T cell infiltration. Images are representative of serial 
midbrain sections taken from n=1 brain dissection.  
1.0 mm
B
C
D
E
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C. D.
B. E.Meninges
Cortex Periventricular
Choroid plexus
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Figure 4.5 Confocal images associated with the quantification of CD3
+
 and CD4
+
 cells in 
murine CNS. C57BL/6 mice were intra-cardially perfused post mortem with PBS and 
fixative. Harvested in tact brain tissue was fixed, sectioned and stained for CD3
+
 (green) and 
CD4
+
 (magenta) then counterstained with DAPI (nuclear stain). Representative confocal 
images of four investigated brain regions are shown A-D. (Left panel). CD3
+
 and CD4
+
 cells 
are indicated by red arrows. The red box (left) indicates an enlarged extracted region, with 
associated single colour and composite images shown in the right panel. Images are 
representative of n=2 independent experiments with 5-12 images captured per experiment.  
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Figure 4.6 The frequency of cells with a CD3
+
, CD4
+
 or CD3
+
CD4
+
 dual expression 
phenotype in four regions of murine brain tissue. C57BL/6 mice were intra-cardially 
perfused post mortem with PBS and fixative. Harvested in tact brain tissue was fixed and 
serial sections taken of the midbrain region. Sections were stained for CD3 and CD4 with a 
nuclear counter-stain. Multiple confocal images were captured of the meningeal layer, the 
cortical region, the periventricular area and the choroid plexus. The frequency of CD3
+
, CD4
+
 
and CD3
+
CD4
+
 in each random field of view was quantified and multiplied to give a cell 
count per unit area for each phenotype. A. Graph showing the mean ± SEM frequency of 
CD3
+ 
single stained cells per mm
2
 in each brain region measured. B. Graph showing the mean 
± SEM frequency of CD4
+ 
single stained cells per mm
2
 in each region. C. Graph shows the 
mean ± SEM frequency of CD3
+
 CD4
+ 
dual stained cells per mm
2
. Data is representative of 
n=2 independent experiments with 4-12 images taken per region in each experiment.     
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4.5 Dissection of rodent CNS tissue for analysis of associated CD4+ T 
cells.  
Having used imaging to investigate the location of CD4
+
 T cells within murine CNS 
compartments, flow cytometry was considered more appropriate for detailed phenotypic 
analysis of CNS-associated T cell subsets in rodent. For these experiments CNS-associated 
lymphocytes were analysed from whole brain tissue, CP and CSF. The T cell composition of 
each compartment was then compared to matched peripheral blood and a preparation of 
splenocytes (the latter acting as a positive control of the system). Brain and CP samples 
required tissue digestion and lymphocyte isolation processes prior to analysis. It was essential 
that the CNS vasculature was completely flushed with saline to evacuate contaminating blood 
lymphocytes. To achieve this, a whole body cardiac perfusion with saline was performed post 
mortem to flush blood out the vasculature. The efficacy of such as procedure was 
demonstrated by addition of Evan’s blue dye to the perfused saline solution (Figure 4.7A). As 
this dye is retained within blood vessels it clearly demarcates successfully perfused areas. The 
staining of meningeal vessels strongly indicated successful perfusion of brain tissue (Figure 
4.7A). Evan’s blue perfusion also highlighted the extent of the heavy vascularisation of the 
CP structure, as seen by the intense blue staining in Figure 4.7C. This staining was 
particularly useful in honing CP dissection techniques as the vasculature of the CP structure is 
its most recognisable feature but in perfused animals this is not visible. CP was most 
successfully dissected from the 4
th
 ventricle, with intact structures measuring approximately 
4mm in diameter in unfixed mouse brain (Figure 4.7B). Under high magnification the 
distinctive ruffled villous structure of perfused choroid tissue was visible on a dissection 
microscope (Figure 4.7D). Lateral ventricle CP was also obtained in both mice and rats, albeit 
less consistently due to its smaller size and anatomical location. Therefore for subsequent 
experiments analysis of this tissue was predominantly restricted to the 4
th
 ventricle structure 
only.    
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Figure 4.7 The perfusion of rodent brain and dissection of choroid plexus. C57BL/6 mice 
were intra-cardially perfused post mortem with 0.5% w/v Evan’s Blue in PBS or PBS alone. 
The brains were removed whole and choroid plexus from the 4
th
 ventricle dissected under a 
dissection microscope. A. Whole mouse brain showing the meningeal vasculature stained blue 
following perfusion with Evan’s Blue dye. B. Intact choroid plexus tissue dissected from the 
4
th
 ventricle post PBS perfusion. C-D. Magnified images of 4
th
 ventricle choroid plexus 
showing its ruffled villous structure. The extent of the tissues dense vascularisation is 
revealed following Evan’s Blue perfusion (C).  
  
A. B.
C. D.
Chapter 4  176 
 
4.6 Analysis of CNS associated T cells in an unchallenged rat model. 
The CD3
+ 
T cell compartment associated with whole perfused brain, CP, CSF, peripheral 
blood and spleen was analysed by flow cytometry in the rat. The methodologies associated 
with the processing of each tissue prior to analysis are detailed in Chapter 2, Sections 2.10-
2.12.  The gating of lymphocytes was set using the forward and side scatter profile of 
lymphocytes in the blood and was kept consistent for each tissue (Figure 4.8A). Due to the 
very high proportion of non-lymphoid cellular matter in the whole brain sample a live gating 
strategy was used to minimise the recording of irrelevant material (Figure 4.8A bottom panel). 
Firstly, the percentage of T cells (CD3
+
) that were CD4
+
 was measured in each compartment 
(Figure 4.8B, Figure 4.8D). The proportion of T cells with a CD4
+
 phenotype was 
significantly reduced in all three CNS compartments (CSF, CP and CNS) when compared to 
peripheral blood (Figure 4.8D), thus indicating that CD4
+
 T cells do not predominate the T 
cell infiltrate into rat CNS. It was also noted that there was little difference in the 
representation of CD4
+
 T cells between the CNS compartments.  The memory status of the 
CD4
+
 T cell population in each tissue was also recorded (Figure 4.8C, Figure 4.8D). Low 
expression of the CD45R isoform CD45RC is associated with a memory-like phenotype in 
rat
[434,435]
. The proportion of CD4
+
 T cells with a CD45RC
lo
 phenotype in the CSF was 
significantly greater than in the blood and the spleen (68.9% ±13.7 as compared to 33.6% 
±2.85 and 38.8% ± 2.9 respectively (mean ± SEM)). A trend of increased memory CD4
+
 T 
cell representation was also observed in the CP and whole brain preparations although these 
observations were not statistically significant.  
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Figure 4.8 Identification of CD4
+
 T cell subsets in the central nervous system of an 
unchallenged rat model. Cerebrospinal fluid (CSF), saline perfused choroid plexus and brain 
tissue were harvested from terminally anesthetised rats. Cell preparations from each 
compartment were analysed by flow cytometry for the presence of CD4
+
 T cells and 
compared with matched peripheral blood and spleen derived samples. A. Representative flow 
cytometry plots showing the forward and side scatter profiles of the different tissue 
preparations. Gating was set consistent with the lymphocyte profile observed in peripheral 
blood samples.  In whole brain samples a live gating strategy was used to reduce the cell 
counts (due to the high cell number).  B. Plots show the presence of lymphocytes (CD3
+
) in 
each tissue. Numbers represent the percentage of the CD3
+
 lymphocytes that are a CD4 
phenotype.  C. Plots show the representation of memory (CD45RC
lo
) within the CD4 T cell 
population each tissue. Numbers indicate the percentage of CD4 T cells that are memory. D. 
Graph of the mean ± SEM percentage of CD3
+
 cells that are CD4
+
. E. Graph of the mean ± 
SEM percentage of CD4 T cells that are a memory phenotype (CD45RC
lo
). *p<0.05, 
**p<0.01, ***P<0.001 (one way ANOVA statistical analysis followed by Bonferroni’s 
multiple comparisons test). A-C. Data is representative of n=4 rats measured in 2 independent 
experiments. D,E. Data is representative of n=3-4 rats measured in 4-8 independent 
experiments.  
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4.7 Analysis of CNS-associated T cells in an unchallenged mouse model. 
The phenotype and memory status of CNS-derived CD4
+
 T cells was then investigated in 
naïve C56BL/6 mice. CD45
+ 
leukocytes were isolated from fresh mouse brain and the cellular 
component of CSF pooled from six mice. It was not possible to retrieve sufficient cellular 
material from murine CP to perform accurate analysis of the CD4
+
 T cell content. Therefore 
this analysis was omitted and the brain and CSF-derived T cell populations were compared to 
those from peripheral blood and spleen. Firstly, the representation of CD4
+
 T cells within the 
total T cell population was analysed by flow cytometry (Figure 4.9). In contrast to 
experiments performed in rat, T cells were identified by expression of the leukocyte marker 
CD45
 
in addition to CD3. Further addition of a CD8 marker then enabled a direct ratio 
between CD4
+
 to CD8
+ 
T cell subsets to be measured in the CD45
+
CD3
+ 
population (gating 
strategy is shown in Figure 4.9A). As was observed in the rat there was a decrease in CD4
+
 
representation in the brain and CSF-derived T cell populations in comparison to those from 
the peripheral blood and spleen (Figure 4.9B, Figure 4.9C). Here this was seen as a bias 
towards a CD8
+
 phenotype and shift away from a CD4
+
 phenotype in the two CNS 
compartments measured.  However, the differences in CD4
+
/CD8 ratio between the tissues 
were more variable than in the rat system and this trend was not statistically significant. With 
consideration to CSF samples this was in part due to an experimental outlier where CD4
+
 T 
cells dominated the T cell population and very few CD8 cells were measured (Figure 4.9C).    
The memory status and phenotype of CD4
+
 T cells from the brain digests and CSF samples 
were then interrogated by flow cytometry. Due to the technical challenges of sampling CSF 
from mouse without perturbing surrounding CNS tissue phenotyping experiments for brain 
and CSF were performed independently. In mouse, the memory (antigen experienced) T cell 
phenotype is characterised by CD44
hi
 expression with the definition between Tcm and Teff 
subsets indicated by CD44
hi
CD62L
hi
 and CD44
hi
CD62L
lo
 respectively
[436–438]
. 
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Figure 4.9 Changes in the distribution of CD4 and CD8 lymphocytes between the CSF, 
brain and peripheral compartments. The cellular component of CSF and brain-derived 
CD45
+
 leukocytes from unchallenged C57BL/6 mice were analysed by flow cytometry. The 
ratio of CD4 to CD8 T cells was compared to T cells from peripheral blood and spleen-
derived cell isolates. A.  Gating strategy for the identification of T cells (CD45
+
CD3
+
 
lymphocytes) within each compartment. Gating strategy is demonstrated by flow cytometry 
plots from a murine spleen sample. B. Representative plots show populations of CD4 and 
CD8 T cells within murine spleen, blood, CSF and brain (plot numbers indicated the 
percentage of cells in each gate). C. Graph shows the mean ± SEM ratio of CD4
+
 to CD8
+
 T 
cells in each compartment (CD4/CD8). ns = no significance at p<0.05 (one way ANOVA 
followed by Bonferroni’s multiple comparisons test). Data is representative of n=6 mice 
measured in 3 independent experiments. CSF data is representative of one sample pooled 
from n=6 mice per experiment.  
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Firstly, the percentage representation of memory (CD44
hi
) cells in the total CD4
+
 population 
was investigated (the gating strategy for CD4
+
 T cells is shown in Figure 4.10A). The 
representation of memory T cells in the CSF fluid was significantly greater than in the 
peripheral blood and spleen with 69.9% ± 6.7 (mean ± SEM) of CSF T cells exhibiting 
CD44
hi
 expression (Figure 4.10B, Figure 4.10C). The CD44
hi
 memory pool in the blood and 
spleen was vastly dominated by a Teff phenotype with very little representation of the Tcm 
subset (Figure 4.10D). This Teff dominance was slightly more pronounced in the CSF 
compartment, although statistically there was no difference in the memory distribution in CSF 
when compared to the blood and spleen populations (Figure 4.10D).  
The memory status of brain-derived CD4
+
 T cells was then analysed for comparative analysis 
with the CSF experiments (Figure 4.11). Brain-derived leukocytes (CD45
+
) were enriched by 
MACS by applying a suspension of enzymatically digested brain tissue labelled with anti-
CD45 microbeads through two magnetic columns (Figure 4.11A). Although the purity of the 
eluted CD45
+
 suspension was low (approximately 6% of cells within a lymphocyte gate), this 
approach was successful as it removed a vast amount of debris and irrelevant material from 
cell preparation (Figure 4.11A). Although the general trend in memory status observed in the 
CSF was recapitulated in the whole brain digests memory T cells were less well represented 
in the brain than in CSF samples (37.1% ± 4.3 compared with 69.9% ± 6.7 (mean±SEM)). 
However, the memory phenotype was still significantly more prevalent in the brain-derived 
population than in matched peripheral blood and spleen (Figure 4.11B, Figure 4.11C).  The 
memory CD4
+
 T cell population associated with brain were predominantly a Teff phenotype 
(Figure 4.11D) as was observed in the CSF. However, in contrast there was a small but 
significant percentage increase of the Teff phenotype in the brain when compared to a matched 
analysis of peripheral blood (95.8% ±2.1 and 84.4% ± 4.1 respectively) (Figure 4.11D).  
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Figure 4.10 Distribution of naïve and memory CD4 T cell subsets in murine CSF. 
Cerebrospinal fluid (CSF) was pooled from unchallenged C57BL/6 mice and cellular 
compartment was analysed by flow cytometry. The distribution of naïve and memory CD4 T 
cells from CSF was compared with matched peripheral blood mononuclear cells and spleen-
derived cell isolates. A. Gating strategy for the identification of CD4 T cells 
(CD45
+
CD3
+
CD8
-
CD4
+ 
lymphocytes) within CSF. Gating strategy is demonstrated using a 
murine spleen sample. B. Representative plots show the distribution of naïve 
(CD62L
hi
CD44
lo
), central memory (CD62L
hi
CD44
hi
), and effector memory (CD62L
lo
CD44
hi
) 
CD4+ T cells in murine spleen, blood and CSF. C. Graph shows the percentage of CD4 T cells 
with a memory phenotype (CD44
hi
). D. The percentage of the memory (CD44
hi
) CD4 
population that is central memory phenotype (CD62L
hi
). ***p<0.001, ns= no significance at 
p<0.05 (one way ANOVA followed by Bonferroni’s multiple comparisons test). Data is 
representative of n=6 mice in measured in 3 experiments.  
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Figure 4.11 Leukocyte isolation from murine CNS tissue and the representation of 
memory cells in the CD4 T cell population. Brain tissue was harvested from 
unchallenged, saline perfused C57BL/6 mice and the associated leukocytes (CD45
+
) 
enriched through magnetic activated cell sorting (MACS). T cells (CD45
+
CD3
+
CD8
-
CD4
+
) from the brain, peripheral blood and spleen cell were analysed by flow cytometry 
for the distribution of memory cells (CD44
hi
). A. Representative plots show the leukocytes 
(CD45
+
) present in digested brain tissue prior to enrichment, and following each stage of a 
consecutive two-step MACS column filtration process. B. Representative plots indicate the 
percentage of the CD4 T cells (all gated) that are a memory phenotype (CD44
hi
) in each 
tissue. C. Graph shows the mean ± SEM percentage of CD4 T cells that are memory. D. 
Graph shows the percentage of memory cells that are an effector memory phenotype 
(CD44
hi
CD26L
lo
). *p<0.05, **p<0.01 ns= no significance at p<0.05 (one way ANOVA 
followed by Bonferroni’s multiple comparisons test). Data is representative of n=6 mice.  
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4.8 The frequency and distribution of CSF-derived T cells in multiple 
human disease cohorts. 
Having analysed peripheral blood and CSF-derived T cell populations in rodent models work 
was translated into human patient cohorts presenting both non-inflammatory and 
inflammatory neurological disorders. It should be noted that the processing of these samples 
was performed by another member of the group (Miss Lindsay Durant). The raw data 
collection was reanalysed by me (the investigator) for the purpose of this study. Central to this 
analysis was a mixed cohort of patients diagnosed with non-inflammatory neurological 
disease (OND) as sampling from this group most closely represented ‘normal’ matched CSF 
and blood. In addition, patients falling under multiple sclerosis (MS) diagnostic criteria were 
categorised into three cohorts in accordance with the clinical course of the disease. These 
included clinically isolated syndrome (CIS), primary progressive MS (PP-MS) and relapsing 
remitting MS (RR-MS). Lastly, a mixed patient cohort with other inflammatory neurological 
diseases (ONID) was included in the comparative analysis. The clinical diagnoses of all 
patients assigned to the OND and ONID groups for this work are described in Section 2 Table 
2.1. The median patient age (with range) for each group is also shown in this table.  
The representation of CD4
+
 and CD8
+
 T cells in the CSF and peripheral blood of each cohort 
was analysed by flow cytometry (gating strategy is shown in Figure 4.12A). When the 
CD4
+
/CD8
+
 ratio of T cells in the CSF was compared to matched peripheral blood samples 
the general trend indicated an increase in CD4
+
 representation in the CSF (Figure 4.12B). The 
exception to this was in the PP-MS cohort where the proportion of T cells with the CD4
+
 
phenotype was elevated in the peripheral blood (as opposed to a decrease in CSF 
representation). Interestingly the CD4
+
/CD8 ratio in the CSF was fairly consistent across all 
the groups measured, with the highest ratio in the CIS group (4.5 (2.6-6.0) median (IQR)) and 
the lowest in the OND group (3.9 (2.7-5.7) median (IQR)).  
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Figure 4.12 Representation of CD4 and CD8 T cells in the cerebrospinal fluid of 
multiple patient cohorts. Peripheral blood and CSF samples were taken from multiple 
patient cohorts
±
. The distribution of CD4 and CD8 T cell subsets in each compartment was 
analysed by flow cytometry. A. Gating strategy for the analysis of CD4
+ 
and CD8
+
 T cell 
distribution. B. The ratio of CD4
+
/CD8
+
 T cell subsets from matched blood and CSF samples 
in five patient groups. C, D. The absolute frequency of CD4 T cells (C.) and CD8 T cells (D.) 
in the CSF of each patient group. Each point represents one patient sample, with the line 
representing the median frequency of each T cell phenotype per ml of CSF. *p<0.05, 
**p<0.01, ***p<0.001, ns = no significance at p<0.05 indicating statistical significance by 
Wilcoxon matched-pairs signed rank test (B.) and Mann-Whitney U statistical test (C, D.). 
± 
CIS; clinically isolated syndrome (n=12), PP-MS; primary progressive multiple sclerosis 
(n=9), RR-MS; relapsing remitting multiple sclerosis (n=20), OND; other neurological 
disease (n=51), ONID; other neurological inflammatory disease (n=12).  
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This consistency suggests that the ratio of CD4
+
/CD8
+
 T cell in the CSF is largely 
independent of inflammatory or disease status (Figure 4.12B).  
The absolute frequency of both CD4
+
 and CD8
+
 T cell populations was also measured in the 
CSF (Figure 4.12C and Figure 4.12D respectively). With the exception of the PP-MS group 
the OND cohort had significantly fewer CD4
+
 T cells per ml/CSF than the other inflammatory 
disease groups (both MS and non-MS). In addition, the PP-MS group had significantly fewer 
CD4
+
 T cells than the CIS and RR-MS groups (Figure 4.12C). These trends were reproduced 
when the frequency of CD8
+
 T cells was measured, where again  fewer cells were found in 
the CSF of the OND and PP-MS groups comparative to the other inflammatory disease 
cohorts (Figure 4.12D).   
Next the distribution of subsets within the memory compartment of the CD4
+
 T cell 
population was assessed. The representation of the central memory phenotype (CCR7
+
) 
within the CD45RO
+
 memory pool was consistent across all of the patient groups (Figure 
4.13). This trend was observed both in the blood and CSF compartments where there was 
consistently a strong bias towards a Tcm phenotype. A slight decrease in the Tcm population (or 
increase in Teff representation) in the RR-MS group was noted but this was not statistically 
significant. The Tcm bias observed in this analysis was the reverse of what was shown in 
mouse studies, where a Teff population dominated both the blood and CSF (Figure 4.10D, 
Figure 4.11D). Given that the predominating blood population was best represented in the 
CSF of both species the relationship between each compartment was then investigated further 
in humans. A correlation analysis was performed where the percentage of memory cells (Tcm 
+ Teff) that were a Tcm phenotype was measured in match peripheral blood and CSF samples 
(Figure 4.14). When OND and ONID (non-MS) cohorts were analysed, results showed that 
the percentage of Tcm cells within the blood memory pool positively correlated with those 
found in the CSF (Figure 4.14A-B, Figure 4.14F). 
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Figure 4.13 The distribution of memory subsets in CD4
+
 T cell populations from human 
peripheral blood and cerebrospinal fluid. Peripheral blood and CSF samples were taken 
from multiple patient cohorts
±
. In the CD4
+
 T cell population, the representation of CCR7
+ 
cells (central memory) within the total memory pool (CD45RO
+
) was analysed by flow 
cytometry. A. Gating strategy for the identification of central and effector memory CD4 T 
cells. B. The percentage of the memory compartment that is a central memory phenotype in 
the blood and CSF. Each point represents one patient sample, with the line representing the 
median percentage representation of central memory. ns = no significance at p<0.05 (Mann-
Whitney U statistical test between pairs of patient groups). 
±
CIS; clinically isolated syndrome 
(n=12), PP-MS; primary progressive multiple sclerosis (n=9), RR-MS; relapsing remitting 
multiple sclerosis (n=20), OND; other neurological disease (n=51), ONID; other neurological 
inflammatory disease (n=12).  
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Figure 4.14 The memory status of CD4 T cell from the blood and matched cerebrospinal 
fluid of patients with and without neuroinflammatory disease. Peripheral blood 
mononuclear cells and the cellular component of CSF were analysed from multiple patient 
groups
±
. The representation of central memory cells (CD45RO
+
CCR7
+
) within the memory 
CD4 T cell population (CD45RO
+
) was analysed by flow cytometry. A-E. Representative 
plots gated on the memory population of CD4 T cells indicating the percentage that are 
central memory in each patient group. Plots represent a CSF (top panel) and matched blood 
(bottom panel) T cell analysis from one patient per disease cohort.  F. Correlation between the 
distribution of central memory in the peripheral blood and CSF memory T cell pool from 
patients without a multiple sclerosis diagnosis (OND; other neurological disease (n=51), 
ONID; other neurological inflammatory disease (n=12)). G. Graph indicates the same 
correlation performed in patients with three clinical disease courses of multiple sclerosis 
(CIS; clinically isolated syndrome (n=12), PP-MS; primary progressive multiple sclerosis 
(n=9), RR-MS; relapsing remitting multiple sclerosis (n=20)). E,F. r number represents the 
spearman correlation value (correlation is significant at the level p<0.001). 
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This trend was also observed across all MS groups, where again the CSF memory distribution 
was a direct reflection of that measured in matched blood (Figure 4.14C-E, Figure 4.14G). 
These results demonstrate that the proportion of Tcm in the CSF is related to that in the 
peripheral blood in the absence of inflammation and that this relationship is not perturbed by 
underlying neuroinflammatory pathology. 
4.9  Discussion. 
The first aim of this investigation was to model ‘normal’ CSF and CNS compartments in 
naïve mice and examine the associated CD4
+
 T cell composition. There are two main 
advantages of using animal modelling for this purpose. Firstly, in the rodent system CSF can 
be sampled in parallel with matched CNS tissue post-mortem. This gives a more complete 
insight into the T cell distribution in multiple CNS compartments simultaneously which is not 
often possible in human histopathological studies. Secondly, obtaining completely normal 
CSF from healthy participants cannot be justified ethically.  Therefore, the closest definition 
of a ‘normal’ CSF cellular composition typically comes from spinal anaesthesia 
procedures
[247]
 or diagnostic sampling where the suspected pathology is not inflammatory in 
nature
[248,288]
. Diagnostic sampling is commonly used to characterise ‘normal’ CSF in the 
literature and so this was utilised for the purpose of this study (OND group). However, it is 
acknowledged that non-inflammatory disorders may have systemic effects that indirectly 
influence immune function in a CNS context.  
The main disadvantage of studying CNS derived T cell populations in rodents is the low 
number of cells that are retrievable from the various compartments for analysis. In the 
absence of inflammation or infection the migration of T cells from the blood into the CSF 
spaces is limited to a very low level recruitment. Studies which investigate T cell association 
with rodent brain are largely restricted to models where activated or CNS-antigen specific T 
cell clones are adoptively transferred in a naïve host
[252,270,439]
. Transferred cells are identified 
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via fluorescent labelling to track their migration, be that through intravital microscopy or 
whole brain sectioning procedures. However, endogenous CNS associated CD4
+
 T cells have 
not been quantified without such experimental intervention. My investigation intended to 
address this question via image capture of serial brain sections to map and quantify T cells 
associated with whole unchallenged mouse brain. Mapping of a whole brain could be 
achieved by capturing multiple images per tissue section and digitally reconstructing the 
images on an epifluorescence microscope as is shown by the nuclear staining in Figure 4.4. 
However, the lack of confocality of this system proved problematic as the serial brain sections 
cut for this exercise were thick (20µm) in order that the whole brain could be represented 
within the analysis. As a result, the high background signal from the out of focus tissue 
masked any signal from specific lymphocyte staining in the epifluorescence system. 
Therefore, an alternative strategy was devised where four brain regions were selected and 
analysed on a confocal microscope to alleviate these issues. Immunofluorescence techniques 
were favoured over immunohistochemistry for this exercise as it permitted the use of more 
markers for cellular identification. It was originally intended that the location of multiple T 
cell subsets could be shown in relation to the CNS vasculature and choroid plexus epithelium 
through additional staining with PECAM-1 and cytokeratin-8 respectively. However, staining 
for up to six markers proved technically challenging and was hampered by high tissue 
autofluorescence and non-specific staining. Although such images of an interpretable quality 
were not produced during this investigation, it is acknowledged this exercise would provide a 
more detailed insight into the localisation of T cells within CNS tissue.    
Results from this investigation did identify a low number of CD3
+
, CD4
+
 and CD3
+
CD4
+
 
associated with distinct gross anatomical locations within the mouse midbrain sections 
(Figure 4.4-4.5). Whereas CD3
+
CD4
+ 
surface expression strongly indicated the presence of 
CD4
+
 T cells it may be assumed that CD3
+ 
population represented the CD8 phenotype. 
However NK and CD4
+
CD8
+
 cells have been described in association with human CNS and 
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an increase in these subsets is associated with inflammatory pathologies
[440,441]
. In my 
experiments the frequency of CD3
+
 cells was greater than the CD3
+
CD4
+ 
population, which is 
consistent with the inverted CD4
+
/CD8
+
 ratio in the CNS that was also identified by flow 
cytometry (Figure 4.9). Interestingly, CD3
+ 
single positive cells were observed in the 
meninges, choroid plexus and periventricular regions, whereas CD3
+
CD4
+ 
T cells were not 
observed in the meninges. A leptomeningeal route of T cell migration from the blood into the 
perivascular CSF-filled spaces of the leptomeninges has been described by Carrithers et al 
(2000)
[252]
. However, intravital studies of the leptomeninges via a cranial window have failed 
to identify T cell capture and migration here in the absence of inflammation
[274]
. Given that 
the perivascular spaces are continuous with the CSF flow it is not possible to say whether 
these CD3
+
 (assumed CD8
+
) T cells represent cells that have migrated via a meningeal route 
or they are derived from another BCSFB pathway and are retained in the meningeal spaces.  
The fact that CD3
+
CD4
-
 (CD8
+
) cells were readily detected in choroid plexus tissue in the rat 
by flow cytometry is evidence against choroid plexus T cell migration being exclusive to the 
CD4
+
 subset (Figure 4.5-4.6). With the assumption that the meningeal and CP-derived T cells 
were behind the BBB/BCSF barrier (inclusion of an endothelial marker would be required for 
conformation), this result suggests differential T cell distribution between these CSF-filled 
compartments. Such a phenomenon has not been previously documented under homeostatic 
conditions in mice and in contrast human studies show that the cellular composition of CSF is 
consistent in both the lumbar and ventricular regions
[283]
. More detailed analyses of T cells co-
localisation with meningeal and CP barriers are required to take these findings forward, in 
addition to more comprehensive T cell phenotyping in these microscopy experiments.     
 Anecdotally, CD3
+
 cells were often seen in proximity to CD4
+ 
cells in the meninges. These 
CD4
+ 
single positive cells may represent a population of perivascular macrophages in the 
meningeal space; an observation which was supported by their size and morphology. Low 
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CD4 expression by both resting macrophage and microglial populations is reported in rodent 
brain, with increased expression in response to activation or in the context of EAE
[442,443]
. 
CD4
+
 expression by CP macrophages (epiplexis cells) is not described in the literature. 
However, CD3
-
CD4
+
 cells were also found to reside in the CP and were again often in the 
same field of view as CD3
+
 T cells (irrespective of CD4 status; Figure 4.5D). These findings 
together with the absolute absence of CD4
+
 T cells or CD4
+
 monocyte lineage in brain 
parenchyma (cortex) suggest that these cells are involved in homeostatic immune surveillance 
in line with a model described by Engelhardt et al (2011) 
[257]
. Immune surveillance is 
performed by T cells residing in the CSF-filled spaces behind the BBB and BCSFB and here 
they interact with perivascular APC. However, in the absence of specific antigen recognition 
the outermost parenchymal basal lamina of the brain (glia limitans) is not breached. With 
these concepts in mind it is acknowledged that CD3
+
 and CD3
+
CD4
+ 
cells were identified in 
the periventricular region adjacent to the CP, thus contradicting this model (Figure 4.5C). 
However, it is unlikely that this region of brain represents true parenchymal tissue and is more 
likely representative of circumventricular organ (CVO) structures. The CP is part of a CVO 
network in the 3
rd
 and 4
th
 ventricles and both structures lack endothelial tight junctions and 
have fenestrated vasculature
[444]
. T cell migration across CVO which lines the ventricles is 
documented, most notably as a proposed route of T cell migration in EAE
[445]
. It is in such 
instances where more comprehensive markers of epithelial and endothelial barriers would be 
useful in this analysis to more accurately define the borders of the parenchyma and ventricular 
structures. It is also acknowledged that my work is only representative of the midbrain region 
and therefore additional sampling of the forebrain and hindbrain structures would be highly 
appropriate in further experiments.  
Flow cytometry was used to investigate the phenotype of CNS-derived T cells in more detail 
than was permissive by microscopy analysis (rodent) and to examine T cell subsets within the 
CSF and blood compartments (rodent and human). In humans, the ratio of CD4
+
/CD8
+
 T cells 
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in the CSF was increased compared to the blood in the non-inflammatory disease cohort 
which is consistent with what is reported elsewhere
[248,446]
.  Interestingly, I found that this 
ratio was reversed in both the mouse and rat CSF models and was consistent with analysis in 
rodent CNS tissue preparations. This finding is contrary to reports by K. Baruch et al (2012) 
who have demonstrated a CD4
+
 T cell bias in unchallenged murine CP (62% ± 2.76 (mean ± 
SEM) in the same mouse strain utilised in this investigation
[447]
. However, this group have not 
reported the CD4
+
/CD8
+
 ratio in the CSF compartment of normal mice. My work may 
indicate a more dominant role of the CD8
+
 T cell subset in normal rodent CNS surveillance. 
Whether this is a result of differential recruitment or increased retention of this subset is open 
to speculation. It may also be indicative of more resident CD8
+
 TRM-type population 
associated with the CNS as is reported post influenza and vesicular stomatitis virus infection 
in mice
[448,449]
. Alternatively, it may simply be reflective of alternative requirements of the 
species for protection against endemic CNS pathogens. 
In line with current understanding of human CSF biology there was a shift in favour of the 
CD4
+
 T cell phenotype in the CSF irrespective of inflammatory disease with the exception of 
the PP-MS group (Figure 4.12). Within the CSF compartment, it is reported that the 
CD4
+
/CD8
+
 T cell ratio is significantly great in MS cohorts
[450]
. I found that the CD4
+
 T cell 
bias in the CSF was only marginally increased in the CIS and RR-MS groups compared with 
the OND cohort, but the difference between the blood and CSF ratios was accentuated (Figure 
4.12B). These findings do not necessarily indicate that migration into CNS is more CD4
+
 
biased in inflammation as a heavy enrichment of CD8
+
 T cells are identified within active MS 
lesions
[451]
. Therefore, it cannot be excluded that migration across the glia limitans favours the 
CD8
+
 subset when there is parenchymal inflammation. Such a phenomenon is also observed 
in inflamed perivascular cuffs where CD4
+
 T cells are retained adjacent to the vessels whereas 
the CD8
+
 subset preferentially migrates into the tissue
[354,355]
.  
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As previous studies have proposed that the CD4
+
 T cell population has a significant role in 
CNS immune surveillance
[257,452]
 the memory status of this population was characterised 
further in this study. Initial animal experiments were performed in rat due to the increased 
volume of CSF and amount of CP tissue obtainable per animal.  Results showed that there 
was an increased proportion of CD4
+
 T cells with CD45RC
lo 
expression in the CSF, CP and 
whole brain (Figure 4.8D). This was consistent with BCSFB migration being restricted to the 
memory phenotype as in the rat antigen experienced CD4
+
 T cells are classically defined by 
CD45RC
lo
 expression whereas naïve cells express CD45RC
hi[434,435]
. However, this definition 
has been repeatedly challenged by evidence that antigen experienced CD45RC
lo 
cells revert 
back to the CD45RC
hi 
isoform in the absence of persistent antigen
[453]
. This implies that 
CD45RC
lo
 expression is more representative of an ‘activated’ as opposed to a true ‘memory’ 
phenotype. In support of this, when rat CD4
+
 T cells were stimulated with PMA/ionomycin as 
part of this investigation all cells lost CD45RC
hi 
expression (as discussed later in Chapter 5). 
Given that a clear definition of memory and distinction between central and effector 
phenotypes was pivotal to this enquiry further use of rat models was restricted. Therefore, 
more detailed investigation was taken forward in the mouse where memory markers are better 
established and more translatable to human immunology.  
The absolute number of T cells in murine CSF and brain was not quantified numerically in 
this investigation and analysis focused on the distribution of T cell subsets. The estimated 
number of CD4
+
 T cells retrieved from CSF was similar to parameters described by Kunis et 
al who previously reported CD4
+
 T cell frequencies at approximately 1.25 cells/ul of CSF
[282]
. 
Given that only 10-20ul of CSF can be collected per mouse this can render the very small 
number of CSF-derived lymphocytes difficult to interpret on flow cytometry plots. As in the 
rat system, mouse CSF from multiple siblings was pooled in these experiments to increase the 
cell numbers and add power to the subsequent statistical analysis (Figure 4.9-4.11). In 
addition, flow cytometry gates were kept consistent and set on the parameters of peripheral 
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blood derived lymphocytes. In mouse the percentage of memory cells (CD44
hi
) in the blood 
was low, which may be expected given that these animals were housed in specific pathogen 
free conditions (Figure 4.10-4.11). As anticipated there was significant enrichment of memory 
T cells in the CSF and brain which is indicative of memory specific migration. It should be 
noted that in these experiments the brain-derived CD4
+
 T cells included CP associated 
populations, as this tissue was not removed from the preparations. Given that microscopy 
identified CP to be the primary site of residing CD4
+
 T cells in the brain, it is likely a 
significant proportion of brain derived cells were of a CP origin.  
In mouse peripheral blood the predominant memory phenotype was effector memory 
(CD44
hi
CD62L
lo
) with little representation of a central memory population (CD44
hi
CD62L
hi
) 
and this distribution was reflected in the both the CSF and brain (Figure 4.10-4.11). There 
was a slight increase in Teff in the brain but this difference may not directly indicate an 
absence of Tcm recruitment but may suggest an apparent under representation of the Tcm due to 
their low frequency combined with the low cell numbers in CSF. Reported findings from 
Baruch et al (2012) describe an enrichment of CD4
+
 Teff phenotype in the CP under the 
assumption that these cells are retained in the CP whilst Tcm migrate away into the CSF
[447] 
(the authors reference to the Tcm predomination in humans). The domination of the Teff subset 
in the CSF in my study challenges this proposal and is more consistent with a lack of specific 
subset recruitment across the BCSFB. Together these findings provoked revision of the 
proposal that the CD4
+
 memory T cell subset distribution in normal CSF is a result of direct 
Tcm recruitment. Instead it was considered whether the memory subset distribution in the CSF 
is reflective of the memory status of the blood. This was tested by examining the 
corresponding memory subsets in the human patient cohorts (Figure 4.13-4.14). The Tcm 
phenotype dominated the memory population in both the blood and the CSF irrespective of 
underlying disease. In the OND group it was found that Tcm representation within the blood 
memory pool was directly proportional to the levels measured from matched CSF.  This data 
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indirectly supports a similar analysis previously reported by P. Kivisäkk et al (2004), where 
the opposing Teff memory phenotype is examined
[249]
. The authors show that the percentage of 
Teff in the peripheral blood is proportional to that in matched CSF in patients without 
inflammatory disease, but here the distinction between Tcm and Teff is defined by expression of 
CD27
hi/lo 
as opposed to CCR7
+/-[249]
. Given that my work shows CCR7
-
 Teff cells are as 
equally well represented in the CSF as the periphery in the absence of inflammation this may 
suggest that homeostatic recruitment across the CP (and potentially leptomeningeal spaces) 
into CSF is not CCR7 dependent (Figure 4.14). The proposal that CD4
+
 T cell recruitment 
into the CSF is dependent upon CCR7 expression is supported by studies where 
lymphoblastic leukaemia is modelled in mice. Here transformed lymphoblastic cells from 
CCR7
-/-
 haemopoietic progenitors are incapable of infiltrating into CNS whereas those from 
wild type progenitors migrate readily
[454]
. However, this work is not necessarily representative 
of homeostatic migration in mice and in response it may be favourable to directly measure 
CCR7 expression in the mouse system presented in this chapter. In humans, the CCR7 ligand 
CCL19 is constitutively expressed on brain post-capillary venules and is detectable in the 
CSF
[285,286]
. Additionally, constitutive expression of the alternative ligand CCL21 is reported 
on choroid plexus epithelium from cadavers without neuroinflammatory disease
[249]
. 
However, the argument that homeostatic CNS migration must involve CCR7 simply because 
it is expressed by the numerically dominant CSF T cell population does not hold in 
accordance with findings present as part of this thesis.  A similar argument is presented in a 
recent study by B. Vander Lugt et al (2013) in the context of lymph node migration
[455]
. 
Despite universal understanding that T cells within secondary lymphoid organs are CCR7
+
 
when irradiated mice are reconstituted with mixed CCR7
+
 and CCR7-deficient T cells, lymph 
node migration occurs independently of CCR7 expression. In line with my work, CCR7 
expression may represent a bystander effect that is not essential in the CNS migration process 
per se.  
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The correlation between the memory subset distribution in the blood and CSF was consistent 
in every MS and non-MS inflammatory disease cohort tested, indicating that this relationship 
is independent of inflammatory disease status (Figure 3.14). This was contrary to finding 
from the P. Kivisäkk et al (2004) study was based on linear regression analysis no such 
relationship was found in an MS patient cohort
[249]
. My results suggest that proportionally 
there was no enrichment of Teff cells in the CSF of any MS cohorts or inflammatory disease 
groups through increased CCR7
-
 Teff recruitment. Conversely, an absence of Teff depletion in 
CSF memory pool is evidence against their preferential migration into the CNS parenchyma. 
However, although the distribution of Tcm and Teff was not significantly altered in 
inflammation it cannot be discounted that their recruitment is via a pathway independent of 
the normal homeostatic routes.  For example, a switch towards a more activation-driven 
chemokine dependent pathway could drive both Tcm and Teff subset recruitment non-
preferentially. CXCR3
+
 T cells are enriched in the CSF in models of MS patients
[360,361]
 and 
CXCR3 blockade is shown to inhibit the onset of disease in adoptive transfer models of 
EAE
[456]
.  However, CXCR3 expression is not exclusive to the Teff subset as shown by work 
examining anti-viral recall responses of Tcm in secondary lymphoid organs
[457]
. Here the 
CXCR3 ligands CXCL9 and CXCL10 are upregulated by activated DC at inflammatory foci. 
Expression of CXCR3 by Tcm is essential for the migration towards these areas and thus 
increases the kinetics of recall responses to viral antigen.   
Enhanced migration of both Tcm and Teff subsets through a concurrent upregulation of 
chemokine receptors could explain why the absolute frequency of CSF CD4
+
 T cells 
increased in inflammation but the distribution of the subsets did not. In support of this there 
were significantly more CD4
+
 and CD8
+
 T cells in the CSF of CIS, RR-MS and ONID 
cohorts than in the non-inflammatory control group (Figure 4.12B). It cannot be discounted 
that in inflammation there is an increased reactivation and proliferation of CD4
+
 and CD8
+
 T 
cell populations behind the BBB and BCSFB in situ. Such T cell expansion has been 
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identified in the leptomeningeal spaces following the induction of EAE
[289]
. Interestingly, 
CD4
+
 and CD8
+
 frequencies from the PP-MS group were comparable to the OND cohort and 
may be reflective of a different disease aetiology compared with the other MS cohorts (Figure 
4.12B). Overall, these findings suggest that differential T cell pleocytosis as opposed to 
memory status in various neuroinflammatory diseases could provide a useful diagnostic 
application. The significance of variable cellularity between disease states was also well 
documented in a meta-analysis of CSF composition by Alvermann et al (2014)
[458]
. 
CHAPTER SUMMARY 
In summary, this line of investigation has challenged current understanding regarding the 
specificity of memory CD4
+
 T cell migration into the CNS under homeostatic conditions. In 
contrast to human studies, enrichment of CD8
+
 T cells was observed in mouse and rat CNS 
which may suggest a more dominant role of this subset in rodent immune homeostasis. 
However, CD4
+
 T cells were identified in normal mouse brain and were predominantly 
localised to the CP regions and the meninges. Evidence suggests that migration from blood to 
CSF is permissive to both central and effector memory CD4
+
 T cell subsets in the absence of 
inflammation. The memory phenotype of these subsets in the CSF is a reflection of their 
representation in the blood in both mice and men. In addition, the distribution of the memory 
subsets is not perturbed in neuroinflammatory pathology and the homeostatic migratory 
pathway persists. Therefore it is the frequency of CSF T cells that is best associated with 
active neuroinflammatory disease with particular respect to primary or reoccurring 
inflammatory episodes in MS.    
   
 
 
 
 
 
 
 
CHAPTER 5 
RESULTS 
THE POTENTIAL OF CD4
+
 T CELLS IN THE  
CNS TO ACTIVATE AND PRODUCE EFFECTOR 
CYTOKINES. 
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5 THE POTENTIAL OF CD4
+
 T CELLS IN THE CNS TO 
ACTIVATE AND PRODUCE EFFECTOR CYTOKINES. 
5.1  Rationale. 
Many publications which review the immunological barriers in the CNS refer to the role of 
CD4
+
 T cells in immune surveillance within the CSF space
[253,257,452]
. Findings that give 
probable cause for a role of adaptive immune surveillance within the CSF include; 1) the 
presence of various antigen presenting cells in the CSF space
[289]
, 2) the circulation and 
outflow of CNS antigens from the CSF fluid
[297,298]
, 3) a more dominant role of a lymphatic 
route of CSF drainage via the cervical lymph nodes than previously credited
[294,295]
. However, 
although memory CD4
+
 T cells are the predominating adaptive immune cell in the CSF very 
few studies have directly examined their functionality in the absence of inflammatory 
pathology. Therefore, the robustness of CD4
+
 T cell activation and cytokine production from 
healthy CSF has not been formally demonstrated. This void is particularly apparent in mouse 
studies where there is an extensive literature on CNS-associated T cell cytokine production in 
EAE and infection models, but few publications addressing T cell responsiveness in naïve 
animals. An exception to this is a study by Kunis et al (2013), who report an enrichment of 
IFNγ and IL-4 producing CD4+ T cells in naïve CP but no such increase in IL-17 or GM-CSF 
secretors
[282]
. However, the authors do not report the cytokine secreting potential of CSF 
CD4
+
 T cells as part of their study. 
My investigation has previously described how CD4
+
 T cells from healthy human peripheral 
blood were stimulated with PMA/ionomycin in vitro to reveal their cytokine potential 
(Chapter 3). In addition, upregulation of the activation marker CD69 was used to measure the 
responses of T cell populations to in vitro stimulation. As the effector function of homeostatic 
CD4
+
 T cells in the CNS is poorly defined these analyses were applied to the CNS and CSF-
derived CD4
+
 T cell populations whose phenotype was examined in Chapter 4. As in 
experiments where the phenotype of these populations was examined, it was favourable to 
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model ‘normal’ CSF (and CNS) in rodent systems in addition to sampling from human patient 
cohorts. In this chapter the expression of CD69 and the proflammatory cytokine IFNγ were 
measured in two rodent systems. When sampling human data, CD69 expression was 
measured from blood and CSF-derived CD4
+
 T cell populations in both non-inflammatory 
and inflammatory disease cohorts. This allowed for comparative analysis between a ‘normal’ 
and inflammatory pathological status in these compartments that could be measured in 
addition to examining intra-cohort differentials between the blood and CSF. 
Preliminary studies prior to this investigation indicated that in the absence of inflammatory 
pathology the cytokine responses of CD4
+
 T cells in the CSF were diminished comparative to 
the peripheral blood (Figure 1.5). Therefore, based on this data the hypotheses are that fewer 
CD4
+
 T cells from non-inflamed human CSF will secrete cytokine but peripheral blood 
responses will remain robust. In addition, cytokine producing CD4
+
 T cells will be enriched in 
the CSF of patients with neuroinflammatory disease. With regard to CD69 expression 
analysis, a hypothesis can be drawn based on evidence presented in the previous two chapters. 
In Chapter 3, a population of memory CD4
+
 T cells that did not express CD69 upon ex vivo 
activation was identified in human peripheral blood. In addition, data presented in Chapter 4 
argued in favour of selective memory CD4
+
 T cell migration into the CSF compartment that 
was equally permissive to both Tcm and Teff subsets in the absence of inflammation. Therefore 
it can be postulated that the representation of non-responsive (CD69
lo
) CD4
+
 T cells in the 
CSF memory compartment will be proportionally consistent with that seen in the peripheral 
blood memory pool. 
5.2 Examination of differential CD69 expression by murine CD4+ T cells 
in the CNS and peripheral blood. 
Flow cytometry was used to examine the expression of CD69 in brain-derived CD4
+
 T cells 
from unchallenged C57BL/6 mice. Findings were compared to analogous populations derived 
from the blood and the spleen. CD4
+
 T cells in the brain were identified by gating on 
Chapter 5 201 
 
CD45
+
CD3
+
CD4
+
 lymphocytes from CD45
+ 
leukocyte preparations. CD45
+ 
leukocytes were 
isolated from a suspension of digested brain by MACS (see Chapter 4 Figure 4.11). All gating 
was set according to parameters identified in lysed peripheral blood cultures. Interestingly, in 
freshly isolated cell preparations it was noted that CD4
+
 T cells in the brain had a slightly 
lower expression of CD4 than those populations in the blood and spleen. Uncultured cell 
isolates were then examined for their expression of CD69 ex vivo (Figure 5.1A, Figure 5.1C). 
Significantly more brain-derived CD4
+
 T cells expressed physiologically elevated levels of 
CD69 than those cells from the peripheral blood and spleen (Figure 5.1C). However, the 
physiological expression of CD69 was notably lower than levels obtained following 
stimulation with PMA/ionomycin as was previously identified in human samples (Figure 
3.16). There was little difference in the percentage of CD69
hi 
CD4
+
 T cells between the blood 
and spleen (11.5% ±2.7 and 13.5% ±1.5 (mean±SEM) respectively), whereas nearly a third of 
CNS-derived cells were of this phenotype (30.8% ± 5.9 (mean±SEM)).  
In a separate analysis, cells from each tissue were cultured for 3 hours with PMA/ionomycin 
and the percentage of CD4
+
 T cells that did not upregulated CD69 was measured (Figure 
5.1B, Figure 5.1D). The classical downregulation of CD4 induced by PMA/ionomycin 
stimulation in human CD4
+
 T cell cultures was not observed in the analogous murine 
population. In contrast, the difference in CD4 expression between CD69
lo
 (non-responsive) 
and CD69
hi 
(responsive) fractions was marginal. In these stimulation assays there was a 
decreased representation of non-responsive (CD69
lo
) CD4
+
 T cells in the brain compared to 
the peripheral blood and spleen. Only 15.0% ± 5.2 (mean±SEM) of brain-derived CD4
+
 T 
cells did not respond to PMA/ionomycin as opposed to 35.9% ± 9.8 in the blood. Although 
this was not statistically significant, this shows that the brain-derived population were at least 
as responsive to the stimulus as the peripheral T cell pool. 
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Figure 5.1  Analysis of CD69 expression by murine CNS derived CD4 T cells. Brain 
tissue was harvested from unchallenged, saline perfused C57BL/6 mice and the associated 
leukocytes (CD45
+
) enriched through magnetic activated cell sorting (MACS). T cells 
(CD45
+
CD3
+
CD8
-
CD4
+
) from the brain-derived leukocytes, peripheral blood and spleen were 
analysed by flow cytometry for elevated CD69 expression as an indicator of recent activation 
in vivo. In additional experiments cell isolates were stimulated for 3h with PMA/ionomycin 
and analysed for the failure to upregulated CD69 (non-responsiveness).  A. Representative 
flow cytometry plots show the percentage of CD69
hi 
CD4
+
 T cells in unstimulated assays. B. 
Plots show the percentage of non-responsive CD4
+ 
T cells (CD69
lo
) in stimulated (+PMA) 
cell cultures. Plot numbers indicate each population as a percentage of total CD4 T cells (all 
gated cells). C. Graphs show the mean ± SEM proportion of CD4
+ 
T cells that are recently 
activated in vivo (CD69
hi
). Data is representative of n=5 mice. D. The mean ± SEM 
percentage of non-responsive CD4
+ 
T cells (CD69
lo
)
 
following in vitro stimulation. Data is 
representative of n=6 mice. ***p<0.001, ns= no significance at p<0.05 (one way ANOVA 
statistical analysis followed by Bonferroni’s multiple comparisons test).  
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 The above findings were reproduced when endogenous and induced CD69 expression was 
examined in CSF-derived CD4
+
 T cell populations (Figure 5.2). As was observed in brain-
derived populations the percentage of CSF CD4
+
 T cells that were recently activated in vivo 
(CD69
hi
) was greater than those cells from the blood and spleen (Figure 5.2A, Figure 5.2C). 
Following stimulation fewer CSF CD4
+
 T cells also failed to upregulate CD69 comparative to 
those in the periphery. Statistically this difference was not significant by means of ANOVA 
statistical testing comparing all three groups despite the apparent trend (Figure 5.2B, Figure 
5.2D). Taken together these results may indicate that the CD4
+
 T cell populations associated 
with the brain and the CSF compartment have a more activated phenotype in vivo and readily 
respond to PMA/ionomycin stimulation.  
5.3  Quantification of ‘non-responsive’ CD4+ T cells in the peripheral 
blood and CSF of patients with non-inflammatory neurological 
disease and multiple sclerosis.  
The ability of peripheral blood and CSF CD4
+
 T cells to activate in response to 
PMA/ionomycin was measured in two patient cohorts and one healthy control group. The 
healthy control group (HC) represented volunteers from the same population demographic as 
was investigated in Chapter 3 and for ethical reasons only blood was taken from these 
participants. To represent ‘normal’ CSF a group diagnosed with non-inflammatory 
neurological disease was examined as characterised in Table 2.3 and described in Chapter 4 
(OND). However, for this experimental purpose sampling of patients with inflammatory 
disease was low and only individuals with a diagnosis of MS were included. Therefore, one 
patient with CIS, three with RR-MS, and four with PP-MS were grouped into a general MS 
cohort for this investigation (n=8).   
In these experiments, cultures were stimulated for 6 hours to reveal the ‘non-responsive’ 
CD4
int
CD69
lo 
phenotype as described in Chapter 3. Firstly, the percentage of non-responsive 
cells in the CD3
+
CD8
-
CD4
+ 
T cell population in the blood was measured by flow cytometry 
and compared between the three groups (Figure 5.3A, Figure 5.3B). 
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Figure 5.2 Analysis of CD69 expression by murine CSF derived CD4 T cells. 
Cerebrospinal fluid (CSF) was pooled from unchallenged C57/BL6 mice and the cellular 
compartment was analysed by flow cytometry. Uncultured T cells (CD45
+
CD3
+
CD8
-
CD4
+
) 
from CSF, peripheral blood, and spleen were analysed for expression of CD69
hi 
as an 
indicator of recent activation in vivo. In additional experiments cell isolates were stimulated 
for 3 hours with PMA/ionomycin and analysed for the failure to upregulated CD69 (non-
responsiveness).  A. Representative flow cytometry plots show the percentage of CD69
hi 
CD4
+ 
T cells in uncultured (-PMA) assays. B. Plots show the percentage of non-responsive 
CD4
+ 
T cells (CD69
lo
) from stimulated (+PMA) cell cultures. Plot numbers indicate each 
population as a percentage of total CD4
+ 
T cells (all gated). C. Graphs show the mean ± SEM 
proportion of CD4
+ 
T cells that are recently activated in vivo (CD69
hi
). Data is representative 
of n=6 mice measured in 3 independent experiments D. The mean ± SEM percentage of non-
responsive CD4
+ 
T cells (CD69
lo
)
 
following in vitro stimulation. Data is representative of n=6 
mice measured in 3 independent experiments. *p<0.05, ns= no significance at p<0.05 (one 
way ANOVA statistical analysis followed by Bonferroni’s multiple comparisons test).  
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The percentage of CD4
int
CD69
lo
 non-responsive cells recorded in the healthy control group 
was low compared with the OND and MS groups (8.2% (3.6-17.3 IQR)). However, the 
representation of non-responsive cells in this control group was notably higher than when 
healthy individuals were analysed previously, where the median percentage was shown to be 
1.2% (0.7-1.9 IQR) (Chapter 3 Figure 3.9). The proportion of non-responsive cells in the 
OND and MS groups was very high and measured at 3.2 times and 3.7 times greater than the 
healthy control group respectively (Figure 5.3B). This increase in the non-responsive cell 
frequency between the HC and both the OND and MS groups was statistically significant but 
there was no statistical difference between the two patient cohorts. When the representation of 
non-responsive cells in the CSF of OND and MS patients was compared there was a notable 
decrease observed in the MS group (Figure 5.3C). No statistical significance was associated 
with this difference due to both high variability in the population’s frequency in the OND 
group and two outliers in the MS cohort where a very high percentage of non-responsive cells 
was recorded. 
The representation of non-responsive cells in the blood was then compared to the 
corresponding frequency in the CSF in OND and MS patient groups (Figure 5.3D, Figure 
5.3E). In the OND group, the frequency of non-responsive cells in the CSF ranged from 3.2-
70.8% and was notably more variable than in the blood. However, the median percentage of 
the population was not significantly different between the blood and CSF (Figure 5.3A, 
Figure 5.3D). In contrast, the non-responsive phenotype in the CSF of the MS group was 
notably reduced comparative to the blood in most individuals (Figure 5.3A, Figure 5.3E). The 
exception to this trend was the two aforementioned outliers whose frequency of non-
responsive cells in the CSF was extremely high. 
To further characterise the non-responsive phenotype in each patient cohort the proportion of 
non-responsive cells in each CD4
+
 T cell subset was measured in the blood and CSF (Figure 
5.4). In Chapter 3 it was identified that the representation of the non-responsive population  
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Figure 5.3 Investigation of hyporesponsive CD4
+
 T cell frequencies in the blood and 
cerebrospinal fluid of patients with neurological and inflammatory neurological disease. 
Peripheral blood mononuclear cells and CSF cell isolates were collected from two patient 
groups (non-inflammatory neurological disease (OND) and multiple sclerosis (MS)) and 
stimulated for 6h with PMA/Ionomycin. The CD4
+ 
T cell population (CD3
+
CD8
-
CD4
+
) was 
analysed by flow cytometry for the failure to upregulate CD69 following stimulation. CD69
lo
 
expression was gated at the fluorescence intensity of unstimulated cultures.  A. Representative 
plots show the responsive (CD4
lo
CD69
hi
) and non-responsive (CD4
int
CD69
lo
) CD4
+ 
T cell 
fractions in the blood and matched CSF of each disease cohort. Numbers indicate the 
percentage of unresponsive cells. B-C. The median percentage of non-responsive CD4
+ 
T 
cells in the blood (B.) and the CSF (C.) of each patient cohort and a healthy control (HC) 
group. D-E. The median non-responsive cell frequency in the blood and CSF was compared 
in the OND (D.) and MS (E.) groups. *p<0.05, **<p<0.01, ns = no significance at p<0.05 
(Mann-Whitney statistical test (B-C.) Wilcoxon matched-pairs signed rank test (D-E.)). Data 
is representative of n=14 CSF and n=18 PBMC samples in the OND cohort and n=8 blood 
and CSF samples in the MS cohort. 
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may be biased by the frequency and distribution of each T cell subset. Therefore, a gating 
strategy was applied to measure the percentage of Tnaive (CD45RA
+
CCR7
+
), Tcm (CD45RA
-
CCR7
+
) and Teff (CD45RA
-
CCR7
-
) cells that were non-responsive, as opposed to examining 
the representation of each subset within the CD4
int
CD69
lo
 population (Figure 5.4A).  
Firstly, peripheral blood samples were analysed to identify the CD4
+
 T cell subset with the 
greatest representation of non-responsive cells. It was found that the Tcm population had the 
highest median frequency of non-responsive cells in both OND and MS groups (around 45% 
and 53% in the OND and MS groups respectively) (Figure 5.4B). There was also a high 
representation of these cells in the Teff subset of both groups, with no statistically significant 
difference in frequency identified between the Tcm and Teff subsets. Consistent with trends 
revealed where healthy controls were sampled in Chapter 3, minimal numbers of Tnaive cells in 
the blood failed to respond to PMA/ionomycin stimulation in both patient groups (Figure 
5.4B). There was also minimal representation of non-responsive cells in the Tnaive 
compartment in the CSF of OND and MS patients (Figure 5.4C). The exception to this trend 
was two outliers in the MS group, but these patients were not shown to have the same clinical 
course of MS. As in the blood the Tcm subset had the highest proportion of the non-responsive 
population in both groups. However, non-responsive cells in the Tcm subset were 2.3 times 
more numerous than the Teff subset in the OND group, whereas this differential 3.3 times in 
favour of the Tcm subset in the MS group (Figure 5.4C). This suggests that Teff cells in the 
CSF of MS patients are proportionally more responsive than Tcm cells when compared with 
individuals that have no underlying inflammatory disease. 
In an alternative analysis of the data set described in Figure 5.4 the percentage of non-
responsive CD4
+
 T cells in each subset was directly compared between the blood and CSF 
compartments within each patient group (Figure 5.5). In the OND group there were no 
statistically significant changes between the responsiveness of blood and CSF-derived T cells 
across all the subsets (Figure 5.5A).  
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Figure 5.4 The effect of disease status upon the subset distribution of non-responsive 
CD4
+
 T cells within the blood and cerebrospinal fluid compartments. Peripheral blood 
mononuclear cells and cerebrospinal fluid (CSF) cells were isolated from patients with non-
inflammatory neurological disease (OND) and multiple sclerosis (MS). Cells were stimulated 
for 6h with PMA/Ionomycin and the naïve (CCR7
+
CD45RA
+
), Central memory 
(CCR7
+
CD45RA
-
) and effector memory (CCR7
-
CD45RA
-
) CD4
+ 
T cell populations analysed 
for the percentage of cells that did not upregulate CD69. A. Flow cytometry gating strategy 
for identifying unresponsive (CD4
int
CD69
lo
) CD4
+ 
T cells in each subset. CD69
lo
 expression 
was gated at the fluorescence intensity of unstimulated cultures. B-C. The percentage of 
unresponsive CD4
+ 
T cells from each subset in the blood (B.) and CSF (C.) of patients with 
non-inflammatory neurological disease and inflammatory neurological pathology. 
***p<0.001, *p<0.05 ns = no significance at p<0.05 (Friedman statistical test, followed by 
Dunn’s multiple comparisons analysis). Data is representative of n=10 CSF and n=18 PBMC 
samples in the OND cohort and n=8 blood and CSF samples in the MS cohort. 
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However, comparative to the blood there was a notable reduction of non-responsive cells in 
the Tcm and Teff subsets in the CSF. In contrast, when the MS group was examined both the 
Tcm and Teff non-responsive populations were markedly diminished in the CSF comparative to 
the blood (Figure 5.5B). Due to two outliers with a very high percentage of non-responsive 
cells in the CSF this decrease was not statistically significant in the Tcm subset. However, 
there were significantly fewer non-responding cells in the Teff subset which strongly indicates 
a differential activation status of this subset in the CSF compartment (Figure 5.5B). 
The dataset was then analysed to examine the effect of inflammation upon the frequency of 
non-responsive cells in each subset derived from the blood and CSF (Figure 5.5C, Figure 
5.5D). In the blood the frequency of non-responsive cells in each subset was comparable 
between the OND and MS subsets (Figure 5.5C). This indicates that inflammatory changes 
associated with MS do not affect the responsiveness of CD4
+
 T cells in the blood. However, 
notable changes in responsiveness were observed between the groups when the CSF was 
examined (Figure 5.5D). The median frequency of non-responsive cells in the Tcm and Teff 
subsets was diminished in the MS cohort comparative to the OND group. This result suggests 
that both memory subsets activate more readily in the CSF on a background of 
neuroinflammation, although no statistical inferences were drawn from these findings (Fig 
5.5D). Surprisingly there were significantly more non-responsive CSF cells in the Tnaive subset 
of MS patients. However, this is largely due to two outliers in the MS cohort that expressed 
very high numbers of non-responsive cells, whereas none of the OND patients had any non-
responsive cells in their samples (Figure 5.5D). Together with the low cell numbers and the 
very low representation of Tnaive cells in the CSF compartment it is unlikely that this 
difference between the groups is truly reflective of a difference in non-responsive cell status.  
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Figure 5.5 Comparative analysis of hyporesponsive CD4
+
 T cells in the blood and 
cerebrospinal fluid of patients with and without neuroinflammatory disease. Peripheral 
blood mononuclear cells and cerebrospinal fluid (CSF) cells were isolated from patients with 
non-inflammatory neurological disease (OND) and multiple sclerosis (MS). Cells were 
stimulated for 6h with PMA/Ionomycin and the naïve (CCR7
+
CD45RA
+
), Central memory 
(CCR7
+
CD45RA
-
) and effector memory (CCR7
-
CD45RA
-
) CD4
+ 
T cell populations were 
analysed for the percentage of cells that did not upregulate CD69 (non-responsive cells). A-B. 
Comparative analysis of the non-responsive cell frequency in each subset derived from the 
peripheral blood and CSF (A. OND group, B. MS group). C-D. Graphs show the non-
responsive cell frequency in each subset identified in blood (C.) and CSF (D) of OND and 
MS patients. *p<0.05 ns = no significance at p<0.05 (Wilcoxon matched-pairs signed rank 
test (A-B.), Mann-Whitney statistical test (C-D.)). Data is representative of n=10 CSF and 
n=18 PBMC samples in the OND cohort and n=8 blood and CSF samples in the MS cohort. 
Graph error bars depict the interquartile range.  
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5.4 Analysis of cytokine expression by peripheral and CNS-derived 
CD4
+
 T cells in the rat.  
Having examined the ability of CSF (and CNS) derived CD4
+
 T cells to activate in response 
to PMA/ionomycin stimulation in both human and mouse the expression of cytokine was 
analysed by flow cytometry to provide further insight into their effector function. Due to the 
low cellularity of CNS and CSF preparations in the mouse it was inappropriate to analyse 
cytokine expression in this system. Therefore, analysis of cytokine expression was performed 
in the rat as more CNS cells were obtainable. Following stimulation with PMA/ionomycin for 
three hours the expression of the archetypal Th1 cytokine IFNγ by rat spleen, blood, CSF, CP 
and brain derived CD3
+
CD4
+
 T cells was analysed by flow cytometry (Figure 5.6).  The 
percentage of IFNγ producing CD4+ T cells in lysed blood and splenocyte cultures was low 
(0.9% ± 0.3 and 1.9% ± 0.5 respectively (mean ± SEM)). In contrast, the proportion of IFNγ+ 
CD4
+
 T cells in the CSF was dramatically increased with over a third of CSF-derived cells 
expressing the cytokine (34.2%  ± 8.6 (mean ± SEM)). Consistent with this increase in IFNγ 
producing cells in the CSF there was also considerable enrichment of the IFNγ+ CD4+ T cells 
in CP and whole brain digests. However, due a limited number of experiments in these tissues 
no statistical inferences could be drawn from these findings. Together these findings indicate 
that in rodents IFNγ producing CD4+ cells are enriched in the CNS compartments. 
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Figure 5.6 Expression of IFNγ by central nervous system CD4+ T cells. Cerebrospinal 
fluid (CSF), saline perfused choroid plexus and brain tissue were harvested from terminally 
anesthetised  rats, and cell preparations from each compartment were stimulated with 
PMA/Ionomycin for 3h. The CD4
+ 
T cell populations were analysed for expression of IFNγ 
by flow cytometry and the expression compared with matched peripheral blood and spleen 
derived samples. A. Gating strategy to define IFNγ expression by CD3+CD4+ T cells. Gating 
is demonstrated using a rat spleen sample. B. Representative plots showing IFNγ expression 
by CD4
+ 
T cells in each tissue compartment. Data is representative of n=2 independent 
experiments. C. Graph of the mean ± SEM percentage of CD4 T cells that express IFNγ.    ns 
= no significance at p<0.05, *p<0.05, **p<0.01 (one way ANOVA statistical analysis 
followed by Bonferroni’s multiple comparisons test). Data is representative of n=1-5 
independent experiments.  
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5.5  Discussion. 
A defining characteristic of memory CD4
+
 T cells is the ability to produce effector cytokine in 
response to an immunogenic stimulus. Therefore, in order to have a role in CNS immune 
surveillance it may be anticipated that CSF CD4
+
 T cells elicit a robust cytokine responses. In 
this chapter, ‘normal’ CSF was modelled in mice and rats to examine the activation status of 
the CD4
+
 T cell compartment. In order to produce cytokine, CD4
+
 T cells must be activated 
which can be measured by surface expression of CD69
[51,411]
. In the absence of an applied 
exogenous stimulus a greater number of CD4
+
 T cells associated with the brain and CSF of 
unchallenged mice expressed the activation marker CD69 than those in the peripheral blood 
(Figure 5.1C, Figure 5.2C). In this investigation the analysis of ex vivo CD69 expression by 
human CSF CD4+ T cells was not examined as all samples were used for experiments where 
cells were stimulated in vitro. However, in support of findings in mouse a human study from 
by P. Kivisäkk et al has previously demonstrated an increased proportion of central memory 
CD4
+
 T cell (CD4
+
CD45RO
+
CD27
+
) in the CSF which exhibit a recently activated CD69
+
 
phenotype
[271]
. It can be speculated that the increase in CD69
+ 
CD4
+
 T cells in the CSF (and 
brain) is brought about by either 1) selective migration of CD69
+ 
memory cells from the 
blood, 2) activation of the memory CD4
+
 T cells during migration across the BCSFB or BBB, 
3) intrathecal activation within the CSF space, 4) residency of CD4
+
 T cells within the CP or 
CSF-filled cavities such as the subarachnoid space. With consideration to the first proposal, 
CD69 expression is not a prerequisite for migration in mature T cell subsets into peripheral 
tissues as shown by unaltered migration of CD4
+
 T cells into intestine, lungs, liver and lungs 
in CD69
-/-
 mice
[459]
. From a surveillance perspective CD69-dependent migration would 
severely restrict the repertoire of CD4
+
 T cells with CSF access given the infrequency of 
CD69
+ 
T cells in the blood. However, as CD69 expression is associated with activation it may 
be that other receptors such as chemokines or integrins that are upregulated with activation 
mediate the migration progress, thus causing the apparent CD69
+
 enrichment. This is 
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consistent with the long standing view that in passive models of EAE only T cells that are 
activated in the periphery can gain access to the CNS
[460,461]
 .  
CD4
+
 T cell interaction with activated endothelium is reported to increase surface CD69
 
expression
[462]
, but in the absence of inflammatory disease or infection it may be assumed the 
CNS endothelium is not activated. As the BCSFB represents a double barrier of endothelium 
and epithelium at the level of the CP it cannot be discounted that CD4
+
 T cells acquire CD69 
expression in the CP stroma. This may be considered more probable than CD69 acquisition in 
the intrathecal space unless interaction of CD4
+
 T cells with the pia mater and ependymal 
lining of the CSF cavities is capable of triggering CD69 expression. This is also under the 
assumption that interaction with APC in the CSF space would not trigger CD69 expression 
without cognate antigen recognition via the TCR and that CD69
 
CD4
+
 T cells are not 
selectively retained within the intrathecal compartment as part of a resident phenotype.  
Aside from the association of CD69 with activation it is also reported to modulate the 
migration patterns of CD4
+
 T cells within secondary lymphoid organs. Given that the CSF can 
be equated to a modified lymphatic of the CNS it can also be speculated that CD69 expression 
has a role in CD4
+
 T cell migration behind the BCSFB and BBB. In the context of peripheral 
mucosal barriers, tissue resident CD4
+
 T cells in the periphery are distinct from their 
circulating counterparts through the constitutive CD69 expression
[463]
. As CD69 expression 
by resident CD4
+
 T cells within the skin mucosa is independent of activation status
[95]
 it is 
possible that CD69
+ 
T cells within the CNS reside there more permanently than previously 
credited. Thus, CD69
+
CD4
+
 T cells may not necessarily represent peripherally-derived 
‘activated’ cells per se.  In support of this, virus-specific CD8+ TRM cells have been shown to 
reside within the CNS of mice for up to a year post infection
[448,449]
. These TRM cells are 
CD103
+
 and parabiosis experiments in mice show that they do not recirculate
[93]
. How 
applicable this model is to TRM persistence without a prior heavy antigen load is not well 
reported. In addition, an analogous CNS CD4
+
 TRM population has not been identified. In a 
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study by Kivisakk et al (2006) where CSF from a small human cohort is sampled the author 
anecdotally describes how CSF CD4
+
 T cells were found to be negative for expression of 
CD103
[464]
. Therefore, it is possible that CD103
+
 T cells are maintained within the CP whilst 
CD103
-
 subsets recirculate in the CSF. Ideally analysis of matched CP and CSF samples 
would be required to confirm this. A basis for this hypothesis could be achieved by examining 
the CD103
+
 expression of those rodent CNS CD4
+
 T cells identified in my investigation to 
test for CD69
+
CD103
+
 TRM in the CP, CSF and whole brain compartments.   
When murine cell cultures were stimulated with PMA/ionomycin CD4
+
 T cells upregulated 
CD69 but did not downregulate CD4 as is characteristically observed in the analogous human 
population (Figure 5.1-5.2). This may suggest that in mouse the coupling of CD4 to p56
lck
 or 
its recycling pathway is not perturbed by PMA in the way it is in humans
[372]
. Stimulation of 
murine CSF and brain-derived leukocyte cultures with PMA/ionomycin resulted in the 
activation of the majority of CD4
+
 T cells. More cells upregulated CD69 than in the 
peripheral blood and spleen which was reflected by a decrease in the non-responsive 
population. This may be in part due to the fact that a greater proportion of the population 
expressed physiologically high levels of CD69 in vivo and therefore would not have fallen 
within the CD69
lo
 non-responsive gate (Figure 5.1-5.2). Therefore, even though less of the 
CD4
+
 population in the CSF and brain didn’t respond to the stimulation this may not 
necessarily mean they are more responsive. Anecdotally, the level of CD69 expression on the 
cells that did respond was similar in the CNS and peripheral compartments as shown by an 
equivocal CD69 MFI. This suggests that CNS-associated CD4
+
 T cells that do activate can 
upregulate CD69 at least as readily as cells in the blood and spleen. Together this is evidence 
that CD4
+
 T cell in the CNS are at least as responsive as those cells in the periphery and the 
microenvironment of the CSF or CNS niches does not diminish their ability to activate. 
However, more work is required to investigate the acquisition of CD69 expression by CNS 
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CD4
+
 T cells in vivo as this may be highly informative with respect to their origins and 
migratory behaviour in addition to their functionality.   
When CD69 expression by CD4
+
 T cells from OND and MS patient blood were examined the 
percentage of non-responsive cells was surprisingly high (5.3A, 5.3B). In addition, the non-
responsive CD4
+
 T cell frequency in the HC group was elevated by around 7% compared with 
the same population demographic sampled in Chapter 3. As another member of the group was 
responsible for processing the HC samples referred to in this chapter it was considered 
whether technical discrepancies between our preparations were accountable for the 
differential hyporesponsiveness between these data sets. As I reanalysed these samples in 
accordance with the gating strategy and parameters used in Chapter 3 our potential differential 
interpretation of flow cytometry plots was not responsible for the variation. To directly 
compare technical variation between individuals on two occasions the entire assay was 
performed in parallel using blood from the same donor. When our corresponding non-
responsive populations were compared on both occasions there were negligible differences in 
the T cell phenotype and responsiveness between our samples. With such internal controls 
established the reasons why the non-responsive cell frequency varied in healthy donors 
between the data sets remains unknown. An untested variable was the time of day at which 
the samples were taken as in Chapter 3 all blood was sampled between 8-9am whereas in this 
data set the time varied according to when patient samples were taken.  
As the OND cohort represented patients with no immunological component to their 
neuropathology it was expected that the percentage of CD4
int
CD69
lo
 non-responsive cells in 
OND blood should match that observed in healthy control (HC) patients. However, there was 
a much higher representation of the non-responsive population in the OND group despite 
these HC assays being performed in parallel to minimise the sampling error. As the HC 
samples were taken within the research lab facility and the OND/MS samples were taken in 
clinic it was questioned whether this differential processing was responsible for the variation 
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in hyporesponsiveness. Much effort was taken to ensure technical variables were not 
responsible for these changes, with independent experiments being performed to directly test 
differences in standard operating procedure (data not shown). In these tests, it was shown that 
the collection of blood into heparinised tubes versus the EDTA anti-coagulant used in the 
clinic had no influence on the responsive population. To account for the increased time that 
sample were held in clinic compared to the lab, the duration of time between blood sampling 
and cell culture was also tested. This also had no bearing on the outcome of CD69 expression.  
Having minimised the impact of technical variation, it is difficult to pinpoint why the 
representation of non-responsive cells was elevated in the OND cohort compared with the HC 
group. It is possible that the increase was related to the co-morbidity of patients in the OND 
group but it is impossible to pinpoint an exact cause given the different disease aetiology in 
this mixed cohort. Despite this, a common feature all the OND patients share is the acute 
stress they were under at the time of sampling as blood was taken at the time of CSF 
collection by lumbar puncture. In addition, another consideration is the chronic stress and 
prolonged anxiety these patients may suffer as a result of their neurological illness. Although 
the impact of stress in this system is not measurable directly there is significant attention to 
the effects of psychological disorders upon immune function in the literature. In rat models it 
is documented that acute and chronic stress can decrease T cell numbers in the blood whilst 
reducing both their IL-2 production and proliferative capacity
[465,466]
.  In humans, chronic 
psychological stress is commonly associated with immune suppression, increased infection 
rates and decreased tumour surveillance
[467–469]
 which is fitting with the T cell 
hyporesponsiveness observed in these assays.  
The same iatrogenic and psychological stressors applied to the MS group and OND group as 
all these patients were sampled in the same way. Therefore, in the context of assessing 
whether inflammation has an impact on the hyporesponsiveness of CD4
+
 T cells the more 
appropriate comparative analysis is between the MS and OND group as opposed to between 
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the MS the HC cohort.  Although the non-responsive population in the blood of MS patients 
was significantly greater than the HC group there was only a marginal increase between the 
MS and the OND cohorts (Figure 5.3B). In addition, the percentage of non-responsive cells in 
both the memory and naïve CD4
+
 T cell subsets was comparable in PBMC cultures from 
OND and MS groups (Figure 5.5C). Therefore, the activation status of the T cell subsets in 
the blood was not skewed by inflammatory pathology. These findings suggest that an 
inflammatory background does not influence the upregulation of CD69 by the circulating 
CD4
+
 T cell population in the blood and thus does not contribute to CD4
+
 T cell 
hyporesponsiveness. This may imply that chronic antigenic stimulation (as a feature of 
ongoing neuroinflammatory pathology), does not drive the hyporesponsiveness of CD4
+
 T 
cells that is revealed by ex vivo stimulation. This is evidence against the suggestion that the 
CD4
int
CD69
lo 
non-responsive phenotype represents cells driven into tolerised or exhausted 
state via persistent antigen exposure as discussed in Chapter 3. However, to add weight to 
these findings increased sampling in the MS group is required and would thus enable the 
multiple disease etiologies represented in the MS cohort to be analysed independently.  
In contrast to findings in the blood, more notable differences in the non-responsive population 
were observed in CSF samples from the OND and MS cohorts (Figure 5.3-5.5). In the OND 
group there was a decreased representation of non-responsive cells within the Tcm and Teff 
subsets in the CSF when compared with the blood, most notably in the Teff subset (Figure 
5.5A). This decrease in CD4
+
 T cell non-responsiveness is consistent with the trends observed 
in mouse experiments (Figure 3.1-3.2) and suggests that in the absence of inflammation CD4
+
 
T cells in the CSF upregulate CD69 at least as readily as their peripheral blood counterparts. 
This is further evidence that without inflammation the CSF microenvironment does not 
promote the CD4
+
 hyporesponsiveness as revealed by PMA/ionomycin stimulation. From an 
alternative perspective as the non-responsive phenotype is not enriched in the CSF this is 
evidence against its selective recruitment from the blood. However, it cannot be discounted 
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that the non-responsive population in the CSF was affected by an increased in vivo expression 
of CD69 in the intrathecal compartment as was identified in mouse (Figure 5.2C). The mouse 
models in this investigation has highlighted the importance of measuring ex vivo CD69 
expression in human systems in the future to examine for features of residency and 
persistence in the CNS.  
In the MS cohort there was a more pronounced reduction of non-responsive CD4
+
 T cells in 
the CSF relative to the blood (Figure 5.3E, 5.5B). The source of this decrease was a reduction 
of cells that failed to respond in both the Tcm and Teff subsets indicating that both intrathecal 
populations are more readily activated. It was also noted that the decrease in Teff non-
responsive cells between the blood and CSF was comparatively greater than in the Tcm subset 
(Figure 5.5B). Although the non-responsive frequency from the Tcm subset was subject to 
extreme variation these findings suggest that the Teff subset was preferentially more readily 
activated in the MS CSF compartment. Together this indicates the predomination of a more 
reactive memory phenotype in the CSF space in MS which is consistent with T cell mediated 
damage associated with the disease. This phenomenon may occur due to either a reversal of 
the hyporesponsive state within the CNS compartment or be reflective of the preferential 
migration of activated cells from the blood. Given the potency of PMA/ionomycin stimulation 
combined with the failure of prior in vitro experiments to reverse the non-responsive state the 
former scenario may be considered less likely. In contrast, there are many reports that 
document an increased recruitment of activated T cells into the CNS via differential 
chemokine receptor expression in MS. This is a mechanism by which increased trafficking of 
relevant (CNS antigen specific) T cell clones to the CNS can occur. An increased expression 
of the chemokine receptors CXCR3 and CCR5 by CD4
+
 T cells is highly associated with 
inflammatory events in MS and coupled with elevated concentrations of chemokine ligand 
within the inflamed CNS
[360,361]
. However, expression of CXCR3 is not exclusive to MS as it 
is reportedly expressed by CD4
+
 T cells in healthy CSF
[288]
. Conversely, Juliá E et al (2006) 
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have previously reported ex vivo CD69 expression that is exclusive to CCR5
+
 CD4
+
 T cells in 
the blood of MS patients
[470]
. Therefore, it is possible that preferential migration of 
CCR5
+
CD69
+ 
CD4
+
 T cells from blood to CSF is responsible for my reported decrease in 
non-responsive CSF T cells in the MS cohort (such cells would not be gated CD4
int
CD69
lo
). It 
is also possible that CCR5
+ 
CD4
+
 T cells are reactivated by APC within the CSF space and 
thus physiological CD69 expression is induced intrathecally. These proposals could be 
substantiated by ex vivo examination of CD69 and CCR5 expression by CD4
+
 T cells in the 
cohorts investigated in this study. Such work is important as the differential CD69 expression 
by CSF CD4
+
 T cells in the OND and MS cohorts may be reflective of alternative 
homeostatic versus inflammatory recruitment pathways in health and disease.    
 Due to the low number of CD4
+
 T cells retrieved from mouse CSF it was not considered 
appropriate to perform cytokine analysis in this system. IFNγ is a highly expressed Th1 
cytokine both in terms of the number of CD4
+
 T cells that can produce it and its level of 
expression on a per cell basis (data shown in Chapter 3 Figure 3.2M). Therefore IFNγ 
expression by CD4
+
 T cells was measured in rat spleen, blood, CSF, CP and brain where the 
cellularity was conducive to a meaningful analysis. In all three CNS compartments the 
percentage of IFNγ+ CD4+ T cells was extremely elevated when compared to the blood and 
spleen (Figure 5.5). However, it was not possible to perform this analysis in the CD4
+
 
memory T cell compartment specifically. This was because the ‘memory’ marker (CD45RC) 
used to define a naïve (CD45RC
hi
) and memory (CD45RC
lo
) T cell phenotype was lost on all 
PMA/ionomycin stimulated cells. In itself this finding is suggestive that CD45 expression is 
more representative of activation status than a true memory marker.  This was frustrating as it 
was not possible to precisely quantify how much of the IFNγ+ enrichment in CNS, CP and 
CSF was attributable to an increased representation of memory cells in these compartments. 
Despite this, what can be drawn from these experiments is that even under the assumption that 
100% of CNS-derived CD4
+
 T cells were a memory phenotype their IFNγ response was 
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substantial in these assays. This work supports the rejection of the hypothesis that cytokine 
responses are diminished in the CNS as IFNγ expression by CNS CD4+ T cells was shown to 
be robust in rat. These results were in line with a study of murine choroid plexus by Kunis et 
al (2013) where approximately 17% of all CP CD4
+
 T cells were found to express IFNγ in a 
similar PMA/ionomycin stimulation assay
[282]
. No data for IFNγ  expression by CSF or whole 
brain CD4
+
 T cells was presented by the author, but in my investigation the corresponding 
value for CP derived cells was approximately 22% in rat (Figure 5.5),. 
The expression of cytokine in human patient samples was not measured directly as part of this 
investigation. However, contrary to preliminary studies data here indicates that CD4
+
 T cells 
activate readily in the CSF space (Figures 5.3-5.5). With the assumption that CD69
+
 
expression is representative of activation together with findings related to IFNγ expression in 
rat CSF, this may suggest that homeostatic CD4
+
 T cells are not significantly influenced by 
tolerogenic mechanisms that are described in association with the CSF compartment. 
However, the reactivity and propensity of these CSF cells to undergo apoptosis would need to 
be measured directly to confirm this. The majority of reports which specifically focus on 
cytokine expression in the CSF document changes which occur in neuroinflammation. For 
example, a study by Ishizu T et al (2005) reports a moderate increase in free IFNγ in MS 
patient CSF (by immunoassay) in addition to an increased percentage of IFNγ producing 
CD4
+
 T cells in this compartment
[471]
. This study also reports a significant increase in free 
TNFα in the CSF of MS patients which is consistent with studies in the 1990’s where CSF 
TNFα levels were shown to positively correlate with the severity of progressive MS 
disease
[472]
.  
An increase in IL-17 expression by CSF CD4
+
 T cells is also documented in 
neuroinflammation. A study by V. Brucklacher-Waldert et al (2009) reports that in a 
neurological disease cohort IL-17 expression in the blood is comparable to that in the CSF, 
but in RR-MS IL-17 expression in the CSF is elevated both in relapse and remission
[473]
. In a 
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more recent report Y. Cao et al (2015) have used libraries of CD4
+
 T cell clones from MS 
patients to show that myelin-specific CD4
+
 T cells that express CCR6 (a chemokine receptor 
associated with Th17 subset) produce higher amounts of IL-17, IFNγ and GM-CSF than 
analogous auto-reactive cells from healthy controls
[474]
. In addition, those CCR6
+
 clones from 
healthy controls were more biased towards IL-10 (Tr1) responses, thus demonstrating a 
skewing of myelin-specific CD4
+
 T cell responses towards a more proinflammatory 
phenotype in MS
[474]
. Continued investigation into the cytokine potential of intrathecal and 
peripheral T cells is essential to further understand aberrant behaviour in neuroinflammatory 
disease and better define current perspectives of CNS immune surveillance and tolerance to 
CNS antigen. 
CHAPTER SUMMARY 
This work has demonstrated that in both mouse and human investigations CSF-derived CD4
+
 
T cells activate readily in response to PMA/ionomycin stimulation as indicated by                                                                           
CSF/CNS derived populations express endogenous levels of CD69 which may be evidence of 
their recent activation or indicative of their residency in CNS tissue. CSF and CNS derived 
CD4
+
 T cells in rat exhibit robust IFNγ responses in vitro. Although cytokine expression by 
human CSF CD4
+
 T cells was not directly measured as part of this investigation, my work 
suggests that CSF-associated CD4
+
 T cells have the functional capability to perform immune 
surveillance, but conversely are capable of evoking a deleterious inflammatory response 
behind the BCSFB/BBB. 
   
 
 
 
 
 
 
 
 
CHAPTER 6  
GENERAL DISCUSSION 
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6 GENERAL DISCUSSION 
6.1 What are non-responsive CD4+ T cells? 
The inability of CD4
+
 T cells to elicit robust pro-inflammatory cytokine responses can be 
associated with a number of deleterious and inter-related immunological states including the 
inappropriate control of infection, exhaustion and senescence. Conversely, the 
hyporesponsiveness associated with T cell tolerance and regulatory cell types is essential for 
preventing autoimmunity through the inhibition of self-reactive T cell clones. Therefore, 
further defining mechanisms by which T cell responses are negatively regulated in vivo is 
essential for the understanding of optimal T cell function and is highly applicable to vaccine 
development and strategies supporting tumour immunotherapy.  
In this study, the proportion of CD4
+
 T cells which failed to make any of thirteen cytokines 
following in vitro stimulation was striking (Figure 3.3). Given this test included many of the 
most abundantly expressed T cell cytokines it could be speculated that there are many 
cytokines and effector molecules yet to be defined both in the Tnaive and Tmemory 
compartments. Alternatively, there may be heterogeneity in the CD4
+
 T cell population’s 
response to PMA/ionomycin and so combined PKCƟ and Ca2+ signalling may be insufficient 
to activate the entire population. Findings here have implications for the interpretation of 
memory CD4
+
 T cell responses when PMA/ionomycin is used as an in vitro stimulus.   
This investigation focused on a population of cytokine
-ve
 CD4
+
 T cells whose hyporesponsive 
phenotype was revealed through PMA/ionomycin stimulation. The failure of these cells to 
downregulate CD4 and upregulate CD69 could not be attributed to LCK or PKCƟ deficiency 
at the mRNA level (Figure 3.31). Therefore, the former may be associated with a 
dysregulation of CD4 and p56
lck
 interaction (absence of receptor uncoupling) or altered 
endosomal trafficking of CD4 leading to decreased receptor internalisation. Ignorance to 
PMA through PKCƟ deficiency may still be related to altered phosphorylation or kinase 
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activity. This could be revealed through Phosflow™ cytometry techniques given the 
insufficient cell numbers required for western blotting. It also cannot be discounted that 
imbalanced as opposed to deficient PKCƟ signalling induces the hyporesponsive phenotype. 
Published work in cell lines and PKCƟ-/- mice shows that PKCƟ modulates both the NF-κB 
and AP-1 transcriptional pathways
[475,476]
, with diminished AP-1 activity inextricably 
associated with T cell anergy
[477,478]
. Therefore, a skewing away from AP-1 signalling coupled 
with an increased sensitivity to Ca
2+
 dependent pathways (raised ionomycin input) could force 
the non-responsive population towards an ‘anergic’ phenotype. However, the addition of 
exogenous IL-2 into my stimulation assays may have readdressed such a signalling imbalance 
but this was shown not to reverse the non-responsive phenotype (Figure 3.24). This suggests 
that these cells are not truly ‘anergic’ in the classical sense. It may be informative to test for 
the elevated expression of anergy associated genes GRAIL, ITCH or Cbl-b in the non-
responsive population to further exclude anergy-associated mechanisms from this enquiry. 
The importance of further investigating non-responsive cells is highlighted by a significant 
elevation in their frequency observed in patient blood samples when compared to healthy 
controls (Figure 5.3B). As the inflammatory nature of the underlying pathology did not 
influence hyporesponsiveness (when comparing OND and MS cohorts), this is evidence that 
other factors such as physical or psychological stress markedly influences the functionality of 
these memory CD4
+
 T cells. Such a theory is also in keeping with the longitudinal analysis of 
non-responsive cells in healthy individuals which identified notable intra-donor variability 
(Figure 3.10). Although the age range of healthy control participants was not conducive to 
assessing the effect of age-related senescence upon the non-responsive population, anecdotal 
analysis between the patient and healthy control cohorts is still informative. The median age 
of healthy control participants (27yrs) was notably lower than the OND and MS groups (44.5 
and 47.5yrs respectively) (Table 2.3). Therefore, it remains possible that the non-responsive 
population is associated with age-related replicative senescence as opposed to disease and the 
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populations co-association with low CD27 expression supports this (Figure 3.15). Testing for 
the absence of CD28 expression coupled with the CD27
lo
 definition may further support an 
association with senescence
[225]
. In addition, as latent viral infections drive replicative 
senescence
[219,479]
 testing for a relationship between CMV seropositivity and the frequency of 
non-responding T cells in both younger adults and aged cohorts may prove informative. 
Further defining the defective CD69 status of non-responsive CD4
+
 T cells may complement 
current literature which describes aberrant cytokine secretion by T cells in replicative 
senescence
[227,233]
.  
Features associated with senescence and exhaustion are more extensively studied in the CD8
+
 
T cell subset as these cells are persistently reactivated through chronic viral infections. 
Identifying the presence and characteristics of non-responsive CD8
+
 T cells could provide 
valuable insight into the biology of this cellular state in future studies. As the CD8 co-receptor 
is not downregulated in response to PMA stimulation like its CD4 counterpart
[480]
 analysis of 
the non-responsive population in the CD8
+
 T cell subset would be restricted to a CD69
lo
 
definition. However, this may be sufficient when combined with other characteristics of the 
CD4
+
 non-responsive phenotype reported here (CD45RA
-
CCR7
-/+
CD62L
lo
CD27
lo
). Both 
virus-specific CD8
+
 and CD4
+
 T cell clones are identifiable in seropositive individuals 
through use of fluorescently labelled MHC I or MHC II-viral peptide tetramer 
complexes
[481,482]
. The frequency of these cells (particularly in the CD8
+
 subset) would permit 
the analysis of their CD69 status post activation. This would provide a means of assessing the 
antigen-specificity of the non-responsive population as well as the contribution of persistent 
antigenic stimulation. It would also be informative to evaluate the PD-1 expression of virus-
specific non-responsive CD8
+
 T cells. In this investigation, PD-1 expression was associated 
with the memory status of CD4
+
 non-responsive T cells but was not shown to be specifically 
elevated within the population (Figure 3.22, Figure 3.23). This observation implies that the 
non-responsive population do not represent physiologically exhausted CD4
+
 T cells. 
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However, the function of the non-responsive population could not be restored with IL-7 or IL-
15 which is a feature consistent with exhaustion
[483]
 and suggests that these memory cells may 
require antigen-specific stimuli to survive (Figure 3.24).  
Although PD-1 expression was not specifically elevated on the non-responsive CD4
+
 T cells it 
cannot be discounted that these cells have recently engaged PD-1 ligand in vivo. PD-L1 
engagement by PD-1 is a reported mechanism of tolerising T cells, with constitutive 
expression of the ligand reported in many non-lymphoid tissues including the heart and 
lungs
[484]
, brain
[315]
, pancreatic islets
[485]
 and renal tubule epithelium
[486]
. Therefore, it is 
possible that some PD-1
+
 T cells trafficking through such sites have recently encountered PD-
L1 and become non-responsive. As PD-1 signalling is also shown to halt cell cycle 
progression and increase apoptosis susceptibility
[200,201,487]
, recent PD-L1 engagement may 
also explain why these traits were identified in the non-responsive population. However, my 
work does not support such a pathway in the context of T cell trafficking via the CNS, 
because although PD-L1 is reported to be expressed by perivascular macrophages in the 
brain
[316]
, I have shown that the non-responsive population was diminished in the CP, CSF 
and brain compartments (Figure 5.1, Figure 5.2). In addition there is no report of PD-L1 
expression by choroid plexus endothelium or epithelium specifically, which are the main 
barriers to homeostatic T cell migration. Therefore, PD-1/PD-L1 induced hyporesponsiveness 
may not be applicable to the CNS compartments, but its association with T cell recirculation 
via other peripheral tissues cannot be ruled out. 
The non-responsive phenotype was most prevalent in the CCR7
-
 effector memory population 
(Figure 3.13) but was disproportionately over-represented in the CCR7
+
 population when 
PBMC were not sorted prior to stimulation (Figure 3.11). Furthermore, purified 
CCR7
+
CD62L
lo
 memory CD4
+
 T cells demonstrated a high frequency of CD4
int
CD69
lo
 cells 
(Figure 3.14). Together this suggests that some non-responsive cells are effector memory cells 
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that have upregulated CCR7, perhaps for the purpose of returning to the circulation from a 
peripheral tissue compartment
[391]
. It is possible that that the non-responsive cells are enriched 
in a memory population that recirculates between the blood, peripheral tissue and the 
lymphatics. A report by S.K Bromley et al (2013) describes ex vivo CCR7
+/-
CD62L
int
CD69
lo
 
expression by recirculating memory cells that home to the skin
[95]
 and such markers are 
consistent with the non-responsive subset identified here. However, the authors found that 
these cells were able to produce IL-2 following stimulation which is not comparable with the    
cytokine
-ve
 CD4
int
CD69
lo
 phenotype I describe here. It is unlikely that any recirculating non-
responsive memory cells failed to upregulate CD69 through its reciprocal inhibition by 
increased S1P1 receptor activity. This is because naïve T cells require such interactions to 
return to the circulation from the lymph nodes and this subset showed minimal non-
responsiveness
[97,98]
. Never-the-less, it cannot be discounted that recirculating memory cells 
are susceptible to becoming hyporesponsive and thus the non-responsive population 
represents a tolerised, exhausted or senescent fraction of a recirculating subset.  
In addition to what the surface marker expression of the non-responsive population suggests 
about their migratory behaviour it is important to consider where these cells may fit in line 
with models of T cell differentiation (as described in Fig1.2A-C). Given their inability to 
proliferate when cultured in vitro, diminished CD27 expression (Figure 3.15) and CD45RA
- 
status (Figure 3.5), it is unlikely these cells represent highly proliferative TSCM which undergo 
self-renewal
[64]
. In addition, in light of their propensity to undergo apoptosis following 
PKCƟ-mediated activation (Figure 3.17) it may be considered improbable that this population 
is positioned centrally in a linear differentiation model. This would imply that non-responsive 
cells could maintain sufficient survival and proliferative potential to differentiate into other 
subsets. However, in line with the linear differentiation model 1 (described in Figure 1.2A) 
there is some evidence that highly differentiated cells (which are paradoxically shown to be 
susceptible to exhaustion and senescence) can provide the basis of stable long term 
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memory
[488]
. This is exemplified in a study where ex vivo expanded tumour antigen-specific 
memory T cells (CD8
+
CD27
lo
CD28
lo
CD62L
-
CCR7
-
CD127
lo
) were transferred into melanoma 
patients for their therapeutic potential. Here it was shown that a proportion of these 
transferred cells re-upregulated CD27 and CD28 and formed a persistent tumour-specific 
memory population
[488]
. Such results are somewhat conflicting with some studies that show 
the loss of CD27 and CD28 expression is non-recoverable with the latter associated with 
permanent transcriptional silencing events
[489–491]
.   
 Although it can be speculated that the non-responsive population are towards the terminal 
end of the differentiation spectrum their persistence in the circulation suggests some 
biological rationale behind their maintenance. With appropriate signals it may be expected 
that they can elicit some functionality. As Treg (CD25
hi
CD127
lo
) were shown to contribute to 
the non-responsive pool (Figure 3.20-3.21) it could be hypothesised that the non-Treg cells 
which numerically dominate this population also have a suppressive function. It is unclear 
whether such suppression could be attributed to bystander effects
[139]
 or filling of the memory 
niche with hyporesponsive cells (as is also described in T cell exhaustion). I am also yet to 
establish whether these cells represent non-classical Treg subsets such as Tr1 or Tr3, although 
these subsets are typically associated with the ability to secrete anti-inflammatory 
cytokine
[161,492]
 which is not a characteristic fitting with the non-responsive cell profile. 
Although as part of this investigation I have established the co-association of the non-
responsive phenotype with a range of phenotypic markers it is imperative that a more 
comprehensive surface receptor profile be established (by microarray) to move this work 
forward. An understanding of their biology has been achieved here but the precise 
mechanisms behind their atypical in vitro responses remain elusive. The physiological 
significance of these cells will be better understood through their identification without the 
requirement for in vitro stimulation, which ultimately drives them into irreversible AICD. 
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Investigations here were limited by the low retrieval of non-responsive cells in healthy 
controls which did not permit the more comprehensive gene expression analysis (microarray) 
required to identify candidate surface makers. cDNA amplification techniques could address 
this issue and boost the amount of genetic material retrieved from the non-responsive cell 
purification experiments shown here (Figure 3.27A). Alternatively, as I have shown that the 
non-responsive cell frequency may increase with age or disease it may be useful to develop 
experimental systems in these cohorts where a higher percentage of these cells can be 
retrieved. With a more complete definition of the non-responsive phenotype established 
processes which restore functionality to these cells may be further investigated. This is 
particularly relevant if non-responsive cells are also found to be present in the CD8
+
 T cell 
compartment or are shown to be enriched in a tumour environment. Such work may be highly 
relevant to studies aiming to boost the activity of tumour specific T cells. A current example 
of this is the blockade of the PD-1 pathway with monoclonal antibodies (Lambrolizumab) to 
increase anti-tumour T cell responses
[493]
. Conversely, the therapeutic benefit of adoptive cell 
transfer techniques for tumour immunotherapy could potentially be improved by removing 
non-responsive cells from ex vivo preparations of anti-tumour antigen specific T cell clones. 
Optimisation strategies in adoptive T cell therapy are important as the differentiation status of 
engrafted cells is shown to influence ultimate clinical outcomes and the transfer of highly 
differentiated cells is proven to be less efficacious
[494]
. In an alternative scenario, tailoring 
vaccine responses to minimise the expansion of non-responsive cells may be considered 
highly advantageous, particularly in the elderly where memory T cell responses become 
compromised
[227,495]
. 
6.2  CD4+ T cell responses are not suppressed in the CNS compartments. 
Pilot studies preceding this investigation suggested that the cytokine responses of CD4
+
 T 
cells in non-inflamed CSF were diminished comparative to the blood (unpublished data, 
Curnow group, University of Birmingham). Such findings were in keeping with a number of 
Chapter 6  230 
 
reports documenting the tolerogenic properties of the CSF milieu
[307,308]
, with some 
suggesting that the CNS is a hostile microenvironment to infiltrating immune cells to protect 
neuronal cells from damage
[304,306]
. However, these proposals are conflicting with the 
paradigm that homeostatic T cell migration is essential for providing immune surveillance in 
the CNS as protection against invading pathogens implies a requirement for robust T cell 
responses
[452]
. The importance of steady-state CNS T cell recruitment is exemplified when 
these processes are pharmacologically inhibited by the integrin blocker Natalizumab which 
can result in fatal JC virus reactivation in the brain
[291]
. In addition to a role in immunity, 
work in mice shows that the cytokine profile of choroid plexus T cells has implications for 
optimal cognitive function and may be dysregulated in age-associated immune 
senescence
[282,447]
. In my investigation I show that CD4
+
 T cells in rat CSF, CP and whole 
brain preparations have robust IFNγ responses when stimulated ex vivo (Figure 5.6). This 
finding supports the maintenance of CD4
+
 T cell cytokine responses in the CNS 
compartments and refutes the original hypothesis of this investigation in showing that 
cytokine responses in the CSF are not diminished.  
The ability of CSF (and brain-derived) T cells to activate in response to ex vivo stimulation 
was also examined as part of my thesis and supported the cytokine data analysis in rat. The 
activation marker CD69 was readily upregulated by normal murine CSF and brain CD4
+
 T 
cells (Figure 5.1-5.2). This trend was reproduced through examination of CD4
+
 T cells from 
non-inflamed human CSF (Figure 5.5A). In contrast to the hypothesis of this investigation 
this work suggests that; 1) Cytokine
-ve
 CD4
+
 T cells are not preferentially recruited from the 
blood, 2) CD4
+
 T cells are not anergised as part of their homeostatic CNS migration and, 3) 
CD4
+
 T cells are not functionally suppressed within the CSF space. This data supports the 
role of CD4
+
 T cells in immune surveillance and has implications for the current 
understanding of CNS immunity.  
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6.3  The representation of non-responsive CD4+ T cells is reduced in the 
CNS compartments.  
At the beginning of this investigation it was questioned whether the CSF CD4
+
 T cells that 
failed to make cytokine in preliminary studies were analogous to the non-responsive subtype 
revealed by PMA/ionomcyin stimulation in the blood. Findings here do not support such a 
relationship on a number of levels. CNS CD4
+
 T cells were shown to activate readily and the 
non-responsive population was not well represented in the CSF (as described in section 6.2). 
In addition, the phenotype of the non-responsive population as defined by work in Chapter 3 
is not consistent with the numerically dominant phenotype in human CSF. The non-
responsive population in human blood was skewed towards an effector memory phenotype, 
whereas the central memory subset dominates the CSF in humans
[247,248]
. This does not mean 
that non-responsive cells are excluded from the CNS by means of their memory 
differentiation as this study demonstrated that CD4
+
 T cell migration from blood to CSF is 
permissive to the effector memory subset (Figure 4.10-4.11, Figure 4.13-4.14). However, 
when the percentage of non-responsive cells was measured within the effector memory 
population in the CSF a reduction in their frequency was recorded (Figure 5.5A). In addition, 
the representation of CD69
lo
 CD4
+
 T cells was reduced in both murine CSF and brain where 
the effector memory population predominates (Figure 5.1, Figure 5.2). This suggests that non-
responsive effector memory CD4
+
 T cells migrate less readily into the CNS compartments 
and supports a model where cytokine-competent, functional CD4
+
 T cells are recruited into 
the CSF as part of an immune surveillance network.  
6.4  A CCR7 and CD69 independent model for homeostatic CD4+ T cell 
recruitment into the CSF. 
In line with the model of CNS immune surveillance described by B. Engelhardt et al (2011) 
findings here support a role for CD4
+
 T cell mediated immune surveillance that is limited to 
the brains outer borders
[257]
 as these cells were not found located within the parenchyma of 
normal mouse brain (Figure 4.5-4.6). The prevalence of CD4
+
 T cells associated with 
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unchallenged murine brain was extremely low and in keeping with reports of low level basal 
recruitment across the choroid plexus into the CSF
[282]
. However, CD4
+
 T cells were 
successfully characterised in association with unchallenged rodent CP and CSF (Figure 4.2-
4.10) which fulfilled a primary objective of this investigation. In contrast to human datasets, 
CD8
+
 T cells dominated the CD4
+
 subset in all measured rodent CNS compartments (Figure 
4.8-4.9) which may suggest a more dominant role of this subset in rodent CNS immunity. If 
this CD8
+
 predominance is reflective of the limited capacity of laboratory animals for T cell 
memory due to limited antigen exposure this may be indicative that accentuated CD4
+
 T cell 
recruitment in humans is driven by exposure to endemic pathogens.  
Data from this study suggest that both Tcm and Teff memory CD4
+
 T cells migrate from the 
blood to CSF by mechanisms that are equally permissive for both subsets, thus refuting the 
hypothesis that this pathway is Tcm specific. In humans, this was identified by a positive 
correlation between the representation of CCR7
+
 Tcm CD4
+
 T cells in the blood and CSF 
(Figure 4.13-4.14).  As both CCR7
+ 
and CCR7
-
 cells are found in human CSF this implies that 
normal CD4
+
 T cell recruitment is independent of CCR7 mediated adhesion. The primary site 
of T cell migration from blood to CSF is across the BSCFB at the CP with the presence of 
CCR7 ligands at this site often used as evidence supporting a CCR7-dependent 
pathway
[249,286]
. However, myeloid DC in the CSF are also shown to express CCR7
[249]
 and 
the requirement of this receptor for lymph node homing is fitting with a model where CSF 
DC’s migrate to the draining CLN[298,299,303]. Therefore, work here suggests a predominant 
role of CCR7 in the migration of CSF DC but redundancy in the recruitment pathway of 
memory CD4
+
 T cells from the blood.  
Consistent with my findings the relationship between blood and CSF memory CD4
+
 T cell 
distribution has been previously reported, albeit using an alternative surface marker definition 
of Tcm
[249]
. Despite this, immune surveillance by CSF T cells is consistently attributed to the 
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Tcm population in current literature with little mention of the Teff population’s contribution. It 
is acknowledged that the frequency of the CSF Teff population in humans is low but my work 
shows that these homeostatically recruited Teff cells can activate readily and produce cytokine 
(Chapter 5). Theoretically this implies that if these cells were reactivated intrathecally their 
potent cytokine-secreting potential may elicit profound effects on the CNS microenvironment. 
Furthermore, findings here suggest that factors which influence the Tcm/Teff balance in the 
peripheral blood will be reflected in the intrathecal compartment, which may have 
implications for CNS immune responses. Interestingly, some groups have reported that both T 
cell deficiency and an imbalance of CD4
+
 T cell cytokines in the CNS is associated with a 
decline in cognitive function in mice
[447,496]
. In addition, cytokine imbalances in the CSF have 
been associated with human pathologies amongst which psychiatric disorders such as 
depression and schizophrenia are included
[497–499]
. 
Perhaps surprisingly, the consistency of the Tcm/Teff ratio between the blood and CSF was not 
perturbed in MS (Figure 4.14) despite a significant elevation in T cell cellularity associated 
with inflammatory disease (Figure 4.12). This is consistent with reports that Tcm 
(CCR7
+
CD27
+
) also are the predominating cell type in the CSF of MS patients
[249,432]
, 
although CCR7
-
 memory T cells are reportedly associated with MS lesion sites
[249,500]
. Given 
the ability of both memory subsets to enter the CSF in the absence of inflammation it is 
relevant to consider their relative contribution in MS pathogenesis. Induction of EAE is 
shown to be dependent upon CCR6
+
 Th17 recruitment
[338]
, but as the Th17 subset is a mixed 
CCR7
+/-
 phenotype it may be informative to assess whether CCR7 status influences the 
encephalitogenic nature of Th17 behind the BCSFB.  In addition, reactivation of CNS-antigen 
specific Tcm and Teff memory CD4
+
 T cells in the CSF may have differential consequences in 
the context of MS relapse events.  
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The consistency of the Tcm/Teff memory CD4
+
 T cell distribution between the blood and CSF 
was also observed in murine datasets (Figure 4.10-4.11). However, it is acknowledged that 
CCR7 was used to separate these phenotypes throughout human datasets but was not applied 
to mouse experiments. This is because the CD44/CD62L memory definition is more 
classically used in the literature to define murine CD4
+
 memory T cell subsets irrespective of 
CCR7 status
[436–438]
. However, in murine models of LCMV infection there is some evidence 
of concurrent CCR7
+
 and CCR7
-
 expression in the CD44
hi
CD62L
lo
 subset within the CD8
+
 T 
cell population
[501]
. Given that my presented findings have implications for the significance of 
CCR7 expression in CNS migration it may be beneficial to correlate CCR7 and CD62L 
expression in future experiments where murine CNS T cells are examined. 
The high level of positive CD69 staining on murine CSF and brain-derived ex vivo CD4
+
 T 
cells may be informative regarding the recruitment and residency of these cells within the 
CNS (Figure 5.1C, Figure 5.2C). With the assumption that the majority of brain-derived CD4
+
 
T cells in these preparations were actually associated with the CP region (Figure 4.6), my 
work identified that around a third of both CP and CSF CD4
+
 T cells have physiologically 
elevated levels of CD69. A model where only recently activated CD69
+
 memory CD4
+
 T cells 
are recruited to the CSF (irrespective of antigen-specificity or CCR7 status) does not account 
for the two thirds of CP and CSF-derived CD4
+
 T cells that do not express CD69. It is more 
probable that recently activated CD4
+
 T cells have the chemokine receptor repertoire that 
facilitates BCSFB migration irrespective of whether their CD69 expression is maximal at the 
time of migration or time of sampling.  Therefore, CD69
+
 CD4
+
 T cells may appear enriched 
in the CNS by proxy. With consideration to the kinetics of CD69 expression it may be useful 
to measure other markers of T cell activation in the CSF compartment. Interestingly, the 
presence of CD25
hi 
and FOXP3
+
 CD4
+
 T cells in human MS CSF samples is reported as an 
enrichment of Treg in some studies
[502]
. However, given the overlap of CD25 and FOXP3 
expression between recently activated and Treg populations it is difficult to discount the 
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possibility that a proportion of such cells may represent recently activated Thelper cells that 
have transiently upregulated FOXP3
[149]
. In an alternative scenario it is possible that CD69 
expression is lost or acquired by some cells once within the CP or CSF. With reference to the 
proposed physiological role of CD69 in dampening T cell activation
[503]
 the acquisition of 
CD69 expression by CP and CSF CD4
+
 T cells may still serve to negatively regulate their 
activation in vivo irrespective of their proven ability to respond to ex vivo stimulation (Figure 
5.1-5.2). Interestingly a population of CD25
-
CD4
+
CD69
+
 T cells is demonstrated to have a 
suppressive function and such findings may be relevant to CNS T cell biology
[504]
. 
With regard to the association between CD69 expression and the tissue residency of memory 
T cells it must also be considered whether the CD69
+
 CP and CSF T cells represent a 
distinctive, stable population. The pulsatile flow of the CSF fluid and its associated drainage 
routes suggests this compartment resembles a lymphatics network and is in constant 
flux
[294,348]
. Therefore, although ‘resident’ macrophages and DC are associated with this 
compartment and some CSF CD4
+
 T cells express CD69, the likelihood of T cell ‘residency’ 
here may seem improbable with acknowledgement to the CSF fluid dynamics. However, it is 
also shown that CD69 has a role in the retention of activated CD4
+
 T cells in the secondary 
lymphoid organs
[97,505]
. In a theoretical model analogous to that assigned to lymph node 
egress the CD69 receptor may have a similar role in retaining CD4
+
 T cell in the CSF. It was 
also considered whether CD69
+
 TRM are retained within the CP whilst recirculating CD69
-
 
memory T cells exit into the CSF space. However, I found a similar representation of CD69
+
 
CD4
+
 T cells in the CSF and whole brain compartments (mainly localised to the CP) which 
does not favour this theory albeit indirectly (Figure 5.1, Figure 5.2). As no CD4
+
 T cells were 
detected in the brain parenchyma it may be assumed that this is not a source of CD69
+ 
TRM in 
these systems where there is no background infection or inflammation (Figure 4.5-4.6).  
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In spite of the arguments which may favour the association of CD69 expression with 
activation as opposed to CNS residency, co-staining of CP and CSF CD4
+
 T cells with CD103 
would be required to identify an absence of TRM in these compartments. The identification of 
a TRM population behind the BBB or BCSFB in health may have significant implications for 
therapeutic intervention in neuroinflammatory diseases including MS. It is shown that 
resident B cell populations are found in the meninges
[363]
, CSF and parenchyma
[506]
 in MS and 
contribute to disease. Interestingly, the drug Fingolimod acts upon both T and B cell 
populations but whereas peripheral B cell numbers are reduced with treatment the frequency 
of resident CNS B cells is unaffected
[507]
. In addition, peripheral blood CD4
+
 T cell 
frequencies are disproportionally reduced comparative to CSF populations. As the CP and 
CSF present a gateway to the CNS tissue such findings exemplify the importance of further 
understanding the interaction between blood and CSF T cell compartments in the 
development of therapeutic targets in MS.  
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Figure 6.1 Model for the recruitment, residency and functionality of homeostatic CD4
+
 T cells in the CSF. Recently activated central (Tcm) 
and effector memory (Teff) CD4
+
 T cells express an unknown chemokine receptor (CCR) repertoire which permits their migration from blood to 
choroid plexus (CP) in a CCR7 independent manner. CP to CSF migration is also CCR7 independent. Tcm and Teff within the CP and CSF have the 
potential to make cytokine if appropriately reactivated, with potential involvement of antigen presenting cells (APC). CCR7 interaction is important 
for dendritic cell (DC) migration behind the blood CSF barrier (BCSFB). Expression of CD69 may or may not indicate the residence of a 
subpopulation of memory CD4
+
 T cells in the CP and CSF spaces.  
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